Document:

Exhibit 10.3.2

 

ARKANSAS DEVELOPMENT
FINANCE AUTHORITY 

INDUSTRIAL DEVELOPMENT REVENUE BONDS 

(BIG RIVER STEEL PROJECT) 

SERIES 2019

 

CERTIFICATE CONFIRMING DEFINITIONS ANNEX

 

The undersigned parties
each hereby certify that the attached Definitions Annex is the document referenced and incorporated in the various documents, agreements
and certificates relating to the above-referenced bonds.

 

IN
TESTIMONY WHEREOF, the undersigned has hereunto set my hand as of this 31st day
of May, 2019.

 

[Signature pages follow]

 

     

     

    

 

	 	BIG RIVER STEEL LLC
	 	 	 
	 	By:	/s/
    David Stickler
	 	 	David Stickler, Chief Executive Officer 

 

	 	BRS INTERMEDIATE HOLDINGS LLC
	 	 	 
	 	By:	/s/
    David Stickler
	 	 	David Stickler, Chief Executive Officer 

 

	 	BRS FINANCE CORP.
	 	 	 
	 	By:	/s/
    David Stickler
	 	 	David Stickler, Chief Executive Officer 

 

Signature Page to Certificate re Definitions Annex

 

     

     

    

 

	 	U.S. BANK NATIONAL ASSOCIATION, as Trustee
			 
	 	By: 	/s/ David A. Schlabacl
	 	 	Name:	David A. Schlabacl 
	 	 	Title:	Vice President

 

Signature Page to
Certificate re Definitions Annex

 

     

     

    

 

	 	ARKANSAS DEVELOPMENT FINANCE AUTHORITY, as Issuer
	 	 	 
	 	By:	/s/
    Cheryl Schluterman
	 	 	Cheryl Schluterman, President

 

Signature Page to Certificate re Definitions Annex

 

     

     

    

 

DEFINITIONS ANNEX

 

“2019 Bonds”
means the bonds designated as the “Arkansas Development Finance Authority Industrial Development Revenue Bonds (Big River
Steel Project), Series 2019.”

 

“ABL Agent”
means Goldman Sachs Bank USA and any successors thereof under the ABL Facility, acting as administrative agents on behalf of the
ABL Facility Lenders.

 

“ABL Cap Amount” has the meaning
specified in the definition of “ABL Obligations.”

 

“ABL Claimholders”
means, at any relevant time, the holders of ABL Obligations and/or the Excess ABL Obligations at that time, including the ABL Facility
Lenders, issuing banks of letters of credit issued pursuant to the ABL Facility, the ABL Agent under the loan documents for the
ABL Facility, the ABL Hedge Provider and the ABL Cash Management Provider (as each such term is defined in the Intercreditor Agreement),
and the successors, replacements and assigns of each of the foregoing, and shall include, without limitation, any former ABL Facility
Lenders, issuing banks of letters of credit issued pursuant to the ABL Facility, the ABL Agent, ABL Hedge Provider and ABL Cash
Management Provider to the extent that any Obligations owing to such Persons were incurred while such Persons were ABL Facility
Lenders, issuing banks of letters of credit issued pursuant to the ABL Facility, the ABL Agent, ABL Hedge Provider or ABL Cash
Management Provider, as applicable, and such Obligations have not been paid or satisfied in full.

 

“ABL Facility”
means (i) the Credit Agreement, dated as of August 23, 2017, among the Company, any Restricted Subsidiary of the Company
designated as a “Borrower” or “Credit Party” thereunder, the lenders party thereto, Goldman Sachs Bank
USA (or an affiliate thereof) as administrative agent, as amended, restated, supplemented, waived, replaced (whether or not upon
termination, and whether with the original agents, lenders or otherwise), restructured, repaid, refunded, refinanced or otherwise
modified from time to time, including any agreement or indenture extending the maturity thereof, refinancing, replacing or otherwise
restructuring all or any portion of the Indebtedness thereunder or under such agreement or agreements or indenture or indentures
or any successor or replacement agreement or agreements or indenture or indentures or increasing the amount loaned or issued thereunder
or altering the maturity thereof, and (ii) whether or not the facility referred to in clause (i) remains outstanding,
if designated in an Officer’s Certificate delivered to the Trustee as “ABL Facility” until such time as the Company
subsequently delivers an Officer’s Certificate to the Trustee to the effect that such facility will no longer constitute
 “ABL Facility”, including one or more (A) debt facilities or commercial paper facilities, providing for revolving
credit loans, term loans, receivables financing (including through the sale of receivables to lenders or to special purpose entities
formed to borrow from lenders against such receivables) or letters of credit, (B) debt securities, indentures or other forms
of debt financing (including convertible or exchangeable debt instruments or bank guarantees or bankers’ acceptances), or
(C) instruments or agreements evidencing any other Indebtedness, in each case, with the same or different borrowers or issuers
and, in each case, as amended, supplemented, modified, extended, restructured, renewed, refinanced, restated, replaced or refunded
in whole or in part from time to time.

 

“ABL Facility Lenders” means the
lenders or holders of Indebtedness under the ABL Facility.

 

“ABL Obligations” means, subject
to clause (5) hereof, the following:

 

		(1)	the “Obligations” (as defined in the ABL Facility);

 

		(2)	all ABL Hedging Obligations (as defined in the Intercreditor Agreement);

 

		(3)	all ABL Cash Management Obligations (as defined in the Intercreditor Agreement);

 

    1 

     

    

 

(4)  to
the extent any payment with respect to any ABL Obligation (whether by or on behalf of any Grantor, as proceeds of security,
enforcement of any right of setoff or otherwise) is declared to be a fraudulent conveyance or a preference in any respect,
set aside or required to be paid to a debtor in possession, any Fixed Asset Pari Passu Lien Claimholders, receiver or similar
Person, then the obligation or part thereof originally intended to be satisfied shall, for the purposes of the Intercreditor
Agreement and the rights and obligations of the ABL Claimholders and the Fixed Asset Pari Passu Lien Claimholders, be deemed
to be reinstated and outstanding as if such payment had not occurred. To the extent that any interest, fees, expenses or
other charges (including Post-Petition Interest) to be paid pursuant to the loan documents for the ABL Facility are
disallowed by order of any court, including by order of a court of competent jurisdiction presiding over an Insolvency or
Liquidation Proceeding, such interest, fees, expenses and charges (including Post-Petition Interest) shall, as between the
ABL Claimholders and the Fixed Asset Pari Passu Lien Claimholders, be deemed to continue to accrue and be added to the amount
to be calculated as the “ABL Obligations”; and

 

(5) 
notwithstanding the foregoing, if the sum of: (1) Indebtedness for borrowed money constituting principal outstanding
under the ABL Facility and the other loan documents for the ABL Facility; plus (2) the aggregate face amount of any
letters of credit issued but not reimbursed under the ABL Facility, is in excess of (i) so long as the Senior Secured
Notes and the Obligations under the Term Loan Agreement remain outstanding, $350,000,000 in the aggregate and (ii) after
discharge in full (pursuant to a covenant defeasance, legal defeasance, upon maturity or otherwise) of the Senior Secured
Notes and the Obligations under the Term Loan Credit Agreement and with the requisite consent of any other then-outstanding
Pari Passu Lien Secured Parties necessary to effectuate required amendments to the Fixed Asset Pari Passu Lien Collateral
Documents and the Intercreditor Agreement, other than Holders of the Bonds, $500,000,000 (the “ABL Cap
Amount”), then only that portion of such Indebtedness and such aggregate face amount of letters of credit equal to
the ABL Cap Amount shall be included in ABL Obligations and interest and reimbursement obligations with respect to such
Indebtedness and letters of credit shall only constitute ABL Obligations to the extent related to Indebtedness and face
amounts of letters of credit included in the ABL Obligations.

 

“ABL Priority
Collateral” means the following of any Grantor: (i) Accounts and chattel paper, in each case other than to the extent
constituting identifiable proceeds of Fixed Asset Priority Collateral; (ii) deposit accounts, securities accounts and commodity
accounts (and all cash, checks and other negotiable instruments, funds, securities, commodity contracts and other evidences of
payment or other assets held therein) (but, in any event, excluding the Revenue Account (which will be used, among other things,
for deposit of identifiable proceeds of Fixed Asset Priority Collateral), other Fixed Asset Accounts and the Fixed Asset Collateral
Proceeds Account); (iii) all Inventory; (iv) to the extent evidencing, governing, securing or otherwise reasonably related
to any of the foregoing, all documents, general intangibles, instruments, commercial tort claims, letters of credit, letter-of-credit
rights and supporting obligations; provided, however, that to the extent any of the foregoing also evidence, govern, secure or
otherwise reasonably relate to any Fixed Asset Priority Collateral only that portion that evidences, governs, secures or reasonably
relates to ABL Priority Collateral shall constitute ABL Priority Collateral; provided, further, that the foregoing shall not include
any intellectual property; (v) all books, records and documents related to the foregoing (including databases, customer lists
and other records, whether tangible or electronic, which contain any information relating to any of the foregoing); (vi) insurance
and claims against third parties to the extent arising on account of ABL Priority Collateral and all of the proceeds of and payments
under all policies of business interruption insurance; and (vii) all proceeds and products of any or all of the foregoing
in whatever form received, but excluding any property that is directly acquired prior to the commencement of any case or proceeding
under the Bankruptcy Code or any similar Bankruptcy Law with cash proceeds of any ABL Priority Collateral and does not otherwise
constitute ABL Priority Collateral upon its acquisition. Subject to certain provisions of the Intercreditor Agreement, upon a Discharge
of Fixed Asset Pari Passu Lien Obligations, all Fixed Asset Priority Collateral shall become ABL Priority Collateral.

 

“Accounts”
means all present and future “accounts” (as defined in Article 9 of the UCC), whether or not the UCC is applicable
thereto, and shall include all rights of payment owed by an issuer of a credit or charge card.

 

“Acquired Indebtedness” means,
with respect to any specified Person,

 

(1) Indebtedness
of any other Person existing at the time such other Person is merged, consolidated or amalgamated with or into or became a Restricted
Subsidiary of such specified Person, including Indebtedness incurred in connection with, or in contemplation of, such other Person
merging, amalgamating or consolidating with or into, or becoming a Restricted Subsidiary of, such specified Person, and

 

    2 

     

    

 

(2) Indebtedness secured by a Lien encumbering
any asset acquired by such specified Person.

 

“Act”
means the Arkansas Development Finance Authority Act, Title 15, Chapter 5, Subchapters 1 through 3 of the Arkansas Code of 1987
Annotated, as amended.

 

“Act 9 Bond
Documents” means (a) the Act 9 Trust Indenture, (b) the Act 9 Lease Agreement, and (c) that certain Payment
in Lieu of Taxes Agreement dated as of April 30, 2015, between the City of Osceola and the Company, and all other documents
executed in connection therewith, as the same may be amended, restated, supplemented or otherwise modified from time to time.

 

“Act 9 Bonds”
means the bonds issued to Big River Steel Holdings LLC and assigned to Parent under the Act 9 Trust Indenture pursuant to Amendment
65 to the Constitution of State of Arkansas and Act No. 9 of the First Extraordinary Session of the Sixty-Second General Assembly
of the State of Arkansas for the year 1960, codified as Ark. Code Ann. Sections 14,164-201 et seq. as amended.

 

“Act 9 Lease
Agreement” means that certain Lease Agreement dated as of April 30, 2015, between the City of Osceola and the Company,
as the same may be amended, restated, supplemented or otherwise modified from time to time.

 

“Act 9 Trust
Indenture” means that certain Trust Indenture dated as of April 30, 2015, between the City of Osceola, as issuer,
and Regions Bank, as trustee for Parent as the owner of the Act 9 Bonds issued thereunder, as the same may be amended, restated,
supplemented or otherwise modified from time to time.

 

“Act of Required Pari Passu Lien Secured
Parties” means, as to any matter,

 

(1)  from
and after August 23, 2017, but prior to the Discharge of Pari Passu Lien Obligations, a direction in writing delivered to
the Collateral Agent by or with the written consent of, the Required Term Lenders until the earliest of (x) the Discharge
of Credit Agreement Obligations (as such term is defined in the Collateral Trust Agreement), (y) the Outstanding Term Loan
Threshold Date (as such term is defined in the Collateral Trust Agreement) and (z) the First Specified Pari Passu Lien Debt
Threshold Date (the date on which the earliest of the foregoing clauses (1)(x), (1)(y) and (1)(z) occurs, the “First
Controlling Change Date”);

 

(2)  from
and after the First Controlling Change Date, but prior to the Discharge of Pari Passu Lien Obligations, a direction in writing
delivered to the Collateral Agent by or with the written consent of, the Required Delayed Draw Term Lenders until the earlier of
(x) the Discharge of Specified Pari Passu Lien Debt Obligations and (y) the Second Specified Pari Passu Lien Debt Threshold
Date (the date on which the earlier of the foregoing clauses (2)(x) and (2)(y) occurs, the “Second Controlling
Change Date”); and

 

(3) 
from and after the Second Controlling Change Date, but prior to the Discharge of Pari Passu Lien Obligations, a direction in
writing delivered to the Collateral Agent by or with the written consent of, the holders of (or the Pari Passu Lien Debt
Representatives representing the holders of) more than 50% of the aggregate outstanding principal amount of Pari Passu Lien
Debt; provided, however, that if at any time prior to the Discharge of Pari Passu Lien Obligations the only remaining Pari
Passu Lien Obligations are Secured Hedging Obligations, then the term “Act of Required Pari Passu Lien Secured
Parties” will mean a direction in writing delivered by the Hedge Bank with the largest amount of Secured Hedging
Obligations owed to it. For purposes of this definition, (a) Pari Passu Lien Debt registered in the name of, or
beneficially owned by, the Company or any Affiliate of the Company will be deemed not to be outstanding and neither the
Company nor any Affiliate of the Company will be entitled to vote such Pari Passu Lien Debt and (b) votes will be
determined as described in the Collateral Trust Agreement and in the Limited Offering Memorandum under the heading
 “SECURITY AND SOURCES OF PAYMENT FOR THE 2019 BONDS AND OTHER PARI PASSU LIEN DEBT—Collateral Trust
Agreement—Voting”.

 

“Additional Bonds” means Bonds
issued under Section 2.06 of the Bond Indenture.

 

    3 

     

    

 

“Additional
Pari Passu Lien Debt” has the meaning specified in clause (1) of the definition of “Additional Pari Passu
Lien Debt Designation”.

 

“Additional
Pari Passu Lien Debt Designation” means a designation under the Collateral Trust Agreement pursuant to which the Company
designates as Pari Passu Lien Debt thereunder any Funded Debt incurred by the Company or any Subsidiary Guarantor after August 23,
2017 in accordance with the terms of all applicable Pari Passu Lien Debt Documents that states that:

 

(1) 
the Company or such other Grantor intends to incur additional Pari Passu Lien Debt (“Additional Pari Passu Lien
Debt”) which will be Pari Passu Lien Debt not prohibited by any Pari Passu Lien Debt Document to be incurred and
secured by a Pari Passu Lien equally and ratably with all previously existing and future Pari Passu Lien Debt;

 

(2)  specifies
the name and address of the Pari Passu Lien Debt Representative for such Additional Pari Passu Lien Debt for purposes of the Collateral
Trust Agreement;

 

(3)  states
that the Company and each other Grantor has duly authorized, executed (if applicable) and recorded (or caused to be recorded) in
each appropriate governmental office all relevant filings and recordations to ensure that the Additional Pari Passu Lien Debt is
secured by the Collateral in accordance with the Pari Passu Lien Security Documents;

 

(4)  attaches
a reaffirmation agreement contemplated by the Collateral Trust Agreement, which has been duly executed by the Company and each
other Grantor; and

 

(5)  states
that the Company has caused a copy of the Additional Pari Passu Lien Debt Designation and the related Collateral Trust Joinder
(if any) to be delivered to each then existing Pari Passu Lien Debt Representative.

 

“Affiliate”
of any specified Person means any other Person directly or indirectly controlling or controlled by or under direct or indirect
common control with such specified Person. For purposes of this definition, “control” (including, with correlative
meanings, the terms “controlling,” “controlled by” and “under common control with”),
as used with respect to any Person, means the possession, directly or indirectly, of the power to direct or cause the direction
of the management or policies of such Person, whether through the ownership of voting securities, by agreement or otherwise.

 

“After-Acquired
Property” means (i) equipment or fixtures acquired by the Company or any other Grantor after August 23, 2017
which constitute accretions, additions or technological upgrades to the equipment or fixtures that form part of the Fixed Asset
Priority Collateral, (ii) any equipment, fixtures and real estate of the Company or any other Grantor acquired after August 23,
2017, (iii) all of the Capital Stock acquired after August 23, 2017 and held by the Company or any other Grantor (other
than any Capital Stock that is an Excluded Asset), (iv) substantially all of the other tangible and intangible assets of the
Company and each Grantor acquired after August 23, 2017 and (v) any asset or other property, whether personal, real or
other, that was designated as an “Excluded Asset,” which asset or other property ceases to constitute an Excluded Asset.

 

“Anti-Corruption
Law” means any provision of the Foreign Corrupt Practices Act of 1977, the Bribery Act 2010 of the United Kingdom or
any other applicable anti-bribery or anti-corruption law.

 

“Applicable
Collateral Agents” has the meaning given to such term in the Intercreditor Agreement and in the Limited Offering Memorandum
under the heading “SECURITY AND SOURCES OF PAYMENT FOR THE 2019 BONDS AND OTHER PARI PASSU LIEN DEBT—Intercreditor
Agreement”.

 

“Applicable
Procedures” means, with respect to any selection of Bonds, the rules and procedures of the Depository, Euroclear
and Clearstream that apply to such selection, transfer or exchange.

 

    4 

     

    

 

“Asset Sale” means:

 

(1)  the
sale, conveyance, transfer or other disposition, whether in a single transaction or a series of related transactions, of property
or assets (including by way of a Sale and Lease-Back Transaction, other than a Specified Sale and Lease-Back Transaction) of the
Company or any Restricted Subsidiary (each referred to in this definition as a “disposition”); or

 

(2)  the
issuance or sale of Equity Interests (other than Preferred Stock or Disqualified Stock of Restricted Subsidiaries issued in
compliance with Section 6.03 of the Bond Financing Agreement and the covenant described in the Limited Offering
Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT— Bond Financing Agreement—Covenants of
the Company— Limitation on Incurrence of Indebtedness and Issuance of Disqualified Stock and Preferred Stock”) of
any Restricted Subsidiary (other than to the Company or another Restricted Subsidiary), whether in a single transaction or a
series of related transactions; in each case, other than: (a) any disposition of (i) Cash Equivalents or Investment
Grade Securities, (ii) obsolete, damaged or worn out property or assets in the ordinary course of business or consistent
with industry practice or any disposition of inventory or goods (or other assets) held for sale or no longer used or useful
in the ordinary course, (iii) assets no longer economically practicable or commercially reasonable to maintain (as
determined in good faith by the management of the Company), (iv) dispositions to landlords of improvements made to
leased real property pursuant to customary terms of leases entered into in the ordinary course of business and
(v) assets for purposes of charitable contributions or similar gifts to the extent such assets are not material to the
ability of the Company and its Restricted Subsidiaries, taken as a whole, to conduct its business in the ordinary course;
(b) the disposition of all or substantially all of the assets of the Company or a Restricted Subsidiary in a manner
permitted pursuant to the provisions of 6.12 of the Bond Financing Agreement (other than under Section 6.12(b)(2)) and
the covenant described in the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT
PROJECT—Covenants of the Company—Merger, Amalgamation, Consolidation or Sale of All or Substantially All
Assets” (other than under clause (2) of the fourth paragraph thereof) or any disposition that constitutes a Change
of Control; (c) any disposition in connection with the making of any Restricted Payment that is permitted to be made
pursuant to Section 6.01 of the Bond Financing Agreement and the covenant described in the Limited Offering Memorandum
under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the
Company—Limitation on Restricted Payments” or any Permitted Investment or any acquisition otherwise
permitted by the Bond Financing Agreement; (d) any disposition of property or assets or issuance or sale of Equity
Interests of any Restricted Subsidiary with an aggregate fair market value for any individual transaction or series of
related transactions of less than the greater of $30.0 million and 20.0% of Consolidated EBITDA of the Company for the most
recently ended Test Period (calculated on a pro forma basis) determined at the time of the making of such disposition;
(e) any disposition of property or assets or issuance of securities by a Restricted Subsidiary to the Company or by the
Company or a Restricted Subsidiary to a Restricted Subsidiary (and in the event such disposition of property or assets or
issuance of securities was made by the Company or a Guarantor, such disposition of property or assets or issuance of
securities is made to a Guarantor); (f) to the extent allowable under Section 1031 of the Code, any exchange of
like property (excluding any boot thereon) for use in a Similar Business; (g) (i) the lease or sub-lease,
assignment, license or sublicense of any real or personal property in the ordinary course of business or consistent with
industry practice, (ii) the lease or sub-lease, assignment, license or sublicense of, or co-location arrangement
relating to, any real or other property of the Company and its Restricted Subsidiaries for the purpose of facilitating the
use by other Persons of such real or other property in connection with the conduct by such other Persons (or their
affiliates) of a Similar Business and, in connection with which, the Company or a Restricted Subsidiary or a Parent Company
enters into a contract or arrangement with such other Person for the sale or acquisition of products or services, and
(iii) the exercise of termination rights with respect to any lease, sub-lease, assignment, license or sublicense or
other agreement or arrangement; (h) any issuance, disposition or sale of Equity Interests in, or Indebtedness, assets or
other securities of, an Unrestricted Subsidiary; (i) foreclosures, condemnation, expropriation, eminent domain or any
similar action (including, for the avoidance of doubt, any casualty event) with respect to assets or the granting of Liens
not prohibited by the Bond Financing Agreement; (j) sales of accounts receivable, or participations therein, or
Securitization Assets or related assets in connection with any Qualified Securitization Facility, sales of receivables in
connection with Receivables Financing Transactions or the disposition of an account receivable in connection with the
collection or compromise thereof in the ordinary course of business or consistent with industry practice or in bankruptcy or
similar proceedings; (k) any financing transaction with respect to property built or acquired by the Company or any
Restricted Subsidiary after August 23, 2017, including asset securitizations permitted by the Bond Financing Agreement;
(l) the sale, lease, assignment, license, sublease or discount of inventory, equipment, accounts receivable, notes
receivable or other current assets in the ordinary course of business or consistent with industry practice or the conversion
of accounts receivable to notes receivable or other dispositions of accounts receivable in connection with the collection
thereof; (m) the licensing or sub- licensing of intellectual property or other general intangibles in the ordinary
course of business or consistent with industry practice; (n) any surrender or waiver of contract rights or the
settlement, release or surrender of contract rights or other litigation claims in the ordinary course of business or
consistent with industry practice; (o) the unwinding of any Hedging Obligations; (p) sales, transfers and other
dispositions of Investments in joint ventures to the extent required by, or made pursuant to, customary buy/sell arrangements
between the joint venture parties set forth in joint venture arrangements and similar binding arrangements; (q) the
lapse, abandonment or other disposition of intellectual property rights in the ordinary course of business or consistent with
industry practice, which in the reasonable good faith determination of the Company are not material to the conduct of the
business of the Company and its Restricted Subsidiaries taken as a whole; (r) the granting of a Lien that is permitted
under Section 6.06 of the Bond Financing Agreement and the covenant described in the Limited Offering Memorandum under
the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the
Company—Liens;” (s) the issuance of directors’ qualifying shares and shares of Capital Stock of
Foreign Subsidiaries issued to foreign nationals as required by applicable law; (t) the disposition of any assets
(including Equity Interests) (i) acquired in a transaction permitted under the Bond Financing Agreement, which assets
are not used or useful in the principal business of the Company and its Restricted Subsidiaries or (ii) made in
connection with the approval of any applicable antitrust authority or otherwise necessary or advisable in the good faith
determination of the Company to consummate any acquisition permitted under the Bond Financing Agreement;
(u) dispositions of property to the extent that such property is exchanged for credit against the purchase price of the
same or similar replacement property; (v) the settlement or early termination of any Permitted Bond Hedge Transaction
and the settlement or early termination of any related Permitted Warrant Transaction; and (w) dispositions of property
in connection with any Specified Sale and Lease-Back Transaction.

 

    5 

     

    

 

“Assigned
Agreements” shall mean any agreement, contract or record to which any Grantor is now or may hereafter become a party,
in each case as such agreements, contracts or other records may be amended, amended and restated, supplemented or otherwise modified
from time to time.

 

“Attributable
Indebtedness” means, on any date, in respect of any Capitalized Lease Obligation or Sale and Lease-Back Transaction of
any Person, (i) in the case of a Capitalized Lease Obligation or a Sale and Lease-Back Transaction that constitutes a Capitalized
Lease Obligation, the amount thereof that would appear as a liability on a balance sheet of such Person prepared as of such date
in accordance with GAAP or (ii) in the case of a Sale and Lease-Back Transaction that does not constitute a Capitalized Lease
Obligation, the present value (discounted at the interest rate implicit in the transaction) of the total obligations of the lessee
for rental payments during the remaining term of the lease included in such Sale and Lease-Back Transaction, including any period
for which such lease has been extended or may, at the option of the lessor, be extended determined in accordance with GAAP.

 

“Authenticating
Agent” means the Trustee and the Registrar for the Bonds and any bank, trust company or other Person designated as an
Authenticating Agent for the Bonds by or in accordance with Section 6.13 of the Bond Indenture.

 

“Authorized
Company Representative” means the person or persons designated at the time to act on behalf of the Company by written
instrument furnished to the Issuer and the Trustee, containing the specimen signature of such person or persons and signed by any
officer of the Company. Such instrument may designate an alternate or alternates.

 

“Authorized
Denominations” shall mean, with respect to the 2019 Bonds, $100,000 or any integral multiple of $5,000 in excess thereof.

 

“Authorized
Issuer Representative” means the Chairman, Vice Chairman, President or any Vice President of the Bond Issuer, or any
other person at the time designated to act on behalf of the Bond Issuer by written certificate furnished to the Company and the
Trustee containing the specimen signature of such person and signed by the Chairman, Vice Chairman, President or any Vice President
of the Bond Issuer. Such certificate may designate an alternate or alternates each of whom shall be entitled to perform all duties
of the Authorized Issuer Representative.

 

    6 

     

    

 

“Bankruptcy Code” means Title 11
of the United States Code.

 

“Bankruptcy
Law” means the Bankruptcy Code and any similar federal, state or foreign law for the relief of debtors, including for
greater certainty, any such law in respect of corporation arrangement, reorganization or scheme, and all other liquidation, conservatorship,
bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, winding-up,
or arrangement (including corporate statutes).

 

“Beneficial
Owner” means, with respect to the Bonds, a Person owning a Beneficial Ownership Interest therein, which has provided
written notice to the Trustee of its Beneficial Ownership Interest of such Bond.

 

“Beneficial
Ownership Interest” means the right of the owner to receive for its own account, held directly or indirectly with a Direct
Participant or Indirect Participant, payments made by the Bond Issuer with respect to a specified principal amount of Bonds with
a specified CUSIP held by the Depository under a Book-Entry System pursuant to the Bond Indenture.

 

“BFA Loan”
means the loan of the proceeds of the Bonds from the Bond Issuer to the Company, pursuant to the Bond Financing Agreement, and
evidenced by the Series 2019 Note.

 

“Book-Entry
Form” or “Book- Entry System” means a form or system, as applicable, under which (a) the Beneficial
Ownership Interests may be transferred only through a book-entry-only system and (b) physical Bond certificates in fully registered
form are registered only in the name of a Depository or its nominee as Holder, with the physical Bond certificates “immobilized”
in the custody of the Depository or the Trustee.

 

“Board of
Directors” means, for any Person, the board of directors, board of managers or other governing body of such Person or,
if such Person does not have such a board of directors, board of managers or other governing body and is owned or managed by a
single entity, the Board of Directors of such entity, or, in either case, any committee thereof duly authorized to act on behalf
of such Board of Directors.

 

“Bond Counsel”
means collectively, Mitchell, Williams, Selig, Gates & Woodyard, PLLC, and Ballard Spahr LLP, or any other firm of attorneys
(other than an employee of the Company) satisfactory to the Bond Issuer and nationally recognized as experienced in matters relating
to the tax-exempt status of obligations issued by or on behalf of states and political subdivisions.

 

“Bond Documents”
means the Bond Indenture, the Bond Financing Agreement, the Purchase Agreement, the Series 2019 Note and the Fixed Asset Pari
Passu Lien Collateral Documents.

 

“Bond
Financing Agreement” means that certain Bond Financing Agreement by and between the Bond Issuer, the Company,
Parent and BRS Finance Corp. to be dated as of the Closing Date.

 

“Bond Financing
Payments” means payments by the Company pursuant to the Bond Financing Agreement towards the principal of, premium, if
any, and interest on the Bonds and related expenses.

 

“Bondholder”
 “Holder” or “Holder of a Bond” at any time, means the Person in whose name a Bond is registered
on the Register pursuant to the Bond Indenture.

 

“Bond
Indenture” means that certain Trust Indenture to be dated as of the Closing Date, by and between the Bond Issuer
and the Trustee.

 

“Bond Issuer”
means the Arkansas Development Finance Authority, a public body corporate and politic created and existing under the Act together
with its successors and assigns.

 

“Bond
Issuer Board” means the Board of Directors of the Bond Issuer.

 

    7 

     

    

 

“Bond
Resolution” means (a) when used with reference to the 2019 Bonds, the resolution of the Bond Issuer Board
providing for their issuance and approving the Bond Financing Agreement, the Bond Indenture and the Purchase Agreement and
related matters; and (b) when used with reference to an issue of Additional Bonds, the resolution of the Bond Issuer
Board providing for the issuance of the Additional Bonds and approving any amendment or supplement to the Bond Financing
Agreement, any Supplemental Indenture and related matters.

 

“Bonds” means the 2019 Bonds and
any Additional Bonds.

 

“Book-Entry
Form” or “Book-Entry System” means a form or system, as applicable, under which (a) the Beneficial
Ownership Interests may be transferred only through a book-entry-only system and (b) physical Bond certificates in fully registered
form are registered only in the name of a Depository or its nominee as Holder, with the physical Bond certificates “immobilized”
in the custody of the Depository or the Trustee.

 

“Borrower
Bonds” mean any Bonds of which ownership is registered in the name of the Company or any Affiliate of Company.

 

“Broker-Dealer
Regulated Subsidiary” means any Subsidiary of the Company that is registered as a broker-dealer under the Exchange Act
or any other applicable laws requiring such registration.

 

“BRS Finance” means BRS Finance
Corp., a Delaware corporation.

 

“BRS Intermediate” means BRS Intermediate
Holdings LLC, a Delaware limited liability company.

 

“Business Day” means any day that
is not a Legal Holiday.

 

“Capex Equity”
means Capital Stock of the Company issued to Parent, the Net Cash Proceeds from the issuance of which, and other cash equity capital
contributions by Parent to the Company, the Net Cash Proceeds of which, are used for purposes of Expansion Capital Expenditures.

 

“Capital Expenditures”
means all expenditures made by the Company, a Subsidiary Guarantor or a Restricted Subsidiary, as applicable, for the acquisition,
leasing (pursuant to a capital lease of fixed or capital assets), construction, development or improvement of assets or additions
to equipment (including replacement, capitalized repairs and improvements during such period) that should be capitalized under
GAAP on a consolidated balance sheet of the Company and its Restricted Subsidiaries.

 

“Capital Markets
Indebtedness” means any Indebtedness consisting of bonds, debentures, notes or other similar debt securities issued in
(a) a public offering registered under the Securities Act, (b) a private placement to institutional investors that is
resold in accordance with Rule 144A or Regulation S under the Securities Act, whether or not it includes registration rights
entitling the holders of such debt securities to registration thereof with the SEC or (c) a private placement to institutional
investors. For the avoidance of doubt, the term “Capital Markets Indebtedness” does not include any Indebtedness under
commercial bank facilities, Indebtedness incurred in connection with a Sale and Lease-Back Transaction, Indebtedness
incurred in the ordinary course of business of the Company, Capitalized Lease Obligations or recourse transfer of any financial
asset or any other type of Indebtedness incurred in a manner not customarily viewed as a “securities offering.”

 

“Capital Stock” means:

 

 (1)  in the case of a corporation, corporate stock or shares in the capital of such corporation;

 

(2)  in
the case of an association or business entity, any and all shares, interests, participations, rights or other equivalents (however
designated) of corporate stock;

 

(3)  
in the case of a partnership or limited liability company, partnership or membership interests (whether general or limited);
and

 

(4)  any
other interest or participation that confers on a Person the right to receive a share of the profits and losses of, or
distributions of assets of, the issuing Person; but excluding from all of the foregoing any debt securities convertible into
or exchangeable for Capital Stock, whether or not such debt securities include any right of participation with Capital
Stock.

 

    8 

     

    

 

“Capitalized
Lease Obligation” means, at the time any determination thereof is to be made, the amount of the liability in respect
of a capital lease that would at such time be required to be capitalized and reflected as a liability on a balance sheet (excluding
the footnotes thereto) prepared in accordance with GAAP; provided that all obligations of any Person that are or would have
been treated as operating leases for purposes of GAAP prior to the issuance by the Financial Accounting Standards Board on February 25,
2016 of an Accounting Standards Update (the “ASU”) shall continue to be accounted for as operating leases for
purposes of all financial definitions and calculations for purposes of the Bond Financing Agreement (whether or not such operating
lease obligations were in effect on such date) notwithstanding the fact that such obligations are required in accordance with the
ASU (on a prospective or retroactive basis or otherwise) to be treated as Capitalized Lease Obligations in the financial statements
to be delivered pursuant to the Bond Financing Agreement and the Continuing Disclosure Agreement.

 

“Capitalized
Software Expenditures” means, for any period, the aggregate of all expenditures (whether paid in cash or accrued as liabilities)
by a Person and its Restricted Subsidiaries during such period in respect of licensed or purchased software or internally developed
software and software enhancements that, in conformity with GAAP, are or are required to be reflected as capitalized costs on the
consolidated balance sheet of a Person and its Restricted Subsidiaries.

 

“Captive Insurance
Subsidiary” means any Subsidiary of the Company that is subject to regulation as an insurance company (or any Subsidiary
thereof).

 

“Cash Equivalents” means:

 

 (1)   United States dollars;

 

(2)   (a) Euros,
Yen, Canadian Dollars, Pounds Sterling or any national currency of any participating member state of the EMU; or (b) in the
case of any Foreign Subsidiary or any jurisdiction in which the Company or its Restricted Subsidiaries conducts business, such
local currencies held by it from time to time in the ordinary course of business or consistent with industry practice;

 

(3)   readily
marketable direct obligations issued or directly and fully and unconditionally guaranteed or insured by the United States government
or any agency or instrumentality thereof the securities of which are unconditionally guaranteed as a full faith and credit obligation
of such government with maturities of 36 months or less from the date of acquisition;

 

(4)   certificates
of deposit, time deposits and eurodollar time deposits with maturities of three years or less from the date of acquisition, demand
deposits, bankers’ acceptances with maturities not exceeding three years and overnight bank deposits, in each case with any
domestic or foreign commercial bank having capital and surplus of not less than $500.0 million in the case of U.S. banks and $100.0
million (or the United States dollar equivalent as of the date of determination) in the case of non-U.S. banks;

 

(5)   repurchase
obligations for underlying securities of the types described in clauses (3) and (4) above or clauses (7) and (8) below
entered into with any financial institution or recognized securities dealer meeting the qualifications specified in clause (4) above;

 

(6)   commercial
paper and variable or fixed rate notes rated at least P-2 by Moody’s or at least A-2 by S&P (or, if at any time neither
Moody’s nor S&P is rating such obligations, an equivalent rating from another nationally recognized statistical rating
agency selected by the Company) and, in each case, maturing within 36 months after the date of acquisition;

 

(7)  
marketable short-term money market and similar liquid funds having a rating of at least P-2 or A-2 from either Moody’s
or S&P, respectively (or, if at any time neither Moody’s nor S&P is rating such obligations, an equivalent
rating from another nationally recognized statistical rating agency selected by the Company);

 

    9 

     

    

 

(8) securities
issued or directly and fully and unconditionally guaranteed by any state, commonwealth or territory of the United States or any
political subdivision or taxing authority of any such state, commonwealth or territory or any public instrumentality thereof having
maturities of not more than 36 months from the date of acquisition;

 

(9) readily
marketable direct obligations issued or directly and fully and unconditionally guaranteed by any foreign government or any political
subdivision or public instrumentality thereof, in each case, having an Investment Grade Rating from either Moody’s or S&P
(or, if at any time neither Moody’s nor S&P is rating such obligations, an equivalent rating from another nationally
recognized statistical rating agency selected by the Company) with maturities of 36 months or less from the date of acquisition;

 

(10) Indebtedness
or Preferred Stock issued by Persons with a rating of “A” or higher from S&P or “A2” or higher from
Moody’s (or, if at any time neither Moody’s nor S&P is rating such obligations, an equivalent rating from another
nationally recognized statistical rating agency selected by the Company) with maturities of 36 months or less from the date of
acquisition;

 

(11) Investments
with average maturities of 36 months or less from the date of acquisition in money market funds rated AAA- (or the equivalent thereof)
or better by S&P or Aaa3 (or the equivalent thereof) or better by Moody’s (or, if at any time neither Moody’s nor
S&P is rating such obligations, an equivalent rating from another nationally recognized statistical rating agency selected
by the Company);

 

(12) investment
funds investing substantially all of their assets in securities of the types described in clauses (1) through (11) above;
and

 

(13) solely
with respect to any Captive Insurance Subsidiary, any investment that the Captive Insurance Subsidiary is not prohibited to make
in accordance with applicable law.

 

In the case of Investments
by any Foreign Subsidiary or Investments made in a country outside the United States, Cash Equivalents will also include (i) investments
of the type and maturity described in clauses (1) through (13) above of foreign obligors, which Investments or obligors (or
the parents of such obligors) have ratings described in such clauses or equivalent ratings from comparable foreign rating agencies
and (ii) other short-term investments utilized by Foreign Subsidiaries in accordance with normal investment practices for
cash management in investments analogous to the foregoing investments in clauses (1) through (13) and in this paragraph. Notwithstanding
the foregoing, Cash Equivalents will include amounts denominated in currencies other than those set forth in clauses (1) and
(2) above; provided that such amounts, except amounts used to pay non-dollar denominated obligations of the Company
or any Restricted Subsidiary in the ordinary course of business, are converted into any currency listed in clause (1) or (2) above
as promptly as practicable and in any event within ten (10) Business Days following the receipt of such amounts.

 

“Cash Management
Agreement” means any agreement entered into from time to time by the Company or any Restricted Subsidiary in connection
with cash management services for collections, other Cash Management Services and for operating, payroll and trust accounts of
such Person, including automatic clearing house services, controlled disbursement services, electronic funds transfer services,
information reporting services, lockbox services, stop payment services and wire transfer services.

 

“Cash Management
Obligations” means Obligations in connection with, or in respect of, Cash Management Services.

 

“Cash
Management Services” means (a) commercial credit cards, employee credit cards, merchant card services,
purchase or debit cards, including non-card e-payables services, (b) treasury management services (including controlled
disbursement, overdraft protections, automatic clearing house arrangements and fund transfer services, return items and
interstate depository network services), (c) foreign exchange, netting and currency management services, (d) any
other demand deposit or operating account relationships or other cash management services, including under any Cash
Management Agreements and (e) any other related services or activities.

 

    10 

     

    

 

“CFC” means a “controlled
foreign corporation” within the meaning of Section 957(a) of the Code.

 

“CFC Holdco”
means a Domestic Subsidiary substantially all of whose assets consists (directly or indirectly through disregarded entities) of
the Capital Stock or indebtedness (in the case of indebtedness, to the extent such indebtedness is treated as equity for U.S. federal
income tax purposes) of one or more Subsidiaries that are CFCs.

 

“Change of Control” means the occurrence
of any of the following after the Closing Date:

 

(1) the
sale, lease, transfer, conveyance or other disposition in one or a series of related transactions (other than by merger, consolidation,
amalgamation or business combination) of all or substantially all of the assets of Parent or the Company and its Subsidiaries,
in each case, taken as a whole, to any Person other than one or more Permitted Holders;

 

(2) the
Company becomes aware of (by way of a report or any other filing pursuant to Section 13(d) of the Exchange Act, proxy,
vote, written notice or otherwise) (a) any Person (other than a Permitted Holder) or (b) Persons (other than one or more
Permitted Holders) constituting a “group” (as such term is used in Sections 13(d) and 14(d) of the Exchange
Act), becoming the “beneficial owner” (as defined in Rules 13(d)-3 and 13(d)-5 under the Exchange Act), directly
or indirectly, of Equity Interests of the Company representing more than fifty percent (50.00%) of the aggregate ordinary voting
power represented by the issued and outstanding Equity Interests of the Company (it being understood and agreed that for purposes
of measuring beneficial ownership held by any Person that is not a Permitted Holder, Equity Interests held by any Permitted Holder
will be excluded), unless the Permitted Holders have, at such time, directly or indirectly, the right or the ability by voting
power, contract or otherwise to elect or designate for election at least a majority of the Board of Directors of the Company; or

 

		(3)	the Company ceases to be directly wholly-owned by Parent.

 

“Change of
Control Offer” means an electronically delivered or mailed redemption notice with respect to all Outstanding Bonds pursuant
to the terms of the Bond Indenture pursuant to which the Company will make an offer to purchase all of the 2019 Bonds as further
described in Section 6.08 of the Bond Financing Agreement and in the Limited Offering Memorandum under the heading “FINANCING
FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Offer to Repurchase Upon Change of Control.”

 

“Clearstream” means Clearstream
Banking, Société Anonyme and its successors.

 

“Closing Date”
means, with respect to the 2019 Bonds, the date of delivery of and payment for the 2019 Bonds, being May 31, 2019, and with
respect to any Additional Bonds, the date of their delivery and payment.

 

“Code” means the Internal Revenue
Code of 1986, as amended from time to time.

 

“Collateral” means all the assets
and properties subject to the Liens created by the Security Documents.

 

“Collateral
Agent” means U.S. Bank National Association, in its capacity as the collateral agent under the Collateral Trust Agreement.

 

“Collateral
Trust Agreement” means the Collateral Trust Agreement dated as of August 23, 2017, among the Collateral Agent, Goldman
Sachs Bank USA, as administrative agent, U.S. Bank National Association, as trustee under the Notes Indenture, the Trustee, the
Commercial Building Lender, the Equipment Lessor, each other Pari Passu Debt Representative with respect to Pari Passu Lien Obligations
from time to time party thereto and the Loan Parties under the Term Loan Credit Agreement.

 

    11 

     

    

 

“Collateral
Trust Joinder” means as to any Series of Pari Passu Lien Debt, the written agreement of a representative of holders
of such Series of Pari Passu Lien Debt, as set forth in the indenture, credit agreement or other agreement governing such
Series of Pari Passu Lien Debt, whereby such Person agrees to become party as a Pari Passu Lien Debt Representative under
the Collateral Trust Agreement and whereby such Person, on behalf of itself and each holder of Pari Passu Lien Obligations in respect
of the Series of Pari Passu Lien Debt for which such Person is acting as Pari Passu Lien Debt Representative agrees, for the
enforceable benefit of all holders of each current and future Series of Pari Passu Lien Debt, each current and future Pari
Passu Lien Debt Representative, and each current and future Pari Passu Lien Secured Party and Pari Passu Lien Obligations and as
a condition to being treated as Pari Passu Lien Debt under the Collateral Trust Agreement that:

 

(1) all
Pari Passu Lien Obligations will be and are secured equally and ratably by all Pari Passu Liens at any time granted by the Company
or any other Grantor to secure any Pari Passu Lien Obligations, whether or not upon property otherwise constituting collateral
for such Pari Passu Lien Obligations, and that all such Pari Passu Liens will be enforceable by the Collateral Agent for the benefit
of all Pari Passu Lien Secured Party equally and ratably; provided, however, that notwithstanding the foregoing, this provision
will not be violated with respect to any particular Collateral and any particular Series of Pari Passu Lien Debt if the Pari
Passu Lien Debt Documents in respect thereof prohibit the applicable Pari Passu Lien Debt Representative from accepting the benefit
of a Pari Passu Lien on any particular asset or property or such Pari Passu Lien Debt Representative otherwise expressly declines
in writing to accept the benefit of a Pari Passu Lien on such asset or property, provided that notwithstanding the foregoing, all
amounts on deposit in the Specified Accounts (as such term is defined in the Collateral Trust Agreement) or credited thereto shall
be for the benefit of all Pari Passu Lien Secured Parties; provided further that funds in the various debt service reserve accounts
and the construction account shall be for the exclusive benefit of specified creditors until those creditors are paid in full,
and otherwise the funds on deposit in the Specified Accounts shall be applied to the Pari Passu Lien Obligations in the order provided
in, and otherwise in accordance with, the Collateral Trust Agreement and/or the Deposit Agreement, as applicable;

 

(2) such
Person and each holder of Pari Passu Lien Obligations in respect of the Series of Pari Passu Lien Debt for which the undersigned
is acting as Pari Passu Lien Debt Representative are bound by the provisions of the Collateral Trust Agreement, including the provisions
relating to the ranking of Pari Passu Liens and the order of application of proceeds from the enforcement of Pari Passu Liens;
and

 

(3) the
Collateral Agent shall perform its obligations under the Collateral Trust Agreement and the other Pari Passu Lien Debt Documents.

 

“Commercial
Building Collateral” means such properties and assets of the Company as are specified in the Commercial Building Security
Documents on which Commercial Building Liens have been granted, or purported to be granted.

 

“Commercial Building Lender” means
First Security Bank, an Arkansas banking corporation.

 

“Commercial
Building Lender Obligations” means all Obligations under the Commercial Building Loan Agreement, including with respect
to the Commercial Building Loan.

 

“Commercial
Building Lien” means a Lien granted, or purported to be granted, by a Commercial Building Security Document to the Commercial
Building Lender to secure Commercial Building Lender Obligations prior to August 23, 2017.

 

“Commercial
Building Loan” means the loan made by the Commercial Building Lender under the Commercial Building Loan Agreement.

 

“Commercial
Building Loan Agreement” means that certain Loan Agreement, dated as of September 8, 2016, by and between the
Company and the Commercial Building Lender, as the same has been amended, supplemented or otherwise modified prior to
August 23, 2017 and as in effect on such date, and as may be further amended, supplemented or otherwise modified from
time to time hereafter to the extent not prohibited by the Intercreditor Agreement.

 

    12 

     

    

 

“Commercial
Building Security Documents” means the Leasehold Mortgage, Assignment of Purchase Option and Security Agreement from
the Company to the Commercial Building Lender, made January 31, 2017 by the Company, as mortgagor, to the Commercial Building
Lender, as mortgagee, the Amended and Restated Recognition of Leasehold and Security Interest, Nondisturbance and Attornment Agreement
made November 17, 2016 among the Company, the City of Osceola, Arkansas, the Equipment Lessor and the Commercial Building
Lender, the Easement Agreement, dated as of January 31, 2017, among City of Osceola, as grantor, Commercial Building Lender
and the Company, and other grants or transfers for security executed and delivered by the Company creating or perfecting (or purporting
to create or perfect) a Lien on properties and assets of the Company in favor of the Commercial Building Lender, in each case as
the same has been amended, supplemented or otherwise modified prior to August 23, 2017 and in effect on such date and as may
be further amended, supplemented or otherwise modified from time to time hereafter to the extent not prohibited by the Intercreditor
Agreement.

 

“Commercial
Building Loan Proportion by Value” means the net proceeds of a Going Concern Sale, multiplied by the proportion
of (x) $20,316, 283, which is the amount of Project Costs expended by the Company to acquire and construct the Commercial
Building Collateral, divided by (y) $1,330,000,000, which is the total amount of Project Costs incurred by the Company
as of August 23, 2017; provided that such amount will not exceed the total amount of the outstanding and unpaid Commercial
Building Lender Obligations.

 

“Common Collateral”
means all of the assets and property of the Company or any Guarantor, whether real, personal or mixed, in or upon which Liens are
granted, or required to be granted, to secure both the ABL Obligations and the Fixed Asset Pari Passu Lien Obligations, including
any property subject to Liens granted pursuant to the first and second paragraphs described in the Limited Offering Memorandum
under the heading “SECURITY AND SOURCES OF PAYMENT FOR THE 2019 BONDS AND OTHER PARI PASSU LIEN DEBT—Intercreditor
Agreement—Insolvency or Liquidation Proceeding” to secure both the ABL Obligations and the Fixed Asset Pari
Passu Lien Obligations.

 

“Company” means Big River Steel
LLC, a Delaware limited liability company, and its successors and assigns.

 

“Consolidated
Depreciation and Amortization Expense” means, with respect to any Person for any period, the total amount of depreciation
and amortization expense of such Person and its Restricted Subsidiaries, including, the amortization of intangible assets, deferred
financing fees, debt issuance costs, commissions, fees and expenses and the amortization of Capitalized Software Expenditures of
such Person and its Restricted Subsidiaries for such period on a consolidated basis and otherwise determined in accordance with
GAAP.

 

    13 

     

    

 

“Consolidated
EBITDA” means, with respect to any Person for any period, the Consolidated Net Income of such Person and its Restricted
Subsidiaries for such period:

 

(1) increased
(without duplication) by the following, in each case (other than clauses (h), (l) and (m)) to the extent deducted (and
not added back) in determining Consolidated Net Income for such period: (a) total interest expense and, to the extent
not reflected in such total interest expense, any losses on Hedging Obligations or other derivative instruments entered into
for the purpose of hedging interest rate risk, net of interest income and gains on such Hedging Obligations or such
derivative instruments, and bank and letter of credit fees, letter of guarantee and bankers’ acceptance fees and costs
of surety bonds in connection with financing activities, together with items excluded from the definition of
 “Consolidated Interest Expense” pursuant to the definition thereof; plus (b) provision for taxes
based on income, profits, revenue or capital, including federal, foreign and state income, franchise and similar taxes, and
foreign withholding taxes paid or accrued during such period (including any other levies that replace or are intended to be
in lieu of such taxes, and any penalties and interest related to taxes or arising from tax examinations) and the net tax
expense associated with any adjustments made pursuant to the definition of “Consolidated Net Income”, and any
payments to a Parent Company in respect of such taxes permitted to be made under the Bond Financing Agreement; plus
(c) Consolidated Depreciation and Amortization Expense for such period; plus (d) any other non-cash charges,
including any write-offs or write-downs reducing Consolidated Net Income for such period (provided that if any such
non-cash charges represent an accrual or reserve for potential cash items in any future period, (A) the Company may
determine not to add back such non-cash charge in the current period and (B) to the extent the Company does decide to
add back such non-cash charge, the cash payment in respect thereof, with the exception of any cash payments related to the
settlement of deferred compensation balances awarded prior to the Closing Date, in such future period shall be subtracted
from Consolidated EBITDA to such extent, and excluding amortization of a prepaid cash item that was paid in a prior period); plus (e) minority
interest expense, the amount of any non-controlling interest consisting of income attributable to non-controlling interests
of third parties in any non-wholly-owned Restricted Subsidiary, excluding cash distributions in respect thereof, and the
amount of any reductions in arriving at Consolidated Net Income resulting from the application of Accounting Standards
Codification Topic No. 810, Consolidation; plus (f) (i) the amount of board of director fees and any
management, monitoring, consulting, transaction, advisory and other fees (including termination fees) and indemnities and
expenses paid or accrued in such period under the Management Services Agreements or otherwise to the extent permitted under
the Bond Financing Agreement and (ii) the amount of payments made to optionholders of such Person or any Parent Company
in connection with, or as a result of, any distribution being made to equityholders of such Person or its Parent Companies,
which payments are being made to compensate such optionholders as though they were equityholders at the time of, and entitled
to share in, such distribution, in each case to the extent permitted under the Bond Financing Agreement; plus (g) the
amount of loss or discount on sale of receivables, Securitization Assets and related assets to any Securitization Subsidiary
in connection with a Qualified Securitization Facility; plus (h) cash receipts (or any netting arrangements
resulting in reduced cash expenditures) not representing Consolidated EBITDA or Consolidated Net Income in any prior period
to the extent non-cash gains relating to such income were deducted in the calculation of Consolidated EBITDA pursuant to
clause (2) below for any previous period and not added back; plus (i) any costs or expenses incurred
pursuant to any management equity plan, stock option plan or any other management or employee benefit plan, agreement or any
stock subscription or shareholder agreement, to the extent that such costs or expenses are funded with cash proceeds
contributed to the capital of such Person or net cash proceeds of an issuance of Equity Interests of such Person (other than
Disqualified Stock); plus (j) any net pension or other post-employment benefit costs representing amortization of
unrecognized prior service costs, actuarial losses, including amortization of such amounts arising in prior periods,
amortization of the unrecognized net obligation (and loss or cost) existing at the date of initial application of FASB
Accounting Standards Codification Topic 715—Compensation— Retirement Benefits, and any other items of a
similar nature; plus (k) any net loss from operations expected to be disposed of, abandoned or discontinued
within twelve months after the end of such period; plus (l) the amount of “run rate” cost savings,
synergies and operating expense reductions related to restructurings, cost savings initiatives or other initiatives that are
projected by the Company in good faith to result from actions either taken or with respect to which substantial steps have
been taken or are expected to be taken (in the good faith determination of the Company) within 24 months after the end of
such period (which cost savings, synergies or operating expense reductions shall be calculated on a pro forma basis as
though such cost savings, synergies or operating expense reductions had been realized on the first day of such period), net
of the amount of actual benefits realized from such actions during such period (it is understood and agreed that “run
rate” means the full recurring benefit that is associated with any action taken or with respect to which substantial
steps have been taken or are expected to be taken, whether prior to or following the Closing Date) (which adjustments may be
incremental to (but not duplicative of) any pro forma cost savings, synergies or operating expense reduction
adjustments as are appropriate and consistent with the pro forma provisions set forth in the definition of Fixed
Charge Coverage Ratio); provided that such cost savings, synergies and operating expenses are reasonably identifiable
and factually supportable; plus (m) any payments in the nature of compensation or expense reimbursement made to
independent board members; plus (n) internal software development costs that are expensed during the period but
could have been capitalized in accordance with GAAP; plus (o) any loss from discontinued operations (but if such
operations are classified as discontinued due to the fact that they are subject to an agreement to dispose of such
operations, only when and to the extent such operations are actually disposed of); plus (p) pre-startup expenses;
and

 

    14 

     

    

 

(2) decreased
(without duplication) by the following, in each case to the extent included in determining Consolidated Net Income for such
period: (a) non-cash gains for such period (excluding any non-cash gain to the extent it represents the reversal of an
accrual or reserve for a potential cash item that reduced Consolidated Net Income or Consolidated EBITDA in any prior period
other than any such accrual or reserve that has been added back to Consolidated Net Income in calculating Consolidated EBITDA
in accordance with this definition); (b) the amount of any non-controlling interest consisting of loss attributable to
non -controlling interests of third parties in any non-wholly-owned Restricted Subsidiary added to (and not deducted from)
Consolidated Net Income in such period; and (c) any income from discontinued operations (but if such operations are
classified as discontinued due to the fact that they are subject to an agreement to dispose of such operations, only when and
to the extent such operations are actually disposed of).

 

“Consolidated Interest Expense”
means, with respect to any Person for any period, without duplication, the sum of:

 

(1) cash
interest expense (including that attributable to Capitalized Lease Obligations), net of cash interest income, with respect to Indebtedness
of such Person and its Restricted Subsidiaries for such period, other than Non-Recourse Indebtedness, including commissions, discounts
and other fees and charges owed with respect to letters of credit and bankers’ acceptance financing and net cash costs under
hedging agreements (other than in connection with the early termination thereof); plus

 

(2) non-cash
interest expense resulting solely from (a) the amortization of original issue discount from the issuance of Indebtedness of
such Person and its Restricted Subsidiaries at less than par (excluding the 2019 Bonds, the Senior Secured Notes and any Indebtedness
borrowed under the Term Loan Credit Agreement or the ABL Facility and any Non-Recourse Indebtedness), plus (b) pay-in-kind
interest expense of such Person and its Restricted Subsidiaries payable pursuant to the terms of the agreements governing Indebtedness
for borrowed money, excluding, in each case, (i) amortization of deferred financing costs, debt issuance costs, commissions,
fees and expenses and any other amounts of non-cash interest other than referred to in clauses (2)(a) and (2)(b) above
(including as a result of the effects of acquisition method accounting or pushdown accounting), (ii) interest expense attributable
to the movement of the mark-to-market valuation of obligations under Hedging Obligations or other derivative instruments, including
pursuant to FASB Accounting Standards Codification Topic 815—Derivatives and Hedging, (iii) costs associated
with incurring or terminating Hedging Obligations and cash costs associated with breakage in respect of hedging agreements for
interest rates, (iv) commissions, discounts, yield, make-whole premium and other fees and charges (including any interest
expense) incurred in connection with any Non-Recourse Indebtedness, (v) “additional interest” owing pursuant to
a registration rights agreement with respect to any securities, (vi) any payments with respect to make-whole premiums or other
breakage costs of any Indebtedness, (vii) penalties and interest relating to taxes, (viii) accretion or accrual of discounted
liabilities not constituting Indebtedness, (ix) interest expense attributable to a Parent Company resulting from push-down
accounting, (x) any expense resulting from the discounting of Indebtedness in connection with the application of recapitalization
or purchase accounting, (xi) any interest expense attributable to the exercise of appraisal rights and the settlement of any
claims or actions (whether actual, contingent or potential), with respect thereto in connection with any acquisition or Investment
and (xii) annual agency fees paid to the administrative agents and collateral agents (including any security or collateral
trust arrangements related thereto) under any Credit Facilities, including the ABL Facility, the Term Loan Credit Agreement, the
Senior Secured Notes and the Bonds. For purposes of this definition, interest on a Capitalized Lease Obligation will be deemed
to accrue at an interest rate reasonably determined by such Person to be the rate of interest implicit in such Capitalized Lease
Obligation in accordance with GAAP.

 

“Consolidated
Net Income” means, for any period, the net income (loss) of the Company and its Restricted Subsidiaries for such period
determined on a consolidated basis in accordance with GAAP, excluding (and excluding the effect of), without duplication,

 

    15 

     

    

 

(1) extraordinary,
non-recurring or unusual gains, losses, fees, costs, charges or expenses (including relating to any strategic initiatives and
accruals and reserves in connection with such gains, losses, charges or expenses); restructuring costs, charges, accruals or
reserves (including restructuring and integration costs related to acquisitions and adjustments to existing reserves, and in
each case, whether or not classified as such under GAAP); costs and expenses related to any reconstruction, decommissioning,
recommissioning or reconfiguration of facilities and fixed assets for alternative uses; Public Company Costs; costs and
expenses related to the integration, consolidation, opening, pre-opening and closing of facilities and fixed assets;
severance and relocation costs and expenses, one-time compensation costs and expenses, consulting fees, signing, retention or
completion bonuses, and executive recruiting costs; costs and expenses incurred in connection with strategic initiatives;
transition costs and duplicative running costs; costs and expenses incurred in connection with non-ordinary course product
and intellectual property development; costs incurred in connection with acquisitions (or purchases of assets) prior to or
after August 23, 2017 (including integration costs); business optimization expenses (including costs and expenses
relating to business optimization programs, new systems design, retention charges, system establishment costs and
implementation costs and project start-up costs), accruals and reserves; operating expenses attributable to the
implementation of cost savings initiatives; curtailments and modifications to pension and post- employment employee benefit
plans (including any settlement of pension liabilities and charges resulting from changes in estimates, valuations and
judgments);

 

(2) the
cumulative effect of a change in accounting principles and changes as a result of the adoption or modification of accounting policies
during such period whether effected through a cumulative effect adjustment or a retroactive application, in each case in accordance
with GAAP;

 

		(3)	expenses incurred in connection with the issuance of the Bonds and the Senior Secured Notes;

 

(4) any
gain (loss) on asset sales, disposals or abandonments (other than asset sales, disposals or abandonments in the ordinary course
of business);

 

(5) the
Net Income for such period of any Person that is an Unrestricted Subsidiary, and, solely for the purpose of determining the amount
available for Restricted Payments under Section 6.01(a)(3) of the Bond Financing Agreement and as described in clause
(a)(3) of the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing
Agreement—Covenants of the Company— Limitation on Restricted Payments,” the Net Income for such period
of any Person that is not a Subsidiary or that is accounted for by the equity method of accounting (provided that the Consolidated
Net Income of a Person will be increased by the amount of dividends or distributions or other payments that are actually paid in
cash or Cash Equivalents (or to the extent converted into cash or Cash Equivalents) to such Person or a Restricted Subsidiary thereof
in respect of such period);

 

(6) solely
for the purpose of determining the amount available for Restricted Payments under Section 6.01(a)(3) of the Bond Financing
Agreement and as described in clause (a)(3) of the Limited Offering Memorandum under the heading “FINANCING FOR THE
TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the Company—Limitation on Restricted Payments,”
the Net Income for such period of any Restricted Subsidiary (other than any Subsidiary Guarantor) to the extent that the declaration
or payment of dividends or similar distributions by that Restricted Subsidiary of its Net Income is not at the date of determination
permitted without any prior governmental approval (which has not been obtained) or, directly or indirectly, by the operation of
the terms of its charter or any agreement, instrument, judgment, decree, order, statute, rule, or governmental regulation applicable
to that Restricted Subsidiary or its stockholders, unless such restriction with respect to the payment of dividends or similar
distributions has been legally waived (or the Company reasonably believes such restriction could be waived and is using commercially
reasonable efforts to pursue such waiver); provided that Consolidated Net Income of a Person will be increased by the amount
of dividends or other distributions or other payments actually paid in cash or Cash Equivalents (or to the extent converted into
cash or Cash Equivalents), or the amount that could have been paid in cash or Cash Equivalents without violating any such restriction
or requiring any such approval, to such Person or a Restricted Subsidiary thereof in respect of such period, to the extent not
already included therein;

 

(7) effects
of adjustments (including the effects of such adjustments pushed down to such Person and its Restricted Subsidiaries) related to
the application of recapitalization accounting or purchase accounting (including in the inventory, property and equipment, software,
goodwill, intangible assets, in process research and development, deferred revenue and debt line items);

 

(8) income
(loss) from the early extinguishment or conversion of (a) Indebtedness, (b) Hedging Obligations or (c) other derivative
instruments;

 

    16 

     

    

 

(9)    any
impairment charge or asset write-off or write-down in each case, pursuant to GAAP, and the amortization of intangibles arising
pursuant to GAAP;

 

(10)  (a) any equity based or non-cash compensation charge or expense, including any such charge or expense arising from
grants of stock appreciation, equity incentive programs or similar rights, stock options, restricted stock or other rights
to, and any cash charges associated with the rollover, acceleration, or payout of, Equity Interests by management of such
Person or of a Restricted Subsidiary or any Parent Company, (b) noncash compensation expense resulting from the
application of Accounting Standards Codification Topic No. 718, Compensation—Stock Compensation or Accounting
Standards Codification Topic 505-50, Equity-Based Payments to Non-Employees, and (c) any income (loss) attributable to
deferred compensation plans or trusts;

 

(11)  any
fees, expenses or charges incurred during such period, or any amortization thereof for such period, in connection with any acquisition, Investment,
Asset Sale, disposition, incurrence or repayment of Indebtedness (including such fees, expenses or charges related to the offering
and issuance of the Senior Secured Notes and the 2019 Bonds and the syndication and incurrence of any Credit Facilities or the
Term Loan Credit Agreement or Other Pari Passu Lien Obligations), issuance of Equity Interests (including by any direct or indirect
parent of the Company), recapitalization, refinancing transaction or amendment or modification of any debt instrument (including
any amendment or other modification of the 2019 Bonds and other securities and any Credit Facilities or the Term Loan Credit Agreement,
Senior Secured Notes or Other Pari Passu Lien Obligations) and including, in each case, any such transaction whether consummated
on, after or prior to the Closing Date and any such transaction undertaken but not completed, and any charges or nonrecurring merger
costs incurred during such period as a result of any such transaction, in each case whether or not successful or consummated (including,
for the avoidance of doubt, the effects of expensing all transaction related expenses in accordance with Accounting Standards Codification
Topic No. 805, Business Combinations);

 

(12)  accruals
and reserves that are established or adjusted in connection with an Investment or an acquisition that are required to be established
or adjusted as a result of such Investment or such acquisition, in each case in accordance with GAAP;

 

(13)  any
expenses, charges or losses to the extent covered by insurance that are, directly or indirectly, reimbursed or reimbursable by
a third party, and any expenses, charges or losses that are covered by indemnification or other reimbursement provisions in connection
with any acquisition, Investment or any sale, conveyance, transfer or other disposition of assets permitted under the Bond
Financing Indenture;

 

(14)  any
non-cash gain (loss) attributable to the mark to market movement in the valuation of Hedging Obligations or other derivative instruments
pursuant to FASB Accounting Standards Codification Topic 815— Derivatives and Hedging or mark to market movement of other
financial instruments pursuant to FASB Accounting Standards Codification Topic 825—Financial Instruments;

 

(15)  any
net unrealized gain or loss (after any offset) resulting in such period from currency transaction or translation gains or losses
including those related to currency remeasurements of Indebtedness (including any net loss or gain resulting from (a) Hedging
Obligations for currency exchange risk and (b) resulting from intercompany indebtedness) and any other foreign currency transaction
or translation gains and losses, to the extent such gain or losses are non-cash items;

 

(16)  any
adjustments resulting from the application of Accounting Standards Codification Topic No. 460, Guarantees, or any comparable
regulation;

 

 (17)  any non-cash rent expense;

 

 (18)  any non-cash expenses, accruals or reserves related to adjustments to historical tax exposures; and

 

(19)  earn-out
and contingent consideration obligations (including to the extent accounted for as bonuses or otherwise) and adjustments thereof
and purchase price adjustments.

    

    17 

     

    

 

In addition, to the
extent not already included in the Consolidated Net Income of such Person and its Restricted Subsidiaries, Consolidated Net Income
will include the amount of proceeds received or receivable from business interruption insurance, the amount of any expenses or
charges incurred by such Person or its Restricted Subsidiaries during such period that are, directly or indirectly, reimbursed
or reimbursable by a third party, and amounts that are covered by indemnification or other reimbursement provisions in connection
with any acquisition, Investment or any sale, conveyance, transfer or other disposition of assets permitted under the Bond
Financing Agreement.

 

Notwithstanding the
foregoing, for the purpose of the Section 6.01 of the Bond Financing Agreement (other than Section 6.01(a)(3)(D) only)
and the covenant described in the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond
Financing Agreement—Covenants of the Company—Limitation on Restricted Payments” (other than (a)(3)(D) only),
there will be excluded from Consolidated Net Income any income arising from any sale or other disposition of Restricted Investments
made by such Person and its Restricted Subsidiaries, any repurchases and redemptions of Restricted Investments from such Person
and its Restricted Subsidiaries, any repayments of loans and advances which constitute Restricted Investments by such Person or
any Restricted Subsidiary, any sale of the stock of an Unrestricted Subsidiary or any distribution or dividend from an Unrestricted
Subsidiary, in each case only to the extent such amounts increase the amount of Restricted Payments permitted under Section 6.01(a)(3)(D) of
the Bond Financing Agreement (or clause (a)(3)(D) of the covenant described in the Limited Offering Memorandum under the heading
 “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the Company—Limitation on Restricted
Payments”).

 

“Consolidated
Secured Debt” means, as of any date of determination, subject to the definition of “Designated Revolving Commitments,”
the aggregate principal amount of Indebtedness of the Company and its Restricted Subsidiaries outstanding on such date, determined
on a consolidated basis in accordance with GAAP, consisting only of Indebtedness for borrowed money, Capitalized Lease Obligations
and purchase money Indebtedness, in each case secured by a lien; provided that Consolidated Secured Debt will not include
Non-Recourse Indebtedness, undrawn amounts under revolving credit facilities and Indebtedness in respect of any (1) letter
of credit, bank guarantees and performance or similar bonds, except to the extent of obligations in respect of drawn standby letters
of credit which have not been reimbursed within three (3) Business Days and (2) Hedging Obligations. The U.S. dollar-equivalent
principal amount of any Indebtedness denominated in a foreign currency will reflect the currency translation effects, determined
in accordance with GAAP, of Hedging Obligations for currency exchange risks with respect to the applicable currency in effect on
the date of determination of the U.S. dollar-equivalent principal amount of such Indebtedness.

 

“Consolidated
Total Debt” means, as of any date of determination, subject to the definition of “Designated Revolving Commitments,”
the aggregate principal amount of Indebtedness of the Company and its Restricted Subsidiaries outstanding on such date, determined
on a consolidated basis in accordance with GAAP, consisting only of Indebtedness for borrowed money, Capitalized Lease Obligations
and purchase money Indebtedness; provided that Consolidated Total Debt will not include Non-Recourse Indebtedness, undrawn
amounts under revolving credit facilities and Indebtedness in respect of any (1) letter of credit, bank guarantees and performance
or similar bonds, except to the extent of obligations in respect of drawn standby letters of credit which have not been reimbursed
within three (3) Business Days and (2) Hedging Obligations. The U.S. dollar-equivalent principal amount of any Indebtedness
denominated in a foreign currency will reflect the currency translation effects, determined in accordance with GAAP, of Hedging
Obligations for currency exchange risks with respect to the applicable currency in effect on the date of determination of the U.S.
dollar-equivalent principal amount of such Indebtedness.

 

“Construction
Fund” means the fund of that name established pursuant to Section 5.01(b) of the Bond Indenture.

 

“Contingent
Obligations” means, with respect to any Person, any obligation of such Person guaranteeing any leases, dividends or other
monetary obligations that do not constitute Indebtedness (“primary obligations”) of any other Person (the “primary
obligor”) in any manner, whether directly or indirectly, including any obligation of such Person, whether or not contingent:
(1) to purchase any such primary obligation or any property constituting direct or indirect security therefor; (2) to
advance or supply funds (a) for the purchase or payment of any such primary obligation, or (b) to maintain
working capital or equity capital of the primary obligor or otherwise to maintain the net worth or solvency of the primary obligor;
or (3) to purchase property, securities or services primarily for the purpose of assuring the owner of any such primary obligation
of the ability of the primary obligor to make payment of such primary obligation against loss in respect thereof.

  

    18 

     

    

 

“Continuing
Disclosure Agreement” means the Continuing Disclosure Agreement dated as of the Closing Date by and between the Company
and the Dissemination Agent.

 

“Controlled
Investment Affiliate” means, as to any Person, any other Person, other than any Investor, which directly or indirectly
is in control of, is controlled by, or is under common control with such Person and is organized by such Person (or any Person
controlling such Person) primarily for making direct or indirect equity or debt investments in the Company and/or other companies.

 

“Controlling Representative” means:

 

(1)   from
and after the Closing Date until the First Controlling Change Date, but prior to the Discharge of Pari Passu Lien Obligations,
the Term Loan Administrative Agent;

 

(2)   from
and after the First Controlling Change Date until the Second Controlling Change Date, but prior to the Discharge of Pari Passu
Lien Obligations, the Specified Pari Passu Lien Debt Representative;

 

(3)   from
and after the Second Controlling Change Date, but prior to the Discharge of Pari Passu Lien Obligations, the Pari Passu Lien Debt
Representative that represents the Series of Pari Passu Lien Debt with the then largest outstanding principal amount (which,
if the proviso contained in the Collateral Trust Agreement under the heading Voting and described in the Limited Offering Memorandum
under the heading “SECURITY AND SOURCES OF PAYMENT FOR THE 2019 BONDS AND OTHER PARI PASSU LIEN DEBT—Collateral Trust
Agreement—Voting” applies, will be the Series of Pari Passu Lien Debt with the then largest outstanding principal
amount which cast its votes); provided, however, that if at any time prior to the Discharge of Pari Passu Lien Obligations
the only remaining Pari Passu Lien Obligations are Secured Hedging Obligations, then the term “Controlling Representative”
will mean the Hedge Bank with the largest amount of Secured Hedging Obligations owed to it.

 

“Convertible
Indebtedness” means Indebtedness of the Company (which may be guaranteed by the Guarantors) permitted to be incurred
under the terms of the Bond Financing Agreement that is either (a) convertible into common stock of the Company (and cash
in lieu of fractional shares) and/or cash (in an amount determined by reference to the price of such common stock) or (b) sold
as units with call options, warrants or rights to purchase (or substantially equivalent derivative transactions) that are exercisable
for common stock of the Company and/or cash (in any amount determined by reference to the price of such common stock).

 

“Credit Facilities”
means, with respect to the Company or any Restricted Subsidiary, one or more debt facilities, including the ABL Facility or other
financing arrangements (including commercial paper facilities or indentures) providing for revolving credit loans, term loans,
note issuances, letters of credit or other long-term indebtedness, including any notes, mortgages, guarantees, collateral documents,
instruments and other agreements executed in connection therewith, and any amendments, supplements, modifications, extensions,
renewals, restatements or refundings thereof, in whole or in part, and any indentures or credit facilities or commercial paper
facilities that replace, refund, supplement, extend, renew, restate, amend, modify or refinance any part of the loans, notes, other
credit facilities or commitments thereunder, including any such exchange, replacement, refunding, supplemental, extended, renewed,
restated, amended, modified or refinancing facility, arrangement or indenture that increases the amount permitted to be borrowed
or issued thereunder or alters the maturity thereof (provided that such increase in borrowings or issuances is permitted
by Section 6.03 of the Bond Financing Agreement and the covenant described in the Limited Offering Memorandum under the heading
 “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the Company—Limitation
on Incurrence of Indebtedness and Issuance of Disqualified Stock and Preferred Stock”) or adds Restricted Subsidiaries as
additional borrowers or guarantors thereunder and whether by the same or any other agent, trustee, lender or group of lenders or
holders. Any agreement or instrument other than the ABL Facility must be designated in an Officer’s Certificate delivered
to the Trustee as a “Credit Facility”
until such time as the Company subsequently delivers an Officer’s Certificate to the Trustee to the effect that such facility
will no longer constitute a “Credit Facility.”

 

    19 

     

    

 

“CTA Parties
Event of Default” means a Pari Passu Lien Debt Default, an “Event of Default” under the Equipment Lease Documents
or an “Event of Default” under the Commercial Building Loan Agreement, as applicable.

 

“CTA Parties
Standstill Period” means with respect to the Equipment Lessor and the Commercial Building Lender in connection with the
Going Concern Collateral that constitutes Equipment Lease Collateral and Commercial Building Loan Collateral, respectively, the
period of time commencing on the date when the other Lender Representatives and the Collateral Agent receive written notice from
a Lender Representative of a CTA Parties Event of Default pursuant to the Collateral Trust Agreement (such date, the “Standstill
Commencement Date”) and ending on the earliest of (x) the date that the Controlling Representative ceases to exercise
commercially reasonable efforts to identify a Going Concern Buyer or to direct the Collateral Agent to consummate a Going Concern
Sale, (y) the date that the Controlling Representative notifies in writing the Equipment Lessor and the Commercial Building
Lender it is no longer pursuing a Going Concern Sale and (z) that date that is 210 days after the Standstill Commencement
Date.

 

“CTA Parties Loan Documents” means,

 

(i) with respect
to the Pari Passu Lien Debt Representatives, Pari Passu Lien Debt Documents, the Pari Passu Lien Security Documents, and the Collateral
Trust Agreement, with the rights and remedies of the Collateral Agent in connection with any enforcement of Liens as provided in
the Collateral Trust Agreement, on behalf of itself and the other Pari Passu Lien Secured Parties, (ii) with respect to the
Equipment Lessor, the Equipment Lease Documents and (iii) with respect to the Commercial Building Lender, the Commercial Building
Loan Agreement and the Commercial Building Security Documents.

 

“Debtor Relief
Laws” means the Bankruptcy Code of the United States, and all other liquidation, conservatorship, bankruptcy, assignment
for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization or similar debtor relief laws
of the United States or other applicable jurisdictions from time to time in effect and affecting the rights of creditors generally.

 

“Debt Service”
means the principal of and premium (if any) and interest on the Bonds, including on the 2019 Bonds, for any period or payable at
any time, whether due on an Interest Payment Date or a Principal Payment Date.

 

“Debt Service Fund” means the fund
of that name established pursuant to the Bond Indenture.

 

“Default”
means any event that is, or with the passage of time or the giving of notice or both would be, an Event of Default.

 

“Default Rate”
with respect to a Bond, the interest rate borne by such Bond plus 1% per annum; provided that the Default Rate shall never exceed
the Maximum Rate.

 

“Deposit Agreement”
means the Security Deposit Agreement, substantially in the form attached to the Collateral Trust Agreement as Exhibit E, (with
such changes as may be reasonably requested by the Depository Bank as are customary for its role as a depository thereunder), to
be entered between the Company, the Collateral Agent, the ABL Agent (as defined in the Intercreditor Agreement), the Equipment
Lessor and the Commercial Building Lender and the Depository Bank, governing the bank accounts established pursuant thereto, as
the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time in accordance with
the term thereof. As of the Closing Date, no Deposit Agreement is required under the Collateral Trust Agreement and no Deposit
Agreement has been entered into pursuant thereto.

 

“Depository”
means any securities depository that is a clearing agency or corporation under federal and state law operating and maintaining,
with its participants or otherwise, a Book-Entry System to record ownership of Book-Entry interests in bonds, and to effect
transfers of Book-Entry interests in bonds in Book-Entry Form, and includes and means initially The Depository Trust Company (a
limited purpose trust company), New York, New York.

  

    20 

     

    

 

“Depository
Bank” means U.S. Bank National Association, as both a “securities intermediary” and a “bank”
under the Deposit Agreement.

 

“Designated
Non-Cash Consideration” means the fair market value of non-cash consideration received by the Company or a Restricted
Subsidiary in connection with an Asset Sale that is so designated as Designated Non-Cash Consideration pursuant to an Officer’s
Certificate, setting forth the basis of such valuation, less the amount of cash or Cash Equivalents received in connection
with a subsequent sale, redemption or repurchase of, or collection or payment on, such Designated Non-Cash Consideration.

 

“Designated
Office” means, as to the 2019 Bonds, initially, as to the Registrar and the Trustee, for Bond transfer/surrender purposes,
U.S. Bank National Association, Global Corporate Trust Services, 1350 Euclid Avenue, Suite 1100, Cleveland, Ohio 44115, and
thereafter such office as each may designate from time to time; provided, that any change in designation shall be effective not
sooner than the fifteenth day following the mailing by first-class mail of notice of that change to the Bond Issuer, the Company,
each Holder that is a registered owner not earlier than the fifth Business Day prior to that mailing, the Paying Agent and, in
the case of (i) the Registrar, to the Trustee and (ii) the Trustee, to the Registrar.

 

“Designated
Preferred Stock” means Preferred Stock of the Company, any Restricted Subsidiary thereof or any Parent Company (in each
case other than Disqualified Stock) that is issued for cash (other than to a Restricted Subsidiary or an employee stock ownership
plan or trust established by the Company or any of its Subsidiaries) and is so designated as Designated Preferred Stock, pursuant
to an Officer’s Certificate on or promptly after the issuance date thereof, the cash proceeds of which are excluded from
the calculation set forth in Section 6.01(a)(3) of the Bond Financing Agreement and as described in clause (a)(3) of
the covenant described in the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond
Financing Agreement—Covenants of the Company—Limitation on Restricted Payments.”

 

“Designated
Revolving Commitments” means any commitments to make loans or extend credit on a revolving basis to the Company or any
Restricted Subsidiary by any Person other than the Company or any Restricted Subsidiary that have been designated in an Officer’s
Certificate delivered to the Trustee as “Designated Revolving Commitments” until such time as the Company subsequently
delivers an Officer’s Certificate to the Trustee to the effect that such commitments will no longer constitute “Designated
Revolving Commitments”; provided that during such time, such Designated Revolving Commitments will be deemed an incurrence
of Indebtedness on such date and will be deemed outstanding for purposes of calculating the Fixed Charge Coverage Ratio, Total
Net Leverage Ratio, Senior Secured Net Leverage Ratio and the availability of any baskets pursuant to the Bond Financing Agreement.

 

“Development”
means the ownership, occupation, design, development, construction, system establishment, testing, start-up, commissioning, implementation,
optimization, repair, operation, maintenance and use of the Phase II Project through final completion of the Phase II Project as
determined by the Board of Directors.

 

“DIP Financing”
has the meaning given to such term in the Limited Offering Memorandum under the heading “SECURITY AND SOURCES OF PAYMENT
FOR THE 2019 BONDS AND OTHER PARI PASSU LIEN DEBT—Intercreditor Agreement—Insolvency or Liquidation Proceeding.”

 

“Direct Agreement”
means any agreement required to be entered into under the Specified Pari Passu Lien Debt Documents or as otherwise entered into
by the Company or any other Grantor, a counterparty to any material contract of the Company or such Grantor and the Collateral
Agent, that grants the consent of such material contract counterparty to the collateral assignment of the applicable material contract
to the Collateral Agent, including the SMS Direct Agreement.

 

“Direct Participant” means a participant
as defined in the Letter of Representations.

  

    21 

     

    

 

“Discharge
of ABL Obligations” means, with respect to any ABL Obligation, the repayment, prepayment, repurchase (including pursuant
to an offer to purchase), redemption, defeasance or other discharge of such Indebtedness, in any such case in whole or in part.

 

“Discharge
of Commercial Building Lender Obligations” means the payment in full in cash of the principal of and interest and premium
(if any) on all Commercial Building Lender Obligations and all other Commercial Building Lender Obligations that are outstanding
and unpaid at the time such principal and interest is paid (other than contingent indemnification obligations not then due).

 

“Discharge
of Equipment Lease Obligations” means the payment in full in cash of all Rent (as defined in the Equipment Lease) and
all other Equipment Lease Obligations that are outstanding and unpaid (other than contingent indemnification obligations not then
due).

 

“Discharge
of Fixed Asset Pari Passu Lien Obligations” means, except to the extent otherwise expressly provided in the
Intercreditor Agreement, the occurrence of each of the following clauses (a) through (c): (a) payment in full in
cash of the principal of and interest (including interest accruing on or after the commencement of any Insolvency or
Liquidation Proceeding, whether or not such interest would be allowed in such Insolvency or Liquidation Proceeding), on all
Indebtedness outstanding under the Fixed Asset Pari Passu Lien Debt Documents; (b) (i) payment in full in cash of
all the Secured Hedging Obligations (other than contingent indemnification obligations not then due) and the expiration or
termination of all outstanding transactions under the Hedge Agreements or (ii) the cash collateralization of all such
Hedging Obligations on terms satisfactory to each applicable Hedge Bank (or other arrangements satisfactory to each such
Hedge Bank shall have been made); and (c) termination or expiration of all commitments, if any, to extend credit that
would constitute Fixed Asset Pari Passu Lien Obligations.

 

“Discharge
of Pari Passu Lien Obligations” means the occurrence of all of the following: (a) termination or expiration of all
commitments to extend credit that would constitute Pari Passu Lien Debt; (b) with respect to each Series of Pari Passu
Lien Debt, either (i) payment in full in cash of the principal of and interest and premium (if any) on all Pari Passu Lien
Debt of such Series or (ii) there has been a legal defeasance or covenant defeasance pursuant to the terms of the applicable
Pari Passu Lien Documents for such Series of Pari Passu Lien Debt; (c) payment in full in cash of all other Pari Passu
Lien Obligations that are outstanding and unpaid at the time the Pari Passu Lien Debt is paid in full in cash; and (d) (i) payment
in full in cash of all Secured Hedging Obligations and the expiration or termination of all outstanding transactions under the
Hedge Agreements or (ii) the cash collateralization of all such Secured Hedging Obligations on terms satisfactory to each
applicable Hedge Bank (or other arrangements satisfactory to each such Hedge Bank shall have been made).

 

“Discharge
of Specified Pari Passu Lien Debt Obligations” means that the Pari Passu Lien Obligations pursuant to the Specified Pari
Passu Lien Debt Documents (other than any contingent indemnification obligations not then due) are no longer secured by, and no
longer required to be secured by, the Collateral pursuant to the terms of the Specified Pari Passu Lien Debt Documents.

 

“Disposition”
means, with respect to any Person, any sale, assignment (except as contemplated by any of the Pari Passu Lien Debt Documents,
the Equipment Lease or the Commercial Building Loan Agreement), conveyance, sale and leaseback, transfer, lease or other disposition
of any property of such Person to any other Person. “Dispose” has a correlative meaning.

   

    22 

     

    

 

“Disqualified
Stock” means, with respect to any Person, any Capital Stock of such Person which, by its terms, or by the terms of
any security into which it is convertible or for which it is redeemable or exchangeable, or upon the happening of any event,
matures or is mandatorily redeemable (other than (i) for any Qualified Equity Interests or (ii) solely as a result
of a change of control, asset sale, casualty, condemnation or eminent domain) pursuant to a sinking fund obligation or
otherwise, or is redeemable at the option of the holder thereof (other than for any Qualified Equity Interests or solely as a
result of a change of control, asset sale, casualty, condemnation or eminent domain), in whole or in part, in each case prior
to the date 91 days after the earlier of the maturity date of the Bonds or the date the Bonds are no longer outstanding; provided
that if such Capital Stock is issued pursuant to any plan for the benefit of future, current or former employees, directors,
officers, members of management, consultants or independent contractors (or their respective Controlled Investment Affiliates
or Immediate Family Members or any permitted transferees thereof) of the Company or its Subsidiaries or any Parent Company or
by any such plan to such employees, directors, officers, members of management, consultants or independent contractors (or
their respective Controlled Investment Affiliates or Immediate Family Members or any permitted transferees thereof), such
Capital Stock will not constitute Disqualified Stock solely because it may be required to be repurchased by the Company or
its Subsidiaries in order to satisfy applicable statutory or regulatory obligations or as a result of such employee’s,
director’s, officer’s, management member’s, consultant’s or independent contractor’s
termination, death or disability; provided, further that any Capital Stock held by any future, current or
former employee, director, officer, member of management, consultant or independent contractor (or their respective
Controlled Investment Affiliates or Immediate Family Members or any permitted transferees thereof) of the Company, any of its
Subsidiaries, any Parent Company, or any other entity in which the Company or a Restricted Subsidiary has an Investment and
is designated in good faith as an “affiliate” by the Board of Directors (or the compensation committee thereof),
in each case pursuant to any equity subscription or equity holders’ agreement, management equity plan or stock option
plan or any other management or employee benefit plan or agreement will not constitute Disqualified Stock solely because it
may be required to be repurchased by the Company or its Subsidiaries in order to satisfy applicable statutory or regulatory
obligations or as a result of such employee’s, director’s, officer’s, management member’s,
consultant’s or independent contractor’s termination, death or disability. For the purposes hereof, the aggregate
principal amount of Disqualified Stock will be deemed to be equal to the greater of its voluntary or involuntary liquidation
preference and maximum fixed repurchase price, determined on a consolidated basis in accordance with GAAP, and the
 “maximum fixed repurchase price” of any Disqualified Stock that does not have a fixed repurchase price will be
calculated in accordance with the terms of such Disqualified Stock as if such Disqualified Stock were purchased on any date
on which the Consolidated Total Debt or Consolidated Secured Debt, as applicable, will be required to be determined pursuant
to the Bond Financing Agreement, and if such price is based upon, or measured by, the fair market value of such Disqualified
Stock, such fair market value shall be determined in good faith by the Company.

 

“Dissemination
Agent” means U.S. Bank National Association in its capacity as dissemination agent under the Continuing Disclosure Agreement.

 

“Domestic
Subsidiary” means any direct or indirect Subsidiary of the Company that is organized or existing under the laws of the
United States, any state thereof or the District of Columbia.

 

“Electronic
Means” shall mean the following communications methods: e-mail, facsimile transmission, secure electronic transmission
containing applicable authorization codes, passwords and/or authentication keys issued by the Trustee, or another method or system
specified by the Trustee as available for use in connection with its services under the Bond Indenture.

 

“Eligible
Investments” for purposes of the Bonds, the Bond Indenture and the Bond Financing Agreement shall mean any of the following
investments, or any combination thereof, so long as such investments at the time of investment are legal investments under the
laws of the State of Arkansas for the moneys proposed to be invested therein:

 

(a)
  (a) direct obligations of the United States of America for the payment of which the full faith and credit of the
United States of America is pledged, including State and Local Government Series (“SLGS”) of such
direct obligations; (b) obligations issued by a person controlled or supervised by and acting as an agency or
instrumentality of the United States of America, the payment of the principal of, premium, if any, and interest on which is
fully guaranteed as a full faith and credit obligation of the United States of America (including any securities described in
(a) or (b) issued or held in book-entry form on the books of the Department of the Treasury of the United States of
America or Federal Reserve Bank); and (c) securities evidencing ownership of the right to payment of specific principal
or interest payments on an obligation described in (a) or (b) above, provided that such securities were created by
or on behalf of the issuer of the applicable obligation and are held in the custody of a bank or trust company having a
reported capital, surplus and undivided profits of at least $25,000,000 and a rating on its unsecured, unenhanced short-term
obligations in the highest short-term category by at least one Rating Agency, in a special account separate from the general
assets of such custodian (“Government Securities”);

  

    23 

     

    

 

 (b)
  Qualified Investments;

 

(c)  unsecured
certificates of deposit having maturities of not more than 365 days which are fully insured by the Federal Deposit Insurance Corporation
(“FDIC”) in one or more of the following institutions: banks, trust companies or savings and loan associations
(including without limitation, the Trustee or any bank affiliated with the Trustee) organized under the laws of the United States
of America or any state thereof, each bank, trust company or savings and loan association having a reported capital, surplus and
undivided profits of at least $25,000,000 and a rating on its unsecured, unenhanced short-term obligations in the highest short-term
category by at least one Rating Agency;

 

(d)  unsecured
and uninsured certificates of deposit having maturities of not more than 365 days in institutions described in clause (c) above,
provided the short-term obligations of such institution are rated in the highest short-term category by at least one Rating Agency;

 

(e)  any investment contract with a bank, trust company or savings and loan association having a reported capital, surplus and
undivided profits of at least $25,000,000 and a rating on its unsecured, unenhanced short-term obligations in the highest
short-term category by at least one Rating Agency, provided further that the investment contract shall contain a provision to
the effect that such investment contract can be terminated by the Trustee without penalty in the event the rating of the
institution falls below the highest short-term category by all of the Rating Agencies then rating such institution or such
institution defaults on the payment of any of its obligations thereunder or to the Company, unless such investment contract
is collateralized with Government Securities (as defined in clause (a) above) held by the Trustee or a third party
custodian acting as agent for the Trustee with a value, marked to market no less frequently than on a weekly basis, of at
least 102% of the principal amount invested under the investment contract or such rating is reinstated to the highest
short-term category by at least one Rating Agency on or prior to such termination date;

 

(f)   any
share in a money market mutual fund provided such fund is (i) rated at least “A” by S&P or the equivalent
by a Rating Agency or (ii) the entire investments of which are limited to investments described in clause (a) above;

 

 (g)  commercial paper rated in the highest short-term rating category by any Rating Agency;

 

(h)  U.S.
denominated deposit account, certificates of deposit and banker’s acceptances of any bank, trust company, or savings and
loan association, including the Trustee or their affiliates, which have a rating on their short-term certificates of deposit on
the date of purchase in one of the two highest short-term rating categories (without regard to any refinement or gradation of rating
category by numerical modifier or otherwise) assigned by any Rating Agency, and which mature not more than 360 days after the date
of purchase;

 

(i)   an
investment agreement, repurchase agreement or forward delivery agreement with a provider or a guarantor that has unsecured, unenhanced
long-term obligations rated at least “A-” or its equivalent by one or more of the Rating Agencies at the time such
agreement is entered into;

 

(j)   certificates
of deposit, bankers’ acceptances or interest-bearing time deposits that are made with the Trustee or with any member of the
Federal Deposit Insurance Corporation, provided that such investments are: (A) fully insured by the Federal Deposit Insurance
Corporation; (B) made with any bank (including the Trustee or any Affiliate thereof) having undivided capital and surplus
of at least $100,000,000, the debt obligations (or in the case of the principal bank holding company, debt obligations of the bank
holding company) of which are rated in the top 2 tier categories by at least one of the recognized rating agencies at the time
of purchase; or (C) continuously secured as to principal , to the extent not insured by the Federal Deposit Insurance Corporation,
by items listed above, or other marketable securities eligible as security for the deposit of trust funds under applicable regulations
of the Comptroller of the Currency of the United States of America, having a market value (exclusive of accrued interest) not less
than the amount of such deposit; and

   

    24 

     

    

 

(k)  Tax-Exempt
Obligations.

 

“EMU”
means the economic and monetary union as contemplated in the Treaty on European Union.

 

“Environmental
Laws” means all laws, regulations, ordinances, rules, orders, judgments, decrees, permits or other legal requirements
of any governmental authority, including, without limitation, any international, foreign, national, state, provincial, regional,
or local authority, relating to pollution, the protection of human health or safety relating to hazardous materials, the environment,
or natural resources, or to use, handling, storage, manufacturing, transportation, treatment, discharge, disposal or release of
hazardous or toxic substances or wastes, pollutants or contaminants.

 

“Environmental
Permit” means any permit, approval, identification number, license or other authorization required under any Environmental
Law.

 

“Equipment
Lease” means each of (i) Equipment Schedule No. 1, dated September 8, 2016, between the Equipment Lessor
and the Company and (ii) Equipment Schedule No. 2, dated December 16, 2016, between the Equipment Lessor and the
Company, in each case incorporating the terms of that certain Master Sub-sublease Agreement, dated as of September 8, 2016,
as the same has been amended, supplemented, assigned or otherwise modified prior to August 23, 2017 and as in effect on such
date and as may be further amended, supplemented, assigned or otherwise modified from time to time hereafter to the extent not
prohibited by the Intercreditor Agreement.

 

“Equipment
Lease Advance” means the sub-lease financings made by the Equipment Lessor under the Equipment Lease.

 

“Equipment
Lease Collateral” means any subleased interest in equipment or real property sold to the Equipment Lessor and leased
back by the Company in accordance with the Equipment Lease, in each case as described in, and as updated from time to time in accordance
with, the Equipment Lease.

 

“Equipment
Lease Documents” means the Equipment Lease, the Leasehold Mortgage, Assignment of Leases and Rents and Security Agreement
from the Company, as mortgagor, to the Equipment Lessor, as mortgagee, with the effective date of September 8, 2016, the Amended
and Restated Recognition of Leasehold and Security Interest, Nondisturbance and Attornment Agreement made November 17, 2016
among the Company, the City of Osceola, Arkansas, the Equipment Lessor and the Commercial Building Lender, the Option Agreement,
dated September 8, 2016, between the Company and the Equipment Lessor, the Amended and Restated Easement Agreement, dated
as of December 16, 2016, among City of Osceola, as grantor, the Company and the Equipment Lessor, the Amended and Restated
Environmental Indemnity Agreement, dated as of December 16, 2016, by the Company, Parent and the Equipment Lessor, the Continuing
Guaranty, dated as of September 8, 2016, made by Parent in favor of the Equipment Lessor, the Guaranty Affirmation Letter
delivered by Parent to the Equipment Lessor on December 16, 2016, and each of the other agreements, documents and instruments
providing for or evidencing any Equipment Lease Obligation, and any other document or instrument executed or delivered at any time
in connection with any Equipment Lease Obligations, in each case as the same has been amended, supplemented, assigned or otherwise
modified prior to the Closing Date and as in effect on the Closing Date and as may be further amended, supplemented, assigned or
otherwise modified from time to time hereafter to the extent not prohibited by the Intercreditor Agreement.

 

“Equipment
Lease Lien” means a Lien granted, or purported to be granted, by the Company to the Equipment Lessor in the Equipment
Lease Collateral to secure the Equipment Lease Obligations.

 

“Equipment
Lease Obligations” means all Rent (as defined in the Equipment Lease Documents), fees, deposits, payments of stipulated
loss value, late charges, reimbursement obligations and other amounts owing in connection with the Equipment Lease Advances issued
under the Equipment Lease Documents.

 

   

    25 

     

    

 

“Equipment Lease Proportion by Value”
means the net proceeds of a Going Concern Sale multiplied by the proportion of (x) $145,979,215, which is the
amount of Project Costs expended by the Company to acquire and construct the Equipment Lease Collateral, divided by
(y) $1,330,000,000, which is the total amount of Project Costs incurred by the Company as of August 23, 2017; provided
that such amount will not exceed the total amount of the outstanding and unpaid Equipment Lease Obligations.

 

“Equipment
Lessor” means SCF, as sub-sublessor under the Equipment Lease and servicer on behalf of other Persons.

 

“Equity Interests”
means, with respect to any Person, the Capital Stock of such Person and all warrants, options or other rights to acquire Capital
Stock of such Person, but excluding any debt security that is convertible into, or exchangeable for, Capital Stock of such Person.

 

“Equity Offering”
means any public or private sale of common equity or Preferred Stock of the Company or any Parent Company (excluding Disqualified
Stock), other than:

 

(1)  public
offerings with respect to the Company’s or any Parent Company’s common equity registered on Form S-4 or Form S-8;

 

 (2)  issuances to any Restricted Subsidiary of the Company; and

 

 (3)  any such public or private sale that constitutes an Excluded Contribution or Capex Equity.

 

“Escrowed
Proceeds” means the proceeds from the offering of any debt securities or other Indebtedness paid into an escrow account
with an independent escrow agent on the date of the applicable offering or incurrence pursuant to escrow arrangements that permit
the release of amounts on deposit in such escrow account upon satisfaction of certain conditions or the occurrence of certain events.
The term “Escrowed Proceeds” shall include any interest earned on the amounts held in escrow.

 

“Euroclear” means Euroclear Bank
S.A./N.V., as operator of the Euroclear system, and its successors.

 

“Euros” means the single currency
of participating member states of the EMU.

 

“Event of
Default” means, with respect to the Bonds, an Event of Default as described in Section 7.01 of the Bond Indenture,
with respect to the Bond Financing Agreement, an Event of Default as described in Article VII of the Bond Financing
Agreement, with respect to the Senior Secured Notes, an Event of Default pursuant to the Notes Indenture and, with respect to the
Term Loan Credit Agreement, an Event of Default as described therein, and with respect to an event of default under any other document
or agreement, the definition given to such term therein.

 

“Excess ABL
Obligations” means any Obligations that would constitute ABL Obligations if not for the ABL Cap Amount.

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations of the SEC promulgated
thereunder.

 

“Excluded
Account” means any deposit or securities account now or hereafter owned by the Company or any other Grantor that is
used solely by the Company or such Guarantor (a) as a payroll account so long as such payroll account is a zero balance
account, (b) as a petty cash account so long as the aggregate amount on deposit in all petty cash accounts of the
Company and all Guarantors does not exceed $50,000 at any one time for all such deposit accounts combined, (c) to hold
amounts required to be paid in connection with workers compensation claims, unemployment insurance, social security benefits
and other similar forms of governmental insurance benefits, (d) to hold amounts which are required to be pledged or
otherwise provided as security as required by law or pension requirement, (e) to hold cash and cash equivalents pledged
to secure Obligations under the ABL Facility consisting of reimbursement obligations in respect of letters of credit and
swing line loans (and/ or any obligations of lenders participating in the facilities under which such letters of credit are
issued and swing line loans made) without granting a Lien thereon to secure any other Obligations under the ABL Facility or
Lenders Debt or any Pari Passu Lien Obligations, (f) to hold cash and cash equivalents pledged to the Equipment Lessor
to secure Equipment Lease Obligations so long as the aggregate amount of cash and cash equivalents so pledged and on deposit
in or credited to all such accounts does not exceed $6,672,335 at any one time or (g) as a withholding tax or fiduciary
account.

 

    26 

     

    

 

“Excluded Assets” means the collective
reference to:

 

(1) 
any lease, license, contract or agreement to which the Company or any other Grantor is a party, and any of its rights or
interest thereunder, if and to the extent that a security interest is prohibited by or in violation of (i) any law,
rule or regulation applicable to the Company or such Guarantor, or (ii) a term, provision or condition of any such
lease, license, contract or agreement (unless such law, rule, regulation, term, provision or condition would be rendered
ineffective with respect to the creation of the security interest hereunder pursuant to Sections 9-406, 9-407, 9-408 or 9-409
of the Uniform Commercial Code (or any successor provision or provisions) of any relevant jurisdiction or any other
applicable law (including the Bankruptcy Code) or principles of equity); provided however that the Excluded Assets
shall not include (and security interest under the Security Documents shall attach) immediately at such time as the
contractual or legal prohibition shall no longer be applicable and to the extent severable, shall attach immediately to any
portion of such lease, license, contract or agreement not subject to the prohibitions specified in subclauses (i) or
(ii) above; provided further that the exclusions referred to in this clause (1) of this definition shall not
include any Proceeds (as defined in the Uniform Commercial Code (or any successor provision or provisions) of any relevant
jurisdiction) of any such lease, license, contract or agreement;

 

(2)  any
portion of Capital Stock that is voting Capital Stock of any Foreign Subsidiary or CFC Holdco to the extent such portion of Capital
Stock represents voting power in excess of 65% of the total combined voting power of all classes of voting stock (within the meaning
of Treasury Regulations section 1.956-2(c)(2)) of such Foreign Subsidiary or CFC Holdco;

 

(3)  any
 “intent-to-use” application for registration of a trademark filed pursuant to Section 1(b) of the Lanham
Act, 15 U.S.C. § 1051, prior to the filing of a “Statement of Use” pursuant to Section 1(d) of the Lanham
Act or an “Amendment to Allege Use” pursuant to Section 1(c) of the Lanham Act with respect thereto, solely
to the extent, if any, that, and solely during the period, if any, in which, the grant of a security interest therein would impair
the validity or enforceability of any registration that issues from such intent-to-use application under applicable federal law;

 

 (4)  any equity interests in, and the assets and properties of, an Excluded Subsidiary; or

 

 (5)  Excluded Accounts.

 

“Excluded
Capital Expenditures” means any Capital Expenditure (whether or not required) made solely for maintenance, replacement
or environmental, human health or safety or other regulatory purposes and not in connection with the incurrence of Expansion Capital
Expenditures.

 

“Excluded
Contribution” means net cash proceeds, the fair market value of marketable securities or the fair market value of Qualified
Proceeds received by the Company from:

 

 (1)  contributions to its common equity capital;

 

(2)  dividends,
distributions, fees and other payments from any joint ventures that are not Restricted Subsidiaries; and

 

(3)  the sale (other than to a Restricted Subsidiary of the Company or to any management equity plan or stock option plan or any
other management or employee benefit plan or agreement of the Company) of Capital Stock (other than Disqualified Stock and
Designated Preferred Stock) of the Company; in each case, designated as Excluded Contributions pursuant to an Officer’s
Certificate or that are excluded from the calculation set forth in Section 6.01(a)(3) of the Bond Financing
Agreement and as described in clause (a)(3) of the covenant described in the Limited Offering Memorandum under the
heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the
Company— Limitation on Restricted Payments.”

 

    27 

     

    

  

 

“Excluded
Subsidiary” means (1) any Subsidiary that is not a Wholly-Owned Subsidiary of the Company or a Subsidiary Guarantor,
(2) any Foreign Subsidiary, (3) any CFC Holdco, (4) any Domestic Subsidiary that is a direct or indirect Subsidiary
of any CFC, (5) any Subsidiary, including any regulated entity that is subject to net worth or net capital or similar capital
and surplus restrictions, that is prohibited or restricted by applicable law or by contractual obligation (including in respect
of assumed Indebtedness permitted hereunder) existing on the Closing Date (or, with respect to any Subsidiary acquired by the Company
or a Restricted Subsidiary after the Closing Date (and so long as such contractual obligation was not incurred in contemplation
of such acquisition), on the date such Subsidiary is so acquired) from providing a Guarantee (including any Broker-Dealer Regulated
Subsidiary), or if such Guarantee would require governmental (including regulatory) or third party (other than the Company or any
Guarantor or their respective Subsidiaries) consent, approval, license or authorization, (6) any special purpose vehicle (or
similar entity) or any Securitization Subsidiary, (7) any Captive Insurance Subsidiary, (8) any not-for-profit Subsidiary,
(9) any Subsidiary that is not a Significant Subsidiary, (10) any other Subsidiary with respect to which, in the reasonable
judgment of the Company, the burden or cost (including any material adverse tax consequences) of providing the Guarantee will outweigh
the benefits to be obtained by the Holders therefrom and (11) each Unrestricted Subsidiary; provided that any such Subsidiary
that is an Excluded Subsidiary pursuant to clause (9) or (10) above will cease to be an Excluded Subsidiary at any time
such Subsidiary guarantees Indebtedness under the Term Loan Credit Agreement, the ABL Facility or Capital Markets Indebtedness
of the Company or any other Subsidiary Guarantor.

 

“Expansion
Capital Expenditures” means (i) any Capital Expenditures carried out for the purpose of increasing the earnings
capacity of the Company or a Subsidiary Guarantor or (ii) any Investment in a Restricted Subsidiary made pursuant to clause
(26) of the definition of “Permitted Investments;” provided further that Expansion Capital Expenditures shall
include any Phase II Project Costs whether or not such Phase II Project Costs are considered capital expenditures in accordance
with GAAP. Excluded Capital Expenditures shall be deemed not to be Expansion Capital Expenditures.

 

“Extraordinary
Services” or “Extraordinary Expenses” means all services rendered and all reasonable expenses incurred
by the Trustee under the Bond Indenture, other than Ordinary Services and Ordinary Expenses.

 

“fair market
value” means, with respect to any asset or liability, the fair market value of such asset or liability as determined
by the Company in good faith.

 

“Financial
Officer” means the chief financial officer, accounting officer, treasurer, controller or other senior financial or accounting
officer of the Company, as appropriate.

 

“First Specified
Pari Passu Lien Debt Threshold Date” means the date on which the sum of (1) the outstanding principal amount of
the term loans under the Specified Pari Passu Lien Debt Documents (as long as the amount of funded term loans is not less than
25% of the aggregate term loan commitments thereunder on the Initial Funding Date (but in no event unless and until the amount
of funded term loans exceeds $275.0 million) plus (2) from and after the occurrence of the Initial Funding Date, the aggregate
term loan commitments subject to the Specified Commitment Condition under the Specified Pari Passu Lien Debt Documents exceeds
(1) 50% of the aggregate outstanding principal amount of all Pari Passu Lien Debt or (2) the aggregate outstanding principal
amount of the largest Series of Pari Passu Lien Debt (other than, for purposes of this clause (2), such loans and such commitments
under the Specified Pari Passu Lien Debt Documents).

 

“Fixed Asset Accounts” has the
meaning ascribed to the term “Accounts” in the Deposit Agreement.

 

“Fixed Asset
Collateral Proceeds Account” means a deposit or securities account which will be used solely for deposit of identifiable
proceeds of Fixed Asset Priority Collateral prior to the date the Deposit Agreement becomes effective.

  

    28 

     

    

  

“Fixed Asset
General Intangibles” means all general intangibles (including intellectual property) which are not ABL Priority Collateral.

 

“Fixed Asset
Mortgages” means a collective reference to each mortgage, deed of trust and any other document or instrument under which
any Lien on real property owned or leased by any Grantor is granted to secure any Fixed Asset Pari Passu Lien Obligations or under
which rights or remedies with respect to any such Liens are governed.

 

“Fixed Asset
Pari Passu Lien Claimholders” means, at any relevant time, the holders of Fixed Asset Pari Passu Lien Obligations at
that time, including the Holders, the Trustee, any other Pari Passu Lien Debt Representative (as defined in the Collateral Trust
Agreement) and the other Pari Passu Lien Secured Parties and the Collateral Agent, and the successors, replacements and assigns
of each of the foregoing, and shall include, without limitation, any former Collateral Agent, Holder, Trustee and other Pari Passu
Lien Debt Representative and Pari Passu Lien Secured Parties to the extent that any Obligations owing to such Persons were incurred
while such Persons were Collateral Agent, Holder, Trustee, Pari Passu Lien Debt Representative or Pari Passu Lien Secured Parties,
as applicable, and such Obligations have not been paid or satisfied in full.

 

“Fixed Asset
Pari Passu Lien Collateral Documents” means the Collateral Trust Agreement, the “Collateral Documents” (as
defined in the Term Loan Credit Agreement), the Security Documents and any other agreement, document or instrument pursuant to
which a Lien is granted securing any Fixed Asset Pari Passu Lien Obligations or under which rights or remedies with respect to
such Liens are governed (other than the Intercreditor Agreement).

 

“Fixed Asset
Pari Passu Lien Debt Documents” means (a) the Term Loan Credit Agreement, the Notes Indenture, the Senior Secured
Notes, the Bond Financing Agreement, any Specified Pari Passu Lien Debt Documents, any other indenture, notes, credit agreement
or other agreement or instrument pursuant to which any Pari Passu Lien Debt (as defined in the Collateral Trust Agreement) is incurred,
the Fixed Asset Pari Passu Lien Collateral Documents and the Intercreditor Agreement and (b) each of the other agreements,
documents and instruments providing for or evidencing any other Fixed Asset Pari Passu Lien Obligation, and any other document
or instrument executed or delivered at any time in connection with any Fixed Asset Pari Passu Lien Obligations, including any intercreditor
or joinder agreement among holders of Fixed Asset Pari Passu Lien Obligations to the extent such are effective at the relevant
time, as each may be amended, restated, supplemented, modified, renewed or extended, replaced or Refinanced from time to time to
the extent permitted pursuant to the Intercreditor Agreement.

 

“Fixed Asset Pari Passu Lien Obligations”
means:

 

(1)  all
Obligations under the Notes Indenture, the Senior Secured Notes, the Term Loan Credit Agreement, the Specified Pari Passu Lien
Debt Documents and other Obligations in respect of Pari Passu Lien Debt (including Obligations under the Bond Financing Agreement
and the Series 2019 Note);

 

 (2)  all Secured Hedging Obligations; and

 

(3)  to
the extent any payment with respect to any Fixed Asset Pari Passu Lien Obligation (whether by or on behalf of any Grantor, as proceeds
of security, enforcement of any right of setoff or otherwise) is declared to be a fraudulent conveyance or a preference in any
respect, set aside or required to be paid to a debtor in possession, any ABL Claimholders, receiver or similar Person, then the
obligation or part thereof originally intended to be satisfied shall, for the purposes of the Intercreditor Agreement and the rights
and obligations of the ABL Claimholders and the Fixed Asset Pari Passu Lien Claimholders, be deemed to be reinstated and outstanding
as if such payment had not occurred. To the extent that any interest, fees, expenses or other charges (including Post-Petition
Interest) to be paid pursuant to the Fixed Asset Pari Passu Lien Debt Documents are disallowed by order of any court, including
by order of a court of competent jurisdiction presiding over an Insolvency or Liquidation Proceeding, such interest, fees, expenses
and charges (including Post-Petition Interest) shall, as between the ABL Claimholders and the Fixed Asset Pari Passu Lien Claimholders,
be deemed to continue to accrue and be added to the amount to be calculated as the “Fixed Asset Pari Passu Lien Obligations.”
For purposes of the Bond Financing Agreement, and for the avoidance
of doubt, “Fixed Asset Pari Passu Lien Obligations” includes (i) Obligations of the Company and the other Grantors
under the Bond Financing Agreement or any of the Security Documents, (ii) Secured Hedging Obligations, and (iii) any
Other Pari Passu Lien Obligations.

   

    29 

     

    

  

“Fixed Asset
Priority Collateral” means the following of any Grantor: (i) Equipment (as defined in the UCC); (ii) Real Estate
Assets; (iii) intellectual property; (iv) Equity Interests in all direct Subsidiaries of any Grantor; (v) intercompany
indebtedness of the Company and its Subsidiaries; (vi) all other assets of any Grantor, whether real, personal or mixed (including
the Revenue Account and other Fixed Asset Accounts and the Fixed Asset Collateral Proceeds Account), in each case, not constituting
ABL Priority Collateral prior to the Discharge of ABL Obligations; (vii) to the extent evidencing, governing, securing or
otherwise reasonably related to any of the foregoing, all documents, general intangibles, instruments, commercial tort claims,
letters of credit, letter-of credit-rights and supporting obligations; provided, however, that to the extent any of the foregoing
also evidence, govern, secure or otherwise reasonably relate to any ABL Priority Collateral only that portion that evidences, governs,
secures or reasonably relates to Fixed Asset Priority Collateral shall constitute Fixed Asset Priority Collateral; (viii) all
books, records and documents related to the foregoing (including databases, customer lists and other records, whether tangible
or electronic, which contain any information relating to any of the foregoing); (ix) insurance and claims against third parties
to the extent arising on account of Fixed Asset Priority Collateral (excluding, however, the proceeds of and payments under all
policies of business interruption insurance); and (x) all proceeds and products of any or all of the foregoing in whatever
form received, but excluding any property that is directly acquired prior to the commencement of any case or proceeding under the
Bankruptcy Code or any similar Bankruptcy Law with cash proceeds of any Fixed Asset Priority Collateral and does not otherwise
constitute Fixed Asset Priority Collateral upon its acquisition. Subject to certain provisions of the Intercreditor Agreement,
upon a Discharge of ABL Obligations, all ABL Priority Collateral shall become Fixed Asset Priority Collateral.

 

“Fixed
Charge Coverage Ratio” means, with respect to any Test Period, the ratio of (1) Consolidated EBITDA of the
Company for such Test Period to (2) the Fixed Charges of the Company and its Restricted Subsidiaries for such Test
Period. In the event that the Company or any Restricted Subsidiary incurs, assumes, guarantees, redeems, repays, retires or
extinguishes any Indebtedness (other than Indebtedness incurred or repaid under any revolving credit facility or line of
credit unless such Indebtedness has been permanently repaid and not replaced) or issues, repurchases or redeems Disqualified
Stock or Preferred Stock or establishes or eliminates any Designated Revolving Commitments, in each case, subsequent to the
commencement of the period for which the Fixed Charge Coverage Ratio is being calculated but prior to or simultaneously with
the event for which the calculation of the Fixed Charge Coverage Ratio is made (the “Fixed Charge Coverage Ratio
Calculation Date”), then the Fixed Charge Coverage Ratio will be calculated giving pro forma effect to such
incurrence, assumption, guarantee, redemption, repayment, retirement or extinguishment of Indebtedness or such issuance,
repurchase or redemption of Disqualified Stock or Preferred Stock, as if the same had occurred at the beginning of the most
recently ended Test Period (and (1) for the purposes of the numerator of the Total Net Leverage Ratio and the Senior
Secured Net Leverage Ratio, as if the same had occurred on the last day of the most recently ended Test Period and
(2) for all purposes, as if Indebtedness in the full amount of any undrawn Designated Revolving Commitments had been
incurred thereunder throughout such period); provided, however, that at the election of the Company, the pro
forma calculation will not give effect to any Indebtedness incurred or Disqualified Stock or Preferred Stock issued on
the Fixed Charge Coverage Ratio Calculation Date pursuant Section 6.03(b) of the Bond Financing Agreement (other
than clause (15) thereof or Indebtedness secured pursuant to clause (4) of the definition of Permitted Liens in the case
of the Senior Secured Net Leverage Ratio) and as described in the second paragraph (other than clause (15) thereof or
Indebtedness secured pursuant to clause (4) of the definition of Permitted Liens in the case of the Senior Secured Net
Leverage Ratio) of the covenant described in the Limited Offering Memorandum under the heading “FINANCING FOR THE
TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of Borrower— Limitation on Incurrence of Indebtedness
and Issuance of Disqualified Stock and Preferred Stock.” For purposes of making the computation referred to above, any
Specified Transaction that has been consummated by the Company or any Restricted Subsidiary during any Test Period or
subsequent to such Test Period and on or prior to or simultaneously with the Fixed Charge Coverage Ratio Calculation Date
will be calculated on a pro forma basis assuming that all such Specified Transactions (and the change in any
associated fixed charge obligations and the change in Consolidated EBITDA resulting therefrom) had occurred on the first day
of the Test Period. If since the beginning of such Test Period any Person that subsequently became a Restricted Subsidiary or
was merged, amalgamated or consolidated with or into the Company or any Restricted Subsidiary since the beginning of such
Test Period will have made any Specified Transaction that would have required adjustment pursuant to this definition, then the Fixed Charge Coverage
Ratio will be calculated giving pro forma effect thereto for such Test Period as if such Specified Transaction had occurred
at the beginning of the most recently ended Test Period. For purposes of this definition in the Bond Financing Agreement,
whenever pro forma effect is to be given to any Specified Transaction, the pro forma calculations will be made in
good faith by a Financial Officer of the Company and may include, for the avoidance of doubt, the amount of “run-rate”
cost savings, operating expense reductions and synergies projected by the Company in good faith to result from or relating to any
Specified Transaction which is being given pro forma effect that have been realized or are expected to be realized and for
which the actions necessary to realize such cost savings, operating expense reductions and synergies are taken or with respect
to which substantial steps have been taken or are expected to be taken (in the good faith determination of the Company) no later
than twenty four (24) months after the date of any such Specified Transaction (in each case as though such cost savings, operating
expense reductions and synergies had been realized on the first day of the applicable period and as if such cost savings, operating
expense reductions and synergies were realized for the entirety of such period). For the purposes of the Bond Financing Agreement,
 “run-rate” means the full recurring benefit for a period that is associated with any action taken or with respect
to which substantial steps have been taken or are expected to be taken (including any savings expected to result from the elimination
of a public target’s compliance costs with public company requirements), net of the amount of actual benefits realized during
such period from such actions. If any Indebtedness bears a floating rate of interest and is being given pro forma effect,
the interest on such Indebtedness will be calculated as if the rate in effect on the Fixed Charge Coverage Ratio Calculation Date
had been the applicable rate for the entire period (taking into account any Hedging Obligations applicable to such Indebtedness).
Interest on Indebtedness that may optionally be determined at an interest rate based upon a factor of a prime or similar rate,
a eurocurrency interbank offered rate, or other rate, will be deemed to have been based upon the rate actually chosen, or, if none,
then based upon such optional rate chosen as the Company may designate.

   

    30 

     

    

  

“Fixed Charge
Coverage Ratio Calculation Date” has the meaning ascribed to such term in the definition of “Fixed Charge Coverage
Ratio.”

 

“Fixed Charges” means, with respect
to any Person for any period, the sum of, without duplication:

 

 (1)   Consolidated Interest Expense of such Person for such period;

 

(2)   all cash dividends or other cash distributions paid (excluding items eliminated in consolidation) on any series of Preferred
Stock during such period; and

 

(3)   all
cash dividends or other cash distributions paid (excluding items eliminated in consolidation) on any series of Disqualified Stock
during such period.

 

“Foreign Subsidiary”
means any direct or indirect Restricted Subsidiary of the Company that is not a Domestic Subsidiary.

 

“Funded Debt” means,
with respect to any specified Person, any indebtedness of such Person (excluding accrued expenses and trade payables), whether
or not contingent:

 

 (1)    in respect of borrowed money or advances; or

 

(2)    evidenced
by indentures, bonds, notes, debentures, loan agreements or similar instruments. For the avoidance of doubt, “Funded Debt”
shall not include Secured Hedging Obligations.

 

“GAAP”
means generally accepted accounting principles in the United States of America set forth in the opinions and pronouncements of
the Accounting Principles Board of the American Institute of Certified Public Accountants and statements and pronouncements of
the Financial Accounting Standards Board or in such other statements by such other entity as have been approved by a significant
segment of the accounting profession, as in effect from time to time. Notwithstanding any other provision contained herein, (i) the
amount of any Indebtedness under GAAP with respect to Capitalized Lease Obligations and Attributable Indebtedness shall be determined
in accordance with the definition of Capitalized Lease Obligations and Attributable Indebtedness, respectively and (ii) all
terms of an accounting or financial nature used herein shall be construed, and all computations of amounts and ratios referred to herein shall be made,
without giving effect to any election under Financial Accounting Standards Board Accounting Standards Codification 825 (or any
other Financial Accounting Standard having a similar result or effect) to value any Indebtedness or other liabilities of the Company
or any of the Company’s Subsidiaries at “fair value,” as defined therein.

  

    31 

     

    

 

“Going
Concern” means that the Project facility is producing any commercially saleable product and capable of operating
as a going concern, as determined in the reasonable discretion of the Controlling Representative.

 

“Going
Concern Buyer” means any purchaser, or potential purchaser, of the Project, that is not an Affiliate of any Grantor,
and that intends, as determined in good faith by the Controlling Representative, to continue to operate the Project as a Going
Concern following the completion of the sale to it of Project assets or the Capital Stock of the Company.

 

“Going
Concern Collateral” means all of the Collateral except for the ABL Priority Collateral, and in any event including
the Equipment Lease Collateral and the Commercial Building Collateral.

 

“Going
Concern Sale” means the sale of the Project (whether through a sale of the Project assets or the sale of the Company’s
Capital Stock) to a Going Concern Buyer.

 

“Governmental
Authority” means the government of the United States or any other nation, or of any political subdivision thereof, whether
state, local, or otherwise, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising
executive, legislative, judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including
any supra-national bodies such as the European Union or the European Central Bank).

 

“Government Securities” has the
meaning given to such term in the definition of “Eligible Investments.”

 

“Grantor”
means, for the purposes of the Collateral Trust Agreement or the Intercreditor Agreement, the Company, Parent, the Guarantors and
any other Person (if any) that at any time provides collateral security for any Pari Passu Lien Obligations, Equipment Lease Obligations
or Commercial Building Lender Obligations; and, for the purposes of the Bond Financing Agreement means the Company, Parent and
any other Guarantor.

 

“guarantee”
means a guarantee (other than by endorsement of negotiable instruments for collection in the ordinary course of business or consistent
with industry practice), direct or indirect, in any manner (including letters of credit and reimbursement agreements in respect
thereof), of all or any part of any Indebtedness or other obligations.

 

“Guarantee”
means the guarantee by any Person of the Company’s Obligations under the Bond Financing Agreement and the Series 2019
Note.

 

“Guarantor” means Parent (or any
successor thereof) and the Subsidiary Guarantors.

 

“Hazardous
Materials” means all explosive or radioactive substances or wastes, and all other substances, wastes, pollutants and
contaminants and chemicals in any form, including petroleum or petroleum distillates, asbestos or asbestos- containing materials,
polychlorinated biphenyls, radon gas and infectious or medical wastes, to the extent any of the foregoing are regulated pursuant
to, or can form the basis for liability under, any Environmental Law.

 

“Hedge Agreement”
means any agreement governing Hedging Obligations; provided that the counterparty thereto has delivered a Collateral Trust
Joinder in respect thereof under the Collateral Trust Agreement. The term “Hedge Agreement” shall include both any
 “master agreement” and any related transaction and the related confirmations that are subject to the terms and conditions
of, or governed by, any Hedge Agreement; it being understood and agreed that a Collateral Trust Joinder shall only be required
once for each master agreement and shall not be required for each individual transaction or confirmation thereunder.

 

 

    32 

     

    

 

“Hedge Bank”
means any Person that is an Agent, a Lender, an Arranger (as each such term is defined in the Term Loan Credit Agreement) or an
Affiliate of any of the foregoing that delivers a Collateral Trust Joinder, whether or not such Person subsequently ceases to be
an Agent, a Lender, an Arranger or an Affiliate of any of the foregoing.

 

“Hedging
Obligations” means, with respect to any Person, the obligations of such Person under any interest rate swap agreement,
interest rate cap agreement, interest rate collar agreement, commodity swap agreement, commodity cap agreement, commodity collar
agreement, foreign exchange contract, currency swap agreement or similar agreement providing for the transfer, modification or
mitigation of interest rate, currency, commodity risks or equity risks either generally or under specific contingencies. For the
avoidance of doubt, any Permitted Convertible Indebtedness Call Transaction will not constitute Hedging Obligations.

 

“Immediate
Family Members” means with respect to any individual, such individual’s child, stepchild, grandchild or more remote
descendant, parent, stepparent, grandparent, spouse, former spouse, qualified domestic partner, sibling, mother-in- law, father-in-law,
son-in-law and daughter- in-law (including, in each case, adoptive relationships) and any trust, partnership or other bona fide
estate planning vehicle the only beneficiaries of which are any of the foregoing individuals or any private foundation or fund
that is controlled by any of the foregoing individuals or any donor-advised fund of which any such individual is the donor.

 

“Incur”
means issue, assume, enter into any guarantee of, incur or otherwise become liable for and the terms “Incurs”,
 “Incurred” and “Incurrence” shall have a correlative meaning.

 

“Incremental
Amounts” has the meaning assigned to such term in the definition of “Refinancing Indebtedness.”

 

“Indebtedness” means, with respect
to any Person, without duplication:

 

(1) any
indebtedness (including principal and premium) of such Person, whether or not contingent:
(a) in respect of borrowed money; (b) evidenced
by bonds, notes, debentures or similar instruments or letters of credit or bankers’ acceptances (or, without
duplication, reimbursement agreements in respect thereof); (c) representing the deferred and unpaid balance of the
purchase price of any property (including Capitalized Lease Obligations and Sale and Lease-Back Transactions other than
Specified Sale and Lease-Back Transactions) due more than twelve months after such property is acquired, except (i) any
such balance that constitutes an obligation in respect of a commercial letter of credit, a trade payable or similar
obligation to a trade creditor, in each case accrued in the ordinary course of business or consistent with industry practice
and (ii) any earn-out obligations until such obligation is reflected as a liability on the balance sheet (excluding any
footnotes thereto) of such Person in accordance with GAAP and is not paid within 60 days after becoming due and payable;
(d) representing the net obligations under any Hedging Obligations; or (e) Attributable Indebtedness; if and to the
extent that any of the foregoing Indebtedness (other than obligations in respect of letters of credit and Hedging
Obligations) would appear as a liability upon a balance sheet (excluding the footnotes thereto) of such Person prepared in
accordance with GAAP; provided that Indebtedness of any Parent Company appearing upon the balance sheet of the Company
solely by reason of push-down accounting under GAAP will be excluded;

 

(2) 
to the extent not otherwise included, any obligation by such Person to be liable for, or to pay, as obligor, guarantor
or otherwise, on the obligations of the type referred to in clause (1) of this definition of a third Person (whether or
not such items would appear upon the balance sheet of such obligor or guarantor), other than by endorsement of negotiable
instruments for collection in the ordinary course of business or consistent with industry practice; and

 

 

    33 

     

    

  

(3)  to
the extent not otherwise included, the obligations of the type referred to in clause (1) of this definition of a third
Person secured by a Lien on any asset owned by such first Person, whether or not such Indebtedness is assumed by such first
Person; provided that the amount of such Indebtedness will be the lesser of (i) the fair market value of such
asset at such date of determination and (ii) the amount of such Indebtedness of such other Person; provided that
notwithstanding the foregoing, Indebtedness will be deemed not to include (a) Contingent Obligations incurred in
the ordinary course of business or consistent with industry practice (including any Contingent Obligations issued in
connection with operating licenses or permits), (b) reimbursement obligations under commercial letters of credit
(provided that unreimbursed amounts under commercial letters of credit will be counted as Indebtedness three
(3) Business Days after such amount is drawn), (c) obligations under or in respect of Qualified Securitization
Facilities; (d) accruals for payroll and other liabilities accrued in the ordinary course of business, and those accrued
in connection with the Management Services Agreements, (e) deferred or prepaid revenues, (f) asset retirement
obligations and obligations in respect of reclamation and workers compensation (including pensions and retiree medical care)
and (g) obligations in connection with a Specified Sale and Lease-Back Transaction; provided, further that
Indebtedness will be calculated without giving effect to the effects of Accounting Standards Codification Topic No. 815,
Derivatives and Hedging, and related interpretations to the extent such effects would otherwise increase or decrease an
amount of Indebtedness for any purpose under the Bond Financing Agreement as a result of accounting for any embedded
derivatives created by the terms of such Indebtedness.

 

“Independent
Assets or Operations” means, with respect to any Parent Company, that Parent Company’s total assets, revenues,
income from continuing operations before income taxes and cash flows from operating activities (excluding in each case amounts
related to its investment in the Company and the Restricted Subsidiaries), determined in accordance with GAAP and as shown on the
most recent balance sheet of such Parent Company, is more than 3.00% of such Parent Company’s corresponding consolidated
amount.

 

“Independent
Financial Advisor” means an accounting, appraisal, investment banking firm or consultant of nationally recognized standing
that is, in the good faith judgment of the Company, qualified to perform the task for which it has been engaged.

 

“Indirect
Participant” means a Person utilizing the Book-Entry System of the Depository by, directly or indirectly, clearing through
or maintaining a custodial relationship with a Direct Participant.

 

“Initial Funding
Date” means the first date on which both (a) the initial advance(s) of term loans has been made under the Specified
Pari Passu Lien Debt Documents and (b) the only conditions to further advances of term loans under the Specified Pari Passu
Lien Debt Documents are conditions precedent substantially similar to the conditions precedent set forth in the Original KfW Credit
Agreement (such condition, the “Specified Commitment Condition”).

 

“Insolvency
or Liquidation Proceeding” means (a) any voluntary or involuntary case or proceeding under the Bankruptcy Code with
respect to the Company or any other Grantor, (b) any other voluntary or involuntary insolvency, reorganization or bankruptcy
case or proceeding, or any receivership, liquidation, reorganization or other similar case or proceeding with respect to the Company
or any other Grantor or with respect to any of its assets, (c) any liquidation, dissolution, reorganization or winding up
of the Company or any other Grantor whether voluntary or involuntary and whether or not involving insolvency or bankruptcy or (d) any
assignment for the benefit of creditors or any other marshalling of assets and liabilities of the Company or any other Grantor.

 

“Intercreditor
Agreement” means that intercreditor agreement dated as of August 23, 2017 by the Collateral Agent, on its own behalf
and on behalf of the Trustee, the trustee for the Senior Secured Notes, the holders of the Senior Secured Notes, the Bondholders
and other Secured Parties, and the ABL Agent, on its own behalf and on behalf of the lenders under the ABL Facility and any other
Lenders Debt (together with the Collateral Agent, the “Applicable Collateral Agents”), the Equipment Lessor, the Commercial
Building Lender, the Company and the other Grantors, as amended, restated, supplemented or otherwise modified from time to time
in accordance with the terms thereof.

 

“Interest
Account” means the account of that name established in the Debt Service Fund pursuant to Section 5.01(a) of
the Bond Indenture.

 

“Interest
Payment Date” or “Interest Payment Dates” means, with respect to the 2019 Bonds, each March 1
and September 1 commencing September 1, 2019.

  

    34 

     

    

 

“Inventory” has the meaning given
to such term in Article 9 of the UCC.

 

“Investment Grade Rating”
means a rating equal to or higher than Baa3 (or the equivalent) by Moody’s and BBB- (or the equivalent) by S&P, or an
equivalent rating by any other Rating Agency selected by the Company.

 

“Investment Grade Securities” means:

 

(1)  securities
issued or directly and fully guaranteed or insured by the United States government or any agency or instrumentality thereof (other
than Cash Equivalents);

 

(2)  debt
securities or debt instruments with an Investment Grade Rating, but excluding any debt securities or debt instruments constituting
loans or advances among the Company and its Subsidiaries;

 

(3)  investments
in any fund that invests substantially all of its assets in investments of the type described in clauses (1) and (2) of
this definition which fund may also hold immaterial amounts of cash pending investment or distribution; and

 

(4)  corresponding
instruments in countries other than the United States customarily utilized for high quality investments.

 

“Investments”
means, with respect to any Person, all investments by such Person in other Persons (including Affiliates) in the form of loans
(including guarantees), advances or capital contributions (excluding accounts receivable, credit card and debit card receivables,
trade credit, advances to customers, commission, travel and similar advances to employees, directors, officers, members of management,
consultants and independent contractors, in each case made in the ordinary course of business or consistent with industry practice)
or purchases or sales or other dispositions for consideration of Indebtedness, Equity Interests or other securities issued by
any other Person. For purposes of the definitions of “Permitted Investments” and “Unrestricted Subsidiary”
and the covenant contained in Section 6.01 of the Bond Financing Agreement and described in the Limited Offering Memorandum
under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the Company—Limitation
on Restricted Payments;” (1) “Investments” will include the portion (proportionate to the Company’s
Equity Interest in such Subsidiary) of the fair market value of the net assets of a Subsidiary of the Company at the time that
such Subsidiary is designated an Unrestricted Subsidiary; provided that upon a redesignation of such Subsidiary as a Restricted
Subsidiary, the Company will be deemed to continue to have a permanent “Investment” in an Unrestricted Subsidiary
in an amount (if positive) equal to: (a) the Company’s “Investment” in such Subsidiary at the time of such
redesignation; minus (b) the portion (proportionate to the Company’s Equity Interest in such Subsidiary) of
the fair market value of the net assets of such Subsidiary at the time of such redesignation; and (2) any property transferred
to or from an Unrestricted Subsidiary will be valued at its fair market value at the time of such transfer. The amount of any
Investment outstanding at any time will be the original cost of such Investment, reduced by any dividend, distribution, interest
payment, return of capital, repayment or other amount received in cash by the Company or a Restricted Subsidiary in respect of
such Investment.

 

“Investor”
means any of Koch Industries, Inc., TPG Capital, L.P., Arkansas Teacher Retirement System, Global Principal Partners LLC any
of their respective Affiliates and funds or partnerships managed or advised by any of them or any of their respective Affiliates
but not including, however, any portfolio company of any of the foregoing.

 

“Laws”
means, collectively, all international, foreign, federal, state and local laws (including common law), statutes, treaties, rules,
guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities and executive orders, including
the interpretation or administration thereof by any Governmental Authority charged with the enforcement, interpretation or administration
thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements
with, any Governmental Authority.

  

    35 

     

    

  

“Legal Holiday”
means Saturday, Sunday or a day on which commercial banking institutions are not required to be open in the State of New York or
at the place of payment.

 

“Lenders Debt”
means all (i) Indebtedness outstanding from time to time under the ABL Facility (including all principal, interest, fees,
costs and expenses thereunder), (ii) any Indebtedness which has a priority security interest relative to the Obligations under
the Bond Financing Agreement in the ABL Priority Collateral pursuant to the Intercreditor Agreement, (iii) all Obligations
with respect to such Indebtedness and any Hedging Obligations directly related to any Lenders Debt and (iv) all Obligations
incurred with the ABL Facility Lenders (or their affiliates) in connection with the delivery of cash management and related services
and other commercial bank products as described in the ABL Facility.

 

“Lender
Representative” means each Pari Passu Lien Debt Representative, acting on behalf of the Pari Passu Lien Secured
Parties represented by such Pari Passu Lien Debt Representative, the Equipment Lessor (acting on its own behalf and as servicer
for certain other Persons) and the Commercial Building Lender (acting on its own behalf).

 

“Letter of
Representations” means the Blanket Issuer Letter of Representations dated July 24, 1995 filed by the Issuer and
accepted by the Depository.

 

“Lien”
means, with respect to any asset, any mortgage, lien (statutory or otherwise), pledge, hypothecation, charge, security interest
or encumbrance of any kind in respect of such asset, whether or not filed, recorded or otherwise perfected under applicable law,
including any conditional sale or other title retention agreement, any lease in the nature thereof, any option or other agreement
to sell or give a security interest in and any filing of or agreement to give any financing statement under the Uniform Commercial
Code (or equivalent statutes) of any jurisdiction; provided that in no event will an operating lease be deemed to constitute a
Lien.

 

“Limited Offering
Memorandum” means the Limited Offering Memorandum (in printed or electronic form) with respect to the 2019 Bonds, dated
as of May 21, 2019, and any amendments or supplements thereto that shall be approved by the Bond Issuer and the Company, in
connection with the limited public offering and sale of the 2019 Bonds.

 

“Majority
Holders” means, with respect to any Series of Pari Passu Lien Debt, the holders of more than 50% of the aggregate
outstanding principal amount (and, if applicable, the unused commitments under the Specified Pari Passu Lien Debt Documents, subject
to the Specified Commitment Condition) in respect thereof.

 

“Management
Services Agreements” means any management services agreement, bonus agreement or similar agreements among one or more
of the Investors or Management Stockholders or certain of their respective management companies or Affiliates thereof associated
with it or their advisors, if applicable, and the Company (and/or any Parent Company) or any amendment thereto or renewal or replacement
thereof so long as any such amendment or replacement is not materially disadvantageous in the good faith judgment of the Board
of Directors to the Holders when taken as a whole, as compared to the Management Services Agreements as in effect on the Closing
Date.

 

“Management
Stockholders” means the members of management (and their Controlled Investment Affiliates and Immediate Family Members
and any permitted transferees thereof) of the Company (or a Parent Company) who are holders of Equity Interests of any Parent Company
on the Closing Date.

 

“Margin Stock”
has the meaning set forth in Regulation U of the Board of Governors of the United States Federal Reserve System, or any successor
thereto.

 

“Market Capitalization”
means an amount equal to (i) the total number of issued and outstanding shares of common Equity Interests of the Company or
the applicable Parent Company, as applicable, on the date of the declaration of a Restricted Payment permitted pursuant to Section 6.01(b)(8) of
the Bond Financing Agreement and clause (b)(8) of the covenant described in the Limited Offering Memorandum under the heading
 “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the Company—Limitation
on Restricted Payments” multiplied by
(ii) the arithmetic mean of the closing prices per share of such common Equity Interests on the principal securities exchange
on which such common Equity Interests are traded for the 30 consecutive trading days immediately preceding the date of declaration
of such Restricted Payment.

  

    36 

     

    

 

 

 

 

“Material
Adverse Effect” means any material adverse change, or any development involving a prospective material adverse
change, whether or not arising from transactions in the ordinary course of business, in or affecting (i) the business,
properties, general affairs, management, financial position, stockholders’ equity or results of operations of the
Company, the Guarantors and their Subsidiaries, taken as a whole, or (ii) the ability of the Company or any Guarantor to
perform in all material respects its obligations under the Borrower Documents, the Existing Debt Documents, the Guarantees or
the Collateral Documents.

 

“Material
Real Property” means any fee-owned real property owned by the Company or leasehold interest of the Company in real property,
in each case, located in the United States and with a fair market value in excess of $10.0 million on the Closing Date (if owned
or leased by the Company on the Closing Date) or at the time of acquisition (if acquired by the Company after the Closing Date).

 

“Maximum Rate”
means, with respect to the 2019 Bonds, the lesser of 15% per annum or the maximum interest rate permitted by applicable Arkansas
law.

 

“Money Laundering
Laws” means anti-money laundering laws, including, but not limited to, the Bank Secrecy Act of 1970, as amended by the
USA PATRIOT ACT of 2001, and the rules and regulations promulgated thereunder, and the anti-money laundering laws of the various
jurisdictions in which any such party or its subsidiaries conduct business.

 

“Mortgaged Property” means any
real property subject to a deed of trust or mortgage.

 

“Mortgages”
means the mortgages, debentures, hypothecs, deeds of trust, deeds to secure Indebtedness or other similar documents securing Liens
on the owned real property or leased real property that is to form a portion of the Collateral.

 

“Mortgaged Premises” means any
real property which shall now or hereafter be subject to a mortgage.

 

“Moody’s” means Moody’s
Investors Service, Inc. and any successor to its rating agency business.

 

“Net Cash
Proceeds,” with respect to any issuance or sale of Capital Stock, means the cash proceeds of such issuance or sale, net
of attorneys’ fees, accountants’ fees, underwriters’ or placement agents’ fees, listing fees, discounts
or commissions and brokerage, consultant and other fees and charges actually incurred in connection with such issuance or sale
and net of taxes paid or payable as a result of such issuance or sale (after taking into account any available tax credit or deductions
and any tax sharing arrangements).

 

“Net Income”
means, with respect to any Person, the net income (loss) of such Person, determined in accordance with GAAP and before any reduction
in respect of Preferred Stock dividends.

 

“Net
Proceeds” means the aggregate cash and Cash Equivalents received by the Company or any Restricted Subsidiary in
respect of any Asset Sale, including any cash and Cash Equivalents received upon the sale or other disposition of any
Designated Non-Cash Consideration received in any Asset Sale, net of the costs relating to such Asset Sale and the sale or
disposition of such Designated Non-Cash Consideration, including legal, accounting and investment banking fees, payments made
in order to obtain a necessary consent or required by applicable law, brokerage and sales commissions, title insurance
premiums, related search and recording charges, survey costs and mortgage recording tax paid in connection therewith, all
dividends, distributions or other payments required to be made to minority interest holders in Restricted Subsidiaries as a
result of any such Asset Sale by a Restricted Subsidiary, the amount of any purchase price or similar adjustment claimed by
any Person to be owed by the Company or any Restricted Subsidiary, until such time as such claim will have been settled or
otherwise finally resolved, or paid or payable by the Company or any Restricted Subsidiary, in either case in respect of such
Asset Sale, any relocation expenses incurred as a result thereof, costs and expenses in connection with unwinding any Hedging
Obligation in connection therewith, other fees and expenses, including title and recordation expenses, taxes paid or payable
as a result thereof or any transactions occurring or deemed to occur to effectuate a payment under the Bond Financing
Agreement, amounts required to be applied to the repayment of principal, premium, if any, and interest on Indebtedness (other
than Subordinated Indebtedness) or amounts required to be applied to the repayments of Indebtedness secured by a Lien on such
assets and required (other than required by Section 6.04(b)(1) of the Bond Financing Agreement and clause
(b)(1) of the covenant described in the Limited Offering Memorandum under the heading “FINANCING FOR THE
TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the Company—Asset Sales”) to be paid
as a result of such transaction and any deduction of appropriate amounts to be provided by the Company or any Restricted
Subsidiary as a reserve in accordance with GAAP against any liabilities associated with the asset disposed of in such
transaction and retained by the Company or any Restricted Subsidiary after such sale or other disposition thereof, including
pension and other post-employment benefit liabilities and liabilities related to environmental matters or against any
indemnification obligations associated with such transaction.

 

    37

     

    

 

“Non-Recourse
Indebtedness” means Indebtedness that is non-recourse to the Company and the Restricted Subsidiaries.

 

“Notes Indenture”
means the Indenture dated as of August 23, 2017 among the Company, as issuer, BRS Finance Corp., as co-issuer, the Parent,
each guarantor that may become a party thereto, and U.S. Bank National Association, as trustee and collateral agent, relating to
7.250% Senior Secured Notes due 2025.

 

“Obligations”
means any principal, interest (including any interest accruing on or subsequent to the filing of a petition in bankruptcy, reorganization
or similar proceeding at the rate provided for in the documentation with respect thereto, whether or not such interest is an allowed
claim under applicable state, federal or foreign law), premium, penalties, fees, indemnifications, reimbursements (including reimbursement
obligations with respect to letters of credit and banker’s acceptances), damages and other liabilities, and guarantees of
payment of such principal, interest, penalties, fees, indemnifications, reimbursements, damages and other liabilities, payable
under the documentation governing any Indebtedness.

 

“OECD” means the Organisation for
Economic Co-Operation and Development.

 

“OECD Rules”
means the OECD Arrangement on Guidelines for Officially Supported Export Credits (TAD/ECG (2017) 1) dated February 1, 2017,
as amended from time to time.

 

“Officer”
means the Chairman of the Board of Directors, the Chief Executive Officer, the Chief Financial Officer, the Chief Operating Officer,
the President, any Executive Vice President, Senior Vice President or Vice President, the Treasurer or the Secretary of any Person.
Unless otherwise indicated, Officer shall refer to an officer of the Company.

 

“Officer’s
Certificate” means a certificate signed on behalf of a Person by an Officer of such Person that meets the requirements
set forth in the Bond Financing Agreement.

 

“ordinary
course of business” means activity conducted in the ordinary course of business of the Company and any Restricted Subsidiary.

 

“Ordinary
Services” or “Ordinary Expenses” means those standard and customary services normally rendered, and
those reasonable expenses normally incurred, by a trustee under instruments similar to the Bond Indenture and the Bond Financing
Agreement.

 

“Original
KfW Credit Agreement” means that certain Senior Facilities Agreement, dated as of June 27, 2014 (as amended, supplemented
or modified from time to time on or prior to August 23, 2017) among the Company, the guarantors party thereto, KfW IPEX-Bank
GmbH, as the lead arranger and the and the other lenders party hereto, KfW IPEX-Bank GmbH, as administrative agent, and Deutsche
Bank Trust Issuer Americas, as collateral agent.

 

    38

     

    

 

“Other Pari
Passu Lien Obligations” means (a) all outstanding Indebtedness under the Notes Indenture, the Senior Secured Notes,
and the Term Loan Credit Agreement, (b) Funded Debt incurred under Specified Pari Passu Lien Debt Documents, and (c) any
other Indebtedness that is permitted to be secured on a pari passu basis with the Liens securing the Obligations under the Bond
Financing Agreement and the Series 2019 Note, by the Collateral and not by any other assets; provided, however,
that a representative or agent with respect to such Indebtedness described in this clause (c) is a Pari Passu Lien Debt Representative
under the Collateral Trust Agreement and such Indebtedness is Additional Pari Passu Lien Debt.

 

“Other Pari
Passu Lien Obligations Debt Limit” means, as at any time of determination, $400 million plus an amount equal to
the product of (x) the aggregate amount of Capex Equity received since the Closing Date through and including such time of
determination multiplied by (y) two.

 

“Outstanding”,
 “Outstanding Bonds” or “Bonds outstanding” means, as of the applicable date, all Bonds which
have been authenticated and delivered, except:

 

(a)           Bonds
canceled or required to be canceled pursuant to the provisions of the Bond Indenture upon surrender, exchange or transfer, or canceled
or required to be canceled pursuant to the provisions of the Bond Indenture because of payment or redemption on or prior to that
date;

 

(b)           On
and after the applicable payment, redemption or purchase date, Bonds, or the portion thereof, for the payment, redemption or purchase
for cancellation of which sufficient money has been deposited and credited with the Trustee or any Paying Agent pursuant to the
Bond Indenture for the purpose of extinguishing the applicable debt; provided, that, in the case of the redemption or purchase
of the applicable Bonds, notice of such redemption or purchase shall have been given as required under the Bond Indenture;

 

(c)            Bonds,
or the portion thereof, which are deemed to have been paid and discharged or caused to have been paid and discharged pursuant to
the provisions of the Bond Indenture;

 

 (d)            Bonds paid pursuant to Section 3.07 of the Bond Indenture; and

 

(e)           Bonds
in lieu of which others have been authenticated pursuant to the Bond Indenture; provided that, in determining whether the Holders
of the requisite percentage of Bonds have concurred in any demand, direction, request, notice, consent, waiver or other action
under the Bond Indenture, Bonds that are owned by the Company or any Person directly or indirectly controlling or controlled by
or under direct or indirect common control with the Company shall be disregarded and deemed not to be outstanding for the purpose
of any such determination (unless all of the Bonds are so owned); provided that for the purposes of determining whether the Trustee
shall be protected in relying on any such direction, consent or waiver, only such Bonds of which the Trustee has actual knowledge
are so owned shall be disregarded. Bonds so owned that have been pledged in good faith may be regarded as Outstanding for such
purpose, if the pledgee shall establish to the satisfaction of the Trustee the pledgee’s right to vote such Bonds and the
pledgee is not a Person directly or indirectly controlling or controlled by or under direct or indirect common control with the
Company. In case of a dispute as to such right, any decision by the Trustee taken upon the advice of counsel shall be full protection
to the Trustee.

 

“Outstanding
Term Loan Threshold Date” means the date on which both (x) the outstanding principal amount of Term Loan under (and
as defined in) the Term Loan Credit Agreement (or the aggregate outstanding principal amount of all loans and other evidences of
indebtedness in respect thereof under any replacement Term Loan Credit Agreement designated as such in accordance with the Collateral
Trust Agreement) is less than 15% of the aggregate outstanding principal amount (and the unused commitments under the Specified
Pari Passu Lien Debt Documents, subject to the Specified Commitment Condition) of all Pari Passu Lien Debt and (y) the aggregate
outstanding principal amount (and the unused commitments under the Specified Pari Passu Lien Debt Documents, subject to the Specified
Commitment Condition) of another Series of Pari Passu Lien Debt exceeds the outstanding principal amount of Term Loans under
the Term Loan Credit Agreement.

 

    39

     

    

 

“Parent”
means BRS Intermediate Holdings LLC, a Delaware limited liability company.

 

“Parent Company” means
any Person that is a direct or indirect parent (which may be organized as, among other things, a partnership) of the Company.

 

“Parent Guarantee” means a Guarantee
of Parent and it successors.

 

“Pari Passu Indebtedness” means:

 

(1)            with
respect to the Company, the Obligations under the Bond Financing Agreement and the Series 2019 Note and any Indebtedness which
ranks pari passu in right of payment thereto; and

 

(2)            with
respect to any Guarantor, its Guarantee and any Indebtedness which ranks pari passu in right of payment to such Guarantor’s
Guarantee.

 

“Pari Passu
Lien” means a Lien granted, or purported to be granted, by a Pari Passu Lien Security Document to the Collateral Agent,
at any time, upon any property of the Company or any other Grantor to secure Pari Passu Lien Obligations.

 

“Pari
Passu Lien Debt” means: (a) any Funded Debt now or hereafter incurred under the Term Loan Credit Agreement;
(b)(i) the Obligations under the Bond Financing Agreement and the Series 2019 Note (and amendments or supplements
thereto of additional note delivered in connection with the issuance of any Additional Bonds) and any Senior Secured Notes
issued on August 23, 2017 and any senior secured notes issued under the Notes Indenture (or a supplemental indenture
thereto) in exchange for the Senior Secured Notes and (ii) any additional Senior Secured Notes issued under the Notes
Indenture (or a supplemental indenture thereto) from time to time and any Senior Secured Notes issued under the Notes
Indenture in exchange for such additional senior secured notes; (c) any other Funded Debt (including, without limitation
(x) Funded Debt incurred under any replacement Notes Indenture, (y) Funded Debt incurred under Specified Pari Passu
Lien Debt Documents or (z) borrowings under any other Pari Passu Lien Debt Documents) that is secured by a Pari Passu
Lien and that was permitted to be incurred and permitted to be so secured under each applicable Pari Passu Lien Debt
Document; provided, in the case of any Funded Debt referred to in this clause (c), that: (i) on or before the date on
which such Funded Debt is incurred by the Company or by another Grantor, such Funded Debt is designated by the Company as
 “Pari Passu Lien Debt” for the purposes of the Pari Passu Lien Debt Documents in an Additional Pari Passu Lien
Debt Designation executed and delivered in accordance with the Collateral Trust Agreement; (ii) unless such Funded Debt
is issued under an existing Pari Passu Lien Debt Document for any Series of Pari Passu Lien Debt whose Pari Passu Lien
Debt Representative is already party to the Collateral Trust Agreement, the Pari Passu Lien Debt Representative for such
Funded Debt executes and delivers a Collateral Trust Joinder in accordance with the Collateral Trust Agreement; and
(iii) all other requirements for the Additional Pari Passu Lien Obligations Debt Designations set forth in the
Collateral Trust Agreement have been complied with. For the avoidance of doubt, (i) Secured Hedging Obligations do not
constitute Pari Passu Lien Debt but may constitute Pari Passu Lien Obligations and (ii) Equipment Lease Obligations and
Commercial Building Lender Obligations do not constitute Pari Passu Lien Debt.

 

“Pari Passu
Lien Debt Default” means any event or condition that, under the terms of any indenture, credit agreement or other agreement
governing any Series of Pari Passu Lien Debt causes, or permits holders of Pari Passu Lien Debt outstanding thereunder (with
or without the giving of notice or lapse of time, or both, and whether or not notice has been given or time has lapsed) to cause,
the Pari Passu Lien Debt outstanding thereunder to become immediately due and payable.

 

“Pari Passu
Lien Debt Documents” means the Bond Financing Agreement, the Notes Indenture, the Term Loan Credit Agreement and any
other indenture, notes, credit agreement or other agreement or instrument pursuant to which any Pari Passu Lien Debt is incurred
(including, without limitation, the Specified Pari Passu Lien Debt Documents) and the Pari Passu Lien Security Documents.

 

“Pari
Passu Lien Debt Proportion by Value” means (x) the net proceeds of a Going Concern Sale minus
(y) the sum of the Equipment Lease Proportion by Value plus the Commercial Building Loan Proportion by Value, provided that
such amount will not exceed the total amount of the outstanding and unpaid Pari Passu Lien Obligations.

 

    40

     

    

 

“Pari Passu Lien Debt Representative”
means:

 

		(1)	in the case of the Bond Financing Agreement, the Trustee (as assignee of the Bond Issuer);

 

(2)   in
the case of the Notes Indenture, the trustee for the Senior Secured Notes and, in the case of the Term Loan Credit Agreement, the
Term Loan Administrative Agent;

 

(3)   in
the case of the Specified Pari Passu Lien Debt Documents, the Specified Pari Passu Lien Debt Representative;

 

(4)   in
the case of any other Series of Pari Passu Lien Debt, the trustee, agent or representative of the holders of such Series of
Pari Passu Lien Debt who maintains the transfer register for such Series of Pari Passu Lien Debt or is appointed as a representative
of the Pari Passu Lien Debt (for purposes related to the administration of the Pari Passu Lien Security Documents) pursuant to
the indenture, credit agreement or other agreement governing such Series of Pari Passu Lien Debt, and who has executed a Collateral
Trust Joinder; and

 

		(5)	in the case of any Secured Hedging Obligations owing to a Hedge Bank, such Hedge Bank.

 

“Pari Passu
Lien Obligations” means the Pari Passu Lien Debt and all other Obligations in respect of Pari Passu Lien Debt, together
with Secured Hedging Obligations, including any Post-Petition Interest whether or not allowable, and all guarantees of any of the
foregoing. In addition to the foregoing, all obligations owing to the Collateral Agent in its capacity as such, whether pursuant
to the Collateral Trust Agreement or one or more of the Pari Passu Lien Debt Documents, shall in each case be deemed to constitute
Pari Passu Lien Obligations (with the obligations described in this sentence being herein the “Collateral Agent Obligations”),
which Collateral Agent Obligations shall be entitled to the priority provided in clause FIRST under “SECURITY AND SOURCES
OF PAYMENT FOR THE 2019 BONDS AND OTHER PARI PASSU LIEN DEBT—Collateral Trust Agreement— Order of Application.”
For the avoidance of doubt, Equipment Lease Obligations and Commercial Building Lender Obligations do not constitute Pari Passu
Lien Obligations.

 

“Pari Passu
Lien Secured Parties” means the holders of Pari Passu Lien Obligations, each Pari Passu Lien Debt Representative and
the Collateral Agent.

 

“Pari Passu
Lien Security Documents” means all security agreements, pledge agreements, collateral assignments, mortgages, deeds of
trust, collateral agency agreements, control agreements, consent or direct arrangements (including any Direct Agreements), or other
grants or transfers for security executed and delivered by the Company or any other Grantor creating or perfecting (or purporting
to create or perfect) or governing rights of enforcement with respect to, a Lien upon Collateral in favor of the Collateral Agent,
for the benefit of any of the Pari Passu Lien Secured Parties, in each case, as amended, modified, renewed, restated or replaced,
in whole or in part, from time to time, in accordance with its terms of the Intercreditor Agreement and as described under the
heading “SECURITY AND SOURCES OF PAYMENT FOR THE 2019 BONDS AND OTHER PARI PASSU LIEN DEBT—Intercreditor Agreement—Amendment
of Pari Passu Lien Security Documents.”

 

“Paying Agent”
means any bank or trust company designated as a Paying Agent by or in accordance with Section 6.12 of the Bonds Indenture.

 

“Permitted
Asset Swap” means the substantially concurrent purchase and sale or exchange of Related Business Assets or a
combination of Related Business Assets and cash or Cash Equivalents between the Company or any Restricted Subsidiary and
another Person; provided that any cash or Cash Equivalents received in connection with a Permitted Asset Swap that
constitutes an Asset Sale must be applied in accordance with Section 6.04 of the Bond Financing Agreement and the
covenant described in the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT
PROJECT—Bond Financing Agreement—Covenants of the Company— Asset Sales.”

 

    41

     

    

 

“Permitted
Bond Hedge Transaction” means any call or capped call option (or substantially equivalent derivative transaction) on
the Company’s common stock purchased by the Company in connection with the issuance of any Convertible Indebtedness; provided
that the purchase price for such Permitted Bond Hedge Transaction, less the proceeds received by the Company from the sale of any
related Permitted Warrant Transaction, does not exceed the net proceeds received by the Company from the sale of such Convertible
Indebtedness issued in connection with the Permitted Bond Hedge Transaction.

 

“Permitted
Convertible Indebtedness Call Transaction” means any Permitted Bond Hedge Transaction and any Permitted Warrant Transaction.

 

“Permitted
Holder” means (1) any of the Investors, Management Stockholders and any group (within the meaning of Section 13(d)(3) or
Section 14(d)(2) of the Exchange Act) of which any of the foregoing are members; provided that in the case of
any such group and without giving effect to the existence of such group or any other group, such Investors and Management Stockholders,
collectively, have, directly or indirectly, beneficial ownership of more than 50.0% of the total voting power of the Voting Stock
of the Company and (2) any Person acting in the capacity of an underwriter (solely to the extent that and for so long as such
Person is acting in such capacity) in connection with a public or private offering of Capital Stock of the Company or any Parent
Company. Any Person or group whose acquisition of beneficial ownership constitutes a Change of Control in respect of which any
required Change of Control Offer is made in accordance with the requirements of the Bond Financing Agreement (or would have required
a Change of Control Offer in the absence of the waiver of such requirement by Holders in accordance with the provisions of the
Bond Financing Agreement) will thereafter, together with its Affiliates, constitute an additional Permitted Holder.

 

“Permitted Investments” means:

 

(1)      any Investment in the Company or
any Guarantor (including guarantees of obligations of the Guarantors);

 

(2)      any
Investment in Cash Equivalents or Investment Grade Securities and Investments that were Cash Equivalents or Investment Grade Securities
when made;

 

(3)      any
Investment by the Company or any Restricted Subsidiary in a Person that is engaged (directly or through entities that will be Restricted
Subsidiaries) in a Similar Business, or in a business unit, line of business or division of such Person, if as a result of such
Investment: (a) such Person becomes a Restricted Subsidiary (and in the event such Investment was made by the Company or a
Guarantor, becomes a Guarantor); or (b) such Person, in one transaction or a series of related transactions, is amalgamated,
merged or consolidated with or into, or transfers or conveys substantially all of its assets or assets constituting such business
unit, line of business or division in which such Investment was made, as applicable, to, or is liquidated into, the Company or
a Restricted Subsidiary (and in the event such Investment was made by the Company or a Guarantor, such amalgamation, merger, consolidation,
transfer or conveyance is made to a Guarantor); and, in each case, any Investment held by such Person; provided that such
Investment was not acquired by such Person in contemplation of such acquisition, merger, amalgamation, consolidation, transfer
or conveyance;

 

(4)      any
Investment in securities or other assets not constituting Cash Equivalents or Investment Grade Securities and received in connection
with an Asset Sale permitted pursuant to Section 6.04 of the Bond Financing Agreement and the covenant described in the Limited
Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants
of the Company—Asset Sales” or any other disposition of assets not constituting an Asset Sale;

 

    42

     

    

 

(5)      any
Investment existing on the Closing Date or made pursuant to binding commitments in effect on such date or an Investment consisting
of any extension, modification, replacement, renewal or reinvestment of any Investment or binding commitment existing on such
date; provided that the amount of any such Investment or binding commitment may be increased only (a) as required
by the terms of such Investment or binding commitment as in existence on such date (including as a result of the accrual or accretion
of interest or original issue discount or the issuance of pay-in-kind securities) or (b) as otherwise permitted under the
Bond Financing Agreement;

 

(6)      any
Investment by the Company or any Restricted Subsidiary: (a) in exchange for any other Investment, accounts receivable or indorsements
for collection or deposit held by the Company or any Restricted Subsidiary in connection with or as a result of a bankruptcy, workout,
reorganization or recapitalization of, or settlement of delinquent accounts and disputes with or judgments against, the issuer
of such other Investment or accounts receivable (including any trade creditor or customer); (b) in satisfaction of judgments
against other Persons; (c) as a result of a foreclosure by the Company or any Restricted Subsidiary with respect to any secured
Investment or other transfer of title with respect to any secured Investment in default; or (d) as a result of the settlement,
compromise or resolution of (A) litigation, arbitration or other disputes or (B) obligations of trade creditors or customers
that were incurred in the ordinary course of business or consistent with industry practice of the Company or any Restricted Subsidiary,
including pursuant to any plan of reorganization or similar arrangement upon the bankruptcy or insolvency of any trade creditor
or customer;

 

(7)      Hedging
Obligations permitted under Section 6.03(b)(11) of the Bond Financing Agreement and in clause (11) of the second paragraph
of the covenant described in the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond
Financing Agreement— Covenants of the Company—Limitation on Incurrence of Indebtedness and Issuance of Disqualified
Stock and Preferred Stock”

 

(8)      any
Investment in a Similar Business, taken together with all other Investments made pursuant to this clause (8) that are at that
time outstanding, not to exceed (as of the date such Investment is made) the greater of (a) $80 million and (b) 50% of
Consolidated EBITDA of the Company and the Restricted Subsidiaries determined at the time of making of such Investment for the
most recently ended Test Period (calculated on a pro forma basis);

 

(9)      Investments
the payment for which consists of, or are funded by the sale of, Equity Interests (other than Disqualified Stock) of the Company
or any Parent Company or are funded from cash equity contributions to the capital of the Company; provided that such Equity
Interests, the proceeds from the sale of any such Equity Interests, and such contributions to the capital of the Company, will
not increase the amount available for Restricted Payments under Section 6.01(a)(3) of the Bond Financing Agreement and
clause (a)(3) of the covenant described in the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT
PROJECT—Bond Financing Agreement—Covenants of the Company—Limitation on Restricted Payments;”

 

(10)    (a)  guarantees
of Indebtedness permitted under Section 6.03 of the Bond Financing Agreement and the covenant described in the Limited Offering
Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the
Company—Limitation on Incurrence of Indebtedness and Issuance of Disqualified Stock and Preferred Stock,” performance
guarantees and Contingent Obligations incurred in the ordinary course of business or consistent with industry practice and (b) the
creation of Liens on the assets of the Company or any Restricted Subsidiary in compliance with Section 6.06 of the Bond Financing
Agreement as described in “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the Company—Liens;”

 

(11)    any
transaction to the extent it constitutes an Investment that is permitted by and made in accordance with the provisions of Section 6.05(b) of
the Bond Financing Agreement (except transaction described in clauses (2), (6), (10), (16) and (23) thereof) and of the covenant
described in the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing
Agreement—Covenants of the Company—Transactions with Affiliates” (except transactions described in clause (b)(2),
(b)(6), (b)(10), (b)(16) or (b)(23) of such covenant);

 

    43

     

    

 

(12)    Investments consisting
of purchases and acquisitions of inventory, supplies, material, services, equipment or similar assets or the licensing or contribution
of intellectual property pursuant to joint marketing arrangements with other Persons;

 

(13)     Investments,
taken together with all other Investments made pursuant to this clause (13) that are at that time outstanding, not to exceed (as
of the date such Investment is made) the greater of (a) $80 million and (b) 50% of Consolidated EBITDA of the Company
determined at the time of making of such Investment for the most recently ended Test Period (calculated on a pro forma basis);

 

(14)    Investments
in or relating to a Securitization Subsidiary that, in the good faith determination of the Company, are necessary or advisable
to effect any Qualified Securitization Facility (including distributions or payments of Securitization Fees) or any repurchase
obligation in connection therewith (including the contribution or lending of Cash Equivalents to Subsidiaries to finance the purchase
of such assets from the Company or any Restricted Subsidiary or to otherwise fund required reserves);

 

(15)    loans
and advances to, or guarantees of Indebtedness of, officers, directors, employees, consultants, members of management and independent
contractors not in excess of $2.0 million outstanding at any one time, in the aggregate;

 

(16)    loans
and advances to employees, directors, officers, members of management, independent contractors and consultants for business-related
travel expenses, moving expenses, payroll advances and other similar expenses or payroll expenses, including pursuant to Management
Services Agreements, in each case incurred in the ordinary course of business or consistent with past practice or consistent with
industry practice or to future, present and former employees, directors, officers, members of management, independent contractors
and consultants (and their Controlled Investment Affiliates and Immediate Family Members) to fund such Person’s purchase
of Equity Interests of the Company or any Parent Company;

 

(17)    advances,
loans or extensions of trade credit or prepayments to suppliers or loans or advances made to distributors, in each case, in the
ordinary course of business or consistent with past practice or consistent with industry practice by the Company or any Restricted
Subsidiary;

 

(18)    any
Investment in any Subsidiary or any joint venture in connection with intercompany cash management arrangements or related activities
arising in the ordinary course of business or consistent with industry practice;

 

(19)    Investments
consisting of purchases and acquisitions of assets or services in the ordinary course of business or consistent with industry practice;

 

(20)    Investments
made in the ordinary course of business or consistent with industry practice in connection with obtaining, maintaining or renewing
client contracts and loans or advances made to distributors;

 

(21)    Investments
in prepaid expenses, negotiable instruments held for collection and lease, utility and workers compensation, performance and similar
deposits entered into as a result of the operations of the business in the ordinary course of business or consistent with industry
practice;

 

(22)    the
purchase or other acquisition of any Indebtedness of the Company or any Restricted Subsidiary to the extent not otherwise prohibited
hereunder;

 

(23)    Investments
in Unrestricted Subsidiaries or joint ventures, taken together with all other Investments made pursuant to this clause (23)
that are at that time outstanding, without giving effect to the sale of an Unrestricted Subsidiary or joint venture to the
extent the proceeds of such sale do not consist of, or have not been subsequently sold or transferred for, Cash Equivalents
or marketable securities, not to exceed (as of the date such Investment is made) the greater of (a) $40 million and
(b) 30% of Consolidated EBITDA of the Company and the Restricted Subsidiaries determined at the time of making of such
Investment for the most recently ended Test Period (calculated on a pro forma basis);

 

    44

     

    

 

(24)    Investments
in the ordinary course of business or consistent with industry practice consisting of Uniform Commercial Code Article 3 endorsements
for collection or deposit and Article 4 customary trade arrangements with customers;

 

(25)   any
Investment by any Captive Insurance Subsidiary in connection with its provision of insurance to the Company or any of its Subsidiaries,
which Investment is made in the ordinary course of business or consistent with industry practice of such Captive Insurance Subsidiary,
or by reason of applicable law, rule, regulation or order, or that is required or approved by any regulatory authority having jurisdiction
over such Captive Insurance Subsidiary or its business, as applicable;

 

(26)    any
Investment, constituting Indebtedness, by the Company or a Subsidiary Guarantor, in a Restricted Subsidiary that is not a Wholly-Owned
Subsidiary of the Company or such Guarantor, the net proceeds of which are used by such Restricted Subsidiary to make any Capital
Expenditures for the purpose of increasing the earnings capacity in such Restricted Subsidiary, in a Similar Business; provided
that (i) such Investment is secured by a first priority Lien on all of the assets and property of such Restricted Subsidiary
that would constitute Fixed Asset Priority Collateral if such property or assets were Collateral (prior to all Liens on such assets
and property that would constitute ABL Priority Collateral if such assets and property were Collateral), (ii) such Investment
is collaterally assigned in favor of the Collateral Agent as Fixed Asset Priority Collateral and (iii) the assets and property
of such Restricted Subsidiary (other than assets and property that would constitute ABL Priority Collateral if such assets and
property were Collateral) are not otherwise subject to any Lien other than Permitted Restricted Subsidiary Liens;

 

(27)    Investments
of assets relating to non-qualified deferred payment plans in the ordinary course of business or consistent with industry practice;

 

(28)    intercompany
current liabilities owed to Unrestricted Subsidiaries or joint ventures incurred in the ordinary course of business or consistent
with industry practice in connection with the cash management operations of the Company and its Subsidiaries;

 

(29)    acquisitions
of obligations of one or more directors, officers or other employees or consultants or independent contractors of any Parent Company,
the Company or any Subsidiary of the Company in connection with such director’s, officer’s, employee’s consultant’s
or independent contractor’s acquisition of Equity Interests of the Company or any direct or indirect parent of the Company,
to the extent no cash is actually advanced by the Company or any Restricted Subsidiary to such directors, officers, employees,
consultants or independent contractors in connection with the acquisition of any such obligations;

 

(30)    Investments
resulting from pledges and deposits permitted pursuant to the definition of “Permitted Liens;”

 

(31)    loans
and advances to any direct or indirect parent of the Company in lieu of and not in excess of the amount of (after giving effect
to any other loans, advances or Restricted Payments in respect thereof) Restricted Payments to the extent permitted to be made
in cash to such parent in accordance with the covenant contained in Section 6.01 of the Bond Financing Agreement and the covenant
described in the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT— Bond Financing
Agreement—Covenants of the Company—Limitation on Restricted Payments” at such time, such Investment being treated
for purposes of the applicable clause of such covenant in Section 6.01 of the Bond Financing Agreement or the corresponding
section of the Limited Offering Memorandum, including any limitations, as if a Restricted Payment were made pursuant to such applicable
clause;

 

    45

     

    

 

(32)    any
other Investments if on a pro forma basis after giving effect to such Investment, the Total Net Leverage Ratio would be
equal to or less than 3.00 to 1.00 as of the last day of the Test Period most recently ended;

 

(33)    Investments
constituting promissory notes or other non-cash proceeds of dispositions of assets to the extent permitted under Section 6.04
of the Bond Financing Agreement and the covenant described in the Limited Offering Memorandum under the heading “FINANCING
FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the Company—Asset Sales;” and

 

		(34)	Permitted Bond Hedge Transactions.

 

For
purposes of determining compliance with this definition, (A) an Investment need not be incurred solely by reference to
one category of Permitted Investments described in this definition but is permitted to be incurred in part under any
combination thereof and of any other available exemption and (B) in the event that an Investment (or any portion
thereof) meets the criteria of one or more of the categories of Permitted Investments, the Company will, in its sole
discretion, classify or reclassify such Investment (or any portion thereof) in any manner that complies with this definition
and with Section 6.01 of the Bond Financing Agreement and the covenant described in the Limited Offering Memorandum
under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement— Covenants of the
Company—Limitation on Restricted Payments.”

 

“Permitted Liens” means, with respect to
any Person:

 

(1)      Liens
securing Obligations in respect of the Bond Financing Agreement and Series 2019 Note, the Senior Secured Notes and any guarantees
thereof and the Guarantees;

 

(2)      Liens
securing Obligations in respect of Indebtedness permitted to be incurred under any Credit Facility, including any letter of credit
facility relating thereto, that was permitted by the terms of Section 6.03(b)(1) of the Bond Financing Agreement and
clause (1) of the second paragraph of the covenant described in the Limited Offering Memorandum under the heading “FINANCING
FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the Company—Limitation on Incurrence
of Indebtedness and Issuance of Disqualified Stock and Preferred Stock;” provided that any such Lien will be subject to the
Intercreditor Agreement, as required therein;

 

(3)      Liens
securing Other Pari Passu Lien Obligations permitted to be incurred pursuant to Section 6.03(b)(2) of the Bond Financing
Agreement and clause (2) of the second paragraph of the covenant described in the Limited Offering Memorandum under the heading
 “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the Company—Limitation
on Incurrence of Indebtedness and Issuance of Disqualified Stock and Preferred Stock;” provided that any such Lien will be
subject to the Collateral Trust Agreement and the Intercreditor Agreement, as required therein;

 

(4)      Liens
securing Pari Passu Lien Obligations in respect of Indebtedness permitted to be incurred under Section 6.03 of the Bond Financing
Agreement and the covenant described in the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond
Financing Agreement—Covenants of the Company—Limitation on Incurrence of Indebtedness and Issuance of Disqualified
Stock and Preferred Stock;” provided that at the time of incurrence (or, in the case of Indebtedness under Designated Revolving
Commitments, on the date such Designated Revolving Commitments are established after giving pro forma effect to the incurrence
of the entire committed amount of Indebtedness thereunder, in which case such committed amount under such Designated Revolving
Commitments may thereafter be borrowed and reborrowed, in whole or in part, from time-to-time, without further compliance with
this subclause) and after giving pro forma effect thereto and the application of the net proceeds therefrom, the Company’s
Senior Secured Net Leverage Ratio for the most recently ended Test Period preceding the date on which such additional Indebtedness
is incurred would not exceed 3.00 to 1.00; provided that any such Lien will be subject to the Collateral Trust Agreement
and the Intercreditor Agreement, as required therein;

 

    46

     

    

 

(5)      Liens,
pledges or deposits by such Person made in connection with (A) workers’ compensation laws, unemployment insurance, health,
disability or employee benefits or other social security laws or similar legislation or regulations, (B) insurance-related
obligations (including, in respect of deductibles, self-insured retention amounts and premiums and adjustments thereto) or indemnification
obligations of (including obligations in respect of letters of credit, bank guarantees or similar documents or instruments for
the benefit of) insurance carriers providing property, casualty or liability insurance, or otherwise supporting the payment of
items set forth in the foregoing clause (A), or (C) bids, tenders, contracts, statutory obligations, surety, indemnity, warranty,
release, appeal or similar bonds, or with regard to other regulatory requirements, completion guarantees, stay, customs and appeal
bonds, performance bonds, bankers’ acceptance facilities, and other obligations of like nature (including those to secure
health, safety and environmental obligations) (other than for the payment of Indebtedness), or deposits to secure public or statutory
obligations of such Person or deposits of cash, Cash Equivalents or U.S. government bonds to secure surety or appeal bonds to which
such Person is a party, or deposits as security for the payment of rent, contested taxes or import duties and obligations in respect
of letters of credit, bank guarantees or similar instruments that have been posted to support the same, in each case incurred in
the ordinary course of business or consistent with industry practice;

 

(6)      Liens
imposed by law, such as landlords’, carriers’, warehousemen’s, materialmen’s, repairmen’s, construction
and mechanics’ Liens and other similar Liens, or similar landlord Liens specifically created by contract, and (i) for
sums not yet overdue for a period of more than 60 days or, if more than 60 days overdue, are unfiled and no other action has been
taken to enforce such Liens or (ii) being contested in good faith by appropriate actions or other Liens arising out of or
securing judgments or awards against such Person with respect to which such Person will then be proceeding with an appeal or other
proceedings for review if such Liens are adequately bonded or adequate reserves with respect thereto are maintained on the books
of such Person in accordance with GAAP;

 

(7)      Liens
for taxes, assessments or other governmental charges not yet overdue for a period of more than 30 days or not yet payable or not
subject to penalties for nonpayment or which are being contested in good faith by appropriate actions if adequate reserves with
respect thereto are maintained on the books of such Person in accordance with GAAP;

 

(8)      Liens
in favor of issuers of performance, surety, bid, indemnity, warranty, release, appeal or similar bonds, instruments or obligations
or with respect to regulatory requirements or letters of credit or bankers’ acceptance issued, and completion guarantees
provided, in each case, pursuant to the request of and for the account of such Person in the ordinary course of its business or
consistent with past practice or industry practice;

 

(9)      survey
exceptions, encumbrances, covenants, conditions, ground leases, easements, restrictions, protrusions, encroachments or reservations
of, or rights of others for, licenses, rights-of-way, servitudes, sewers, electric lines, drains, telegraph, telephone and cable
television lines and other similar purposes, or zoning, building codes or other restrictions (including minor defects or irregularities
in title and similar encumbrances) as to the use of real properties or Liens incidental to the conduct of the business of such
Person or to the ownership of its properties that were not incurred in connection with Indebtedness and that do not in the aggregate
materially impair their use in the operation of the business of such Person;

 

    47

     

    

 

(10)    Liens
securing obligations in respect of Indebtedness, Disqualified Stock or Preferred Stock permitted to be incurred or issued
pursuant to Section 6.03(b), clauses (5), (7), (14), (15) or (16) of the Bond Financing Agreement and as described in
clauses (5), (7), (14), (15) or (16) of the second paragraph of the covenant described in the Limited Offering Memorandum
under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the
Company—Limitation on Incurrence of Indebtedness and Issuance of Disqualified Stock and Preferred Stock;” provided
that: (a) Liens securing obligations relating to any Indebtedness, Disqualified Stock or Preferred Stock permitted to be
incurred or issued pursuant to Section 6.03(b)(14) of the Bond Financing Agreement and clause (14) of the second
paragraph of the covenant described in the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT
PROJECT—Bond Financing Agreement—Covenants of the Company—Limitation on Incurrence of Indebtedness and
Issuance of Disqualified Stock and Preferred Stock” relate only to obligations relating to Refinancing Indebtedness
that is secured by Liens on the same assets as the assets securing the Refinanced Debt (as defined in the definition of
Refinancing Indebtedness), plus improvements, accessions, proceeds or dividends or distributions in respect thereof and
After-Acquired Property, or serves to refund, refinance, extend, replace, renew or defease Indebtedness incurred under
Section 6.03(b)(5) or (14) of the Bond Financing Agreement and clause (5) or (14) of the second paragraph of
the covenant described in the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT
PROJECT—Bond Financing Agreement—Covenants of the Company—Limitation on Incurrence of Indebtedness and
Issuance of Disqualified Stock and Preferred Stock,” (b) [Reserved], (c) Liens securing obligations in
respect of Indebtedness, Disqualified Stock or Preferred Stock permitted to be incurred pursuant to
Section 6.03(b)(5) of the Bond Financing Agreement and clause (5) of the second paragraph of the covenant
described in the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond
Financing Agreement— Covenants of the Company—Limitation on Incurrence of Indebtedness and Issuance of
Disqualified Stock and Preferred Stock” extend only to the assets so purchased, constructed, replaced, leased or
improved and proceeds and products thereof; provided, further that individual financings of assets provided by a
counterparty may be cross-collateralized to other financings of assets provided by such counterparty, (d) Liens securing
Obligations in respect of Indebtedness permitted to be incurred pursuant to Section 6.03(b)(15)(b) of the Bond
Financing Agreement and clause (15)(b) of the second paragraph of the covenant described in the Limited Offering
Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of
the Company—Limitation on Incurrence of Indebtedness and Issuance of Disqualified Stock and Preferred Stock” are
solely on acquired property or the assets of the acquired entity, and (e) Liens securing Obligations in respect of
Indebtedness permitted to be incurred pursuant to Section 6.03(b)(15) of the Bond Financing Agreement and clause (15) of
the second paragraph of the covenant described in the Limited Offering Memorandum under the heading “FINANCING FOR THE
TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the Company—Limitation on Incurrence of
Indebtedness and Issuance of Disqualified Stock and Preferred Stock,” after giving pro forma effect to such
Indebtedness secured by such Lien and the application of the net proceeds therefrom, the Company’s Senior Secured Net
Leverage Ratio for the most recently ended Test Period preceding the date on which such additional Indebtedness is incurred
after giving pro forma effect to the incurrence of the entire committed amount of Indebtedness thereunder, would
(a) be no less than the Senior Secured Net Leverage Ratio immediately prior to giving effect to such incurrence of
Indebtedness secured by such Lien or (b) not exceed 3.00 to 1.00;

 

(11)    Liens
existing, or provided for under binding contracts existing, on the Closing Date (other than Liens securing Obligations under the
Term Loan Credit Agreement, the ABL Facility or to secure the Senior Secured Notes and related guarantees, the Obligations under
the Bond Financing Agreement and related Guarantees);

 

(12)    Liens
on property or shares of stock or other assets of a Person at the time such Person becomes a Subsidiary (provided that such
Liens are not created or incurred in connection with, or in contemplation of, such other Person becoming such a Subsidiary ); and
any replacement, extension or renewal of any such Lien (to the extent the Indebtedness and other obligations secured by such replacement,
extension or renewal Liens are permitted by the Bond Financing Agreement); provided that such replacement, extension or renewal
Liens do not cover any property other than the property that was subject to such Liens prior to such replacement, extension or
renewal;

 

(13)    Liens
on property or other assets at the time the Company or a Restricted Subsidiary acquired the property or such other assets, including
any acquisition by means of a merger, amalgamation or consolidation with or into the Company or any Restricted Subsidiary (provided
that such Liens are not created or incurred in connection with, or in contemplation of, such acquisition, amalgamation, merger
or consolidation) and any replacement, extension or renewal of any such Lien (to the extent the Indebtedness and other obligations
secured by such replacement, extension or renewal Liens are permitted by the Bond Financing Agreement); provided that such
replacement, extension or renewal Liens do not cover any property other than the property that was subject to such Liens prior
to such replacement, extension or renewal;

 

    48

     

    

 

(14)    Liens
securing obligations in respect of Indebtedness or other obligations of a Restricted Subsidiary owing to the Company or another
Restricted Subsidiary permitted to be incurred in accordance with Section 6.03 of the Bond Financing Agreement and the covenant
described in the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing
Agreement—Covenants of the Company—Limitation on Incurrence of Indebtedness and Issuance of Disqualified Stock and
Preferred Stock;”

 

 (15)    Liens securing (x) Hedging Obligations and (y) obligations in respect of Cash Management Services;

 

(16)    Liens
on specific items of inventory or other goods and proceeds of any Person securing such Person’s accounts payable or similar
obligations in respect of bankers’ acceptances or letters of credit issued or created for the account of such Person to facilitate
the purchase, shipment or storage of such inventory or other goods;

 

(17)    leases,
subleases, licenses or sublicenses (or other agreement under which the Company or any Restricted Subsidiary has granted rights
to end users to access and use the Company’s or any Restricted Subsidiary’s products, technologies or services) that
do not either (a) materially interfere with the business of the Company and its Restricted Subsidiaries, taken as a whole,
or (b) secure any Indebtedness;

 

(18)    Liens
arising from Uniform Commercial Code (or equivalent statutes) financing statement filings regarding operating leases, consignments
or accounts entered into by the Company and its Restricted Subsidiaries in the ordinary course of business or consistent with industry
practice or purported Liens evidenced by the filing of precautionary Uniform Commercial Code (or equivalent statutes) financing
statements or similar public filings;

 

 (19)    Liens in favor of the Company or any Guarantor;

 

(20)    Liens
on equipment or vehicles of the Company or any Restricted Subsidiary granted in the ordinary course of business or consistent with
industry practice;

 

(21)    Liens
on accounts receivable, Securitization Assets and related assets incurred in connection with a Qualified Securitization Facility
and Liens on any receivables transferred in connection with a Receivables Financing Transaction, including Liens on such receivables
resulting from precautionary Uniform Commercial Code filings or from recharacterization of any such sale as a financing or a loan;

 

(22)    Liens
to secure any modification, refinancing, refunding, extension, renewal, replacement or defeasance (or successive
modification, refinancing, refunding, extensions, renewals, replacements or defeasances) as a whole, or in part, of any
Indebtedness, Disqualified Stock or Preferred Stock secured by any Lien referred to in clauses (1), (3), (4), (10), (11),
(12), (13) or this clause (22) of this definition; provided that (a) such new Lien will be limited to all or part
of the same property that secured the original Lien (plus improvements, accessions, proceeds or dividends or
distributions in respect thereof and After-Acquired Property) and (b) the Indebtedness secured by such Lien at such time
is not increased to any amount greater than the sum of (i) the outstanding principal amount or, if greater, committed
amount of the Indebtedness described under clauses (1), (3), (4), (10), (11), (12), (13) or this clause (22) of this
definition at the time the original Lien became a Permitted Lien under the Bond Financing Agreement, plus
(ii) any accrued and unpaid interest on the Indebtedness being so modified, refinanced, extended, replaced, refunded,
renewed or defeased plus (iii) the amount of any tender premium or penalty or premium required to be paid under
the terms of the instrument or documents governing such refinanced Indebtedness and any defeasance costs and any fees and
expenses (including original issue discount, upfront fees or similar fees) incurred in connection with the issuance of such
new Indebtedness or the modification, extension, replacement, refunding, refinancing, renewal or defeasance of such
refinanced Indebtedness; provided, further that that in the case of any Liens to secure any refinancing, refunding,
extension or renewal of Indebtedness secured by a Lien referred to in clauses (4) or (10), the principal amount of any
Indebtedness Incurred for such refinancing, refunding, extension or renewal shall be deemed secured by a Lien under clauses
(4) or (10) and not this clause (22) for purposes of determining the principal amount of Indebtedness outstanding
under clause (4) or (10);

 

    49

     

    

 

(23)   deposits
made or other security provided to secure liability to insurance brokers, carriers, underwriters or self-insurance arrangements,
including Liens or insurance policies and the proceeds thereof securing the financing of the premiums with respect thereto;

 

(24)   other
Liens securing obligations in an aggregate outstanding amount not to exceed (as of the date any such Lien is incurred) the greater
of (i) $100.0 million and (ii) 60% of Consolidated EBITDA of the Company and the Restricted Subsidiaries determined at
the time of incurrence of such Lien for the most recently ended Test Period (calculated on a pro forma basis);

 

(25)   Liens
in favor of customs and revenue authorities arising as a matter of law to secure payment of customs duties in connection with the
importation of goods;

 

(26)   (i) the
prior rights of consignees and their lenders under consignment arrangements entered into in the ordinary course of business or
consistent with industry practice, (ii) Liens arising out of conditional sale, title retention or similar arrangements for
the sale of goods in the ordinary course of business or consistent with industry practice and (iii) Liens arising by operation
of law under Article 2 of the Uniform Commercial Code;

 

(27)   Liens
securing judgments for the payment of money not constituting an Event of Default under Section 7.07 of the Bond Financing
Agreement and clause (g) of the provisions described in the Limited Offering Memorandum under the heading “FINANCING
FOR THE TAX-EXEMPT PROJECT— Bond Financing Agreement—Events of Default;”

 

(28)   Liens
(a) of a collection bank arising under Section 4-208 or 4-210 of the Uniform Commercial Code on items in the course of
collection, (b) attaching to commodity trading accounts or other brokerage accounts incurred in the ordinary course of business
or consistent with industry practice, and (c) in favor of banking or other institutions or other electronic payment service
providers arising as a matter of law or under general terms and conditions encumbering deposits or margin deposits or other funds
maintained with such institution (including the right of set off) and that are within the general parameters customary in the banking
industry;

 

(29)   Liens
deemed to exist in connection with Investments in repurchase agreements permitted under the Bond Financing Agreement; provided
that such Liens do not extend to assets other than those that are subject to such repurchase agreements;

 

(30)   Liens
that are contractual rights of set-off (a) relating to the establishment of depository relations with banks or other deposit-taking
financial institutions or other electronic payment service providers and not given in connection with the issuance of Indebtedness,
(b) relating to pooled deposit or sweep accounts to permit satisfaction of overdraft or similar obligations incurred in the
ordinary course of business or consistent with industry practice of the Company and its Restricted Subsidiaries or (c) relating
to purchase orders and other agreements entered into with customers of the Company or any Restricted Subsidiary in the ordinary
course of business or consistent with industry practice;

 

(31)   Liens
on cash proceeds (as defined in Article 9 of the Uniform Commercial Code) of assets sold that were subject to a Lien permitted
hereunder;

 

(32)   any
encumbrance or restriction (including put, call arrangements, tag, drag, right of first refusal and similar rights) with respect
to Capital Stock of any joint venture or similar arrangement pursuant to any joint venture or similar agreement;

 

    50

     

    

 

(33)    Liens
(a) on cash advances or cash earnest money deposits in favor of the seller of any property to be acquired in an
Investment permitted under the Bond Financing Agreement to be applied against the purchase price for such Investment and
(b) consisting of a letter of intent or an agreement to sell, transfer, lease or otherwise dispose of any property in a
transaction permitted pursuant to Section 6.04 of the Bond Financing Agreement and the covenant described in the Limited
Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—
Covenants of the Company—Asset Sales;”

 

(34)    ground
leases, subleases, licenses or sublicenses in respect of real property on which facilities owned or leased by the Company or any
of its Subsidiaries are located; provided such ground leases, subleases, licenses or sublicenses do not materially impair the use
of the remainder of the Mortgaged Property and are subordinate to the lien of the Mortgages;

 

(35)   Liens
in connection with a Specified Sale and Lease-Back Transaction and any leasehold mortgage or similar Lien on the associated Lease;

 

 (36)   Liens on Capital Stock or other securities of an Unrestricted Subsidiary;

 

(37)   any
interest or title of a lessor, sublessor, licensor or sublicensor or secured by a lessor’s, sublessor’s, licensor’s
or sublicensor’s interest under leases or licenses entered into by the Company or any of the Restricted Subsidiaries in the
ordinary course of business or consistent with industry practice;

 

(38)   deposits
of cash with the owner or lessor of premises leased and operated by the Company or any of its Subsidiaries in the ordinary course
of business or consistent with industry practice of the Company and such Subsidiary to secure the performance of the Company’s
or such Subsidiary’s obligations under the terms of the lease for such premises;

 

(39)    rights
of set-off, banker’s liens, netting arrangements and other Liens arising by operation of law or by the terms of documents
of banks or other financial institutions in relation to the maintenance or administration of deposit accounts, securities accounts,
cash management arrangements or in connection with the issuance of letters of credit, bank guarantees or other similar instruments;

 

(40)    Liens
on cash and Cash Equivalents used to satisfy or discharge Indebtedness; provided that such satisfaction or discharge is
permitted under the Bond Financing Agreement;

 

(41)    receipt
of progress payments and advances from customers in the ordinary course of business or consistent with industry practice to the
extent the same creates a Lien on the related inventory and proceeds thereof and Liens on property or assets under construction
arising from progress or partial payments by a third party relating to such property or assets;

 

(42)    agreements
to subordinate any interest of the Company or any Restricted Subsidiary in any accounts receivable or other proceeds arising from
inventory consigned by the Company or any Restricted Subsidiary pursuant to an agreement entered into in the ordinary course of
business or consistent with industry practice;

 

(43)    Liens
securing Guarantees of any Indebtedness or other obligations otherwise permitted to be secured by a Lien under the Bond Financing
Agreement;

 

(44)    Liens
arising pursuant to Section 107(l) of the Comprehensive Environmental Response, Compensation and Liability Act or similar
provision of any environmental law;

 

(45)    Liens
disclosed by the title insurance reports or policies delivered on or prior to the Closing Date and any replacement, extension or
renewal of any such Lien (to the extent the Indebtedness and other obligations secured by such replacement, extension or renewal
Liens are permitted by the Bond Financing Agreement); provided that such replacement, extension or renewal Liens do not cover any
property other than the property that was subject to such Liens prior to such replacement, extension or renewal;

 

    51

     

    

 

(46)    rights
reserved or vested in any Person by the terms of any lease, license, franchise, grant or permit held by the Company or any of its
Restricted Subsidiaries or by a statutory provision, to terminate any such lease, license, franchise, grant or permit, or to require
annual or periodic payments as a condition to the continuance thereof;

 

(47)    restrictive
covenants affecting the use to which real property may be put; provided that the covenants are complied with;

 

(48)    security
given to a public utility or any municipality or governmental authority when required by such utility or authority in connection
with the operations of that Person in the ordinary course of business or consistent with industry practice;

 

(49)   zoning,
building and other similar land use restrictions, including, without limitation, site plan agreements, development agreements and
contract zoning agreements; provided that such restrictions and agreements are complied with;

 

(50)    Liens
on assets of Restricted Subsidiaries that are Foreign Subsidiaries (i) securing Indebtedness and other obligations of such
Foreign Subsidiaries or (ii) to the extent arising mandatorily under applicable law;

 

(51)    Liens
on Escrowed Proceeds for the benefit of the related holders of debt securities or other Indebtedness (or the underwriters, trustee,
escrow agent or arrangers thereof) or on cash set aside at the time of the incurrence of any Indebtedness or government securities
purchased with such cash, in either case to the extent such cash or government securities prefund the payment of interest on such
Indebtedness and are held in an escrow account or similar arrangement to be applied for such purpose; and

 

		(52)	any Lien contemplated by clause (26) of the definition of “Permitted Investments.”

 

If any Liens
are incurred to secure obligations incurred to refinance obligations initially incurred in reliance on a basket measured by reference
to a percentage of Consolidated EBITDA, and such refinancing would cause the percentage of Consolidated EBITDA to be exceeded if
calculated based on the Consolidated EBITDA on the date of such refinancing, such percentage of Consolidated EBITDA will not be
deemed to be exceeded to the extent the principal amount of such obligations secured by such newly incurred Lien does not exceed
the principal amount of such obligations secured by such Liens being refinanced, plus any accrued and unpaid interest on the Indebtedness
(and with respect to Indebtedness under Designated Revolving Commitments, including an amount equal to any unutilized Designated
Revolving Commitments being refinanced, extended, replaced, refunded, renewed or defeased to the extent permanently terminated
at the time of incurrence of such refinancing Indebtedness) plus the amount of any tender premium or penalty or premium
required to be paid under the terms of the instrument or documents governing such refinanced Indebtedness, and any defeasance costs
and any fees and expenses (including original issue discount, upfront fees or similar fees) incurred in connection with the issuance
of such new Indebtedness, or the extension, replacement, refunding, refinancing, renewal or defeasance of such refinanced Indebtedness.
For purposes of this definition, the term “Indebtedness” will be deemed to include interest and other obligations payable
on and with respect to such Indebtedness.

 

“Permitted
Prior Lien” means any Lien that has priority over the Lien of the Collateral Agent for the benefit of the Pari
Passu Lien Secured Parties which Lien was permitted under each Pari Passu Lien Debt Document.

 

“Permitted
Restricted Subsidiary Liens” means clauses (5) through (9), (10) (with respect to clauses (5),
(7) and (14) of Section 6.03(b) of the Bond Financing Agreement and the same clauses of the covenant described
in the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing
Agreement—Covenants of the Company—Limitation on Incurrence of Indebtedness and Issuance of Disqualified Stock
and Preferred Stock;” provided that, with respect to such clause (14), only with respect to such clause (5)),
(12) through (21), (22) (with respect to clauses (12), (13) and (22)), (23) through (35), (37) through (42), (44) through
(49), (51) and (52) of the definition of “Permitted Liens.”

 

    52

     

    

 

“Permitted
Warrant Transaction” means any call option, warrant or right to purchase (or substantially equivalent derivative transaction)
on the Company’s or a Parent Company’s common stock sold by the Company or a Parent Company substantially concurrently
with a related Permitted Bond Hedge Transaction.

 

“Person”
means any individual, corporation, limited liability company, partnership, joint venture, association, joint stock company, trust,
unincorporated organization, government or any agency or political subdivision thereof or any other entity.

 

“Phase II
Project” means any capacity addition, line extension or addition of value-added product facilities, in a Similar Business,
at the steel mini-mill located in Mississippi County, Arkansas.

 

“Phase II
Project Costs” means all costs and expenses to be incurred by Parent, the Company or any Restricted Subsidiary in connection
with the Development of the Phase II Project, and incurred after August 23, 2017, including, without limitation, the purchase
of equipment and related services, the training of personnel relating to the Phase II Project, the financing of the Phase II Project,
including interest expense incurred during Development, and activities reasonably related thereto.

 

“Post-Petition
Interest” means interest, fees, expenses and other charges that pursuant to the ABL Credit Agreement, the Term Loan Credit
Agreement, the Notes Indenture or any other Fixed Asset Pari Passu Lien Debt Documents (including the Bond Financing Agreement
and any Specified Pari Passu Lien Debt Documents), continue to accrue after the commencement of any Insolvency or Liquidation Proceeding,
whether or not such interest, fees, expenses and other charges are allowed or allowable under the Bankruptcy Law or in any such
Insolvency or Liquidation Proceeding.

 

“Predecessor
Bond” of any particular Bond means every previous Bond evidencing all or a portion of the same debt as that evidenced
by the particular Bond. For the purposes of this definition, any Bond authenticated and delivered under Section 3.07 of the
Bond Indenture in lieu of a lost, stolen or destroyed Bond shall, except as otherwise provided in said Section 3.07, be deemed
to evidence the same debt as the lost, stolen or destroyed Bond.

 

“Preferred
Stock” means any Equity Interest with preferential rights of payment of dividends or upon liquidation, dissolution, or
winding up.

 

“Principal
Account” means the account of that name established in the Debt Service Fund pursuant to Section 5.01(a) of
the Bond Indenture.

 

“Principal
Payment Date” means any date on which any amounts payable with respect to the principal of the Bonds shall become due,
whether upon redemption (including without limitation sinking fund redemption), acceleration, maturity or otherwise.

 

“Project”
means the construction, start-up and operation and maintenance by the Company of one or more flat-roll steel mini mills constructed
or to be constructed on land located in Mississippi County, Arkansas.

 

“Project
Costs” means all costs and expenses incurred by the Grantors and their Subsidiaries in connection with the ownership,
occupation, construction, testing, starting, repair, operation, maintenance and use of the Project, the training of personnel relating
to the Project, the financing of the Project and activities reasonably related thereto, in each case incurred prior to August 23,
2017.

 

“Public Company
Costs” means the initial costs relating to establishing compliance with the Sarbanes-Oxley Act of 2002, as amended, and
other expenses arising out of or incidental to the Company’s or its Restricted Subsidiaries’ initial establishment
of compliance with the obligations of a reporting company, including costs, fees and expenses (including legal, accounting and
other professional fees) relating to compliance with provisions of the Securities Act and the Exchange Act.

 

    53

     

    

 

“Purchase
Agreement” means the Bond Purchase Agreement with respect to the 2019 Bonds, dated the date of the Limited Offering Memorandum,
by and among the Bond Issuer, the Company and the Underwriter, and any similar agreement with respect to Additional Bonds.

 

“Purchase
Money Obligations” means any Indebtedness incurred to finance or refinance the acquisition, leasing, construction or
improvement of property (real or personal) or assets (other than Capital Stock), and whether acquired through the direct acquisition
of such property or assets, or otherwise.

 

“Qualified
Capital Contribution” means cash common equity capital contributions to, or cash proceeds from the issuance of Capital
Stock in, Big River Steel Holdings LLC, a Delaware limited liability company, which Big River Steel Holdings LLC, upon receipt,
contributes to Parent, which in turn, upon receipt, contributes to the Company.

 

“Qualified
Equity Interests” means Equity Interests that are not Disqualified Stock.

 

“Qualified
Institutional Buyer” has the meaning set forth in Rule 144A promulgated under the Securities Act of 1933, as amended.

 

“Qualified
Investments” means (a) any of the following: bonds, debentures, notes or other evidence of indebtedness, other than
subordinated or junior bonds, debentures, notes or other evidence of indebtedness, issued or guaranteed, other than on a subordinated
or junior basis, by any of the following federal agencies, and any other agency or other instrumentality subsequently created by
an act of the United States Congress, which are not backed by the full faith and credit of the United States of America: U.S. Export-Import
Bank (Eximbank) direct obligations or fully guaranteed certificates of beneficial ownership; Farmers Home Administration certificates
of beneficial ownership; securities of the Federal Financing Bank; Federal Housing Administration debentures; General Services
Administration participation certificates; Federal National Mortgage Association senior debt obligations and mortgage-backed securities;
Federal Home Loan Mortgage Corporation senior debt obligations and mortgage-backed securities; Federal Farm Credit Bank senior
debt obligations and mortgage-backed securities; Government National Mortgage Association guaranteed mortgage-backed bonds and
guaranteed pass- through obligations; Student Loan Marketing Association senior debt obligations; U.S. Maritime Administration
guaranteed Title XI financing obligations; and U.S. Department of Housing and Urban Development project notes, local authority
bond, new communities debentures-U.S. government guaranteed debentures and U.S. public housing notes and bonds-U.S. government
guaranteed public housing notes and bonds and (b) securities evidencing ownership of the right to payment of specific principal
or interest payments on an obligation described in (a) above, provided that such securities were created by or on behalf of
the issuer of the applicable obligation and are held in the custody of a bank or trust company having a reported capital, surplus
and undivided profits of at least $ 25,000,000 and a rating on its unsecured, unenhanced short-term obligations in the highest
short- term category by at least one Rating Agency, in a special account separate from the general assets of such custodian.

 

“Qualified
Proceeds” means the fair market value of assets that are used or useful in, or Capital Stock of any Person engaged in,
a Similar Business.

 

“Qualified
Securitization Facility” means any Securitization Facility (1) constituting a securitization financing facility
that meets the following conditions: (a) the Board of Directors will have determined in good faith that such Securitization
Facility (including financing terms, covenants, termination events and other provisions) is in the aggregate economically fair
and reasonable to the Company and the applicable Restricted Subsidiary or Securitization Subsidiary and (b) all sales and/or
contributions of Securitization Assets and related assets to the applicable Person or Securitization Subsidiary are made at fair
market value (as determined in good faith by the Company) or (2) constituting a receivables financing facility.

 

“Rating” means the credit rating
of the Bonds by the Rating Agencies.

 

“Rating Agencies”
means Moody’s and S&P or if Moody’s or S&P or if both do not make a rating on the Bonds publicly available,
a nationally recognized statistical rating agency or agencies, as the case may be, selected by the Company which will be substituted
for Moody’s or S&P or both, as the case may be.

 

    54

     

    

 

“Ratings Reaffirmation”
means in the case of an event or proposed event, a reaffirmation by either of the Rating Agencies rating the Bonds that the then
current Ratings on the 2019 Bonds will not be lower, after giving effect to the event or proposed event, than the Ratings of the
2019 Bonds in effect immediately prior to such event or proposed event.

 

“Real Estate
Asset” means, at any time of determination, any interest (fee, leasehold or otherwise) of any Grantor in any real property,
including Mortgaged Premises, distribution centers and warehouses and corporate headquarters and administrative offices.

 

“Rebate Fund” means the fund of
that name established pursuant to Section 5.01(c) of the Bond Indenture.

 

“Receivables
Financing Transaction” means any transaction or series of transactions entered into by the Company, BRS Finance Corp.
or any Restricted Subsidiary pursuant to which such party consummates a “true sale” of its receivables to a nonrelated
third party on market terms as determined in good faith by the Company; provided that such Receivables Financing Transaction
is (i) non-recourse to Parent, the Company, BRS Finance Corp. and the Restricted Subsidiaries and their assets, other than
any recourse solely attributable to a breach by Parent, the Company, BRS Finance Corp. or any Restricted Subsidiary of representations
and warranties that are customarily made by a seller in connection with a “true sale” of receivables on a non-recourse
basis and (ii) consummated pursuant to customary contracts, arrangements or agreements entered into with respect to the “true
sale” of receivables on market terms for similar transactions.

 

“Redemption
Account” means the account of that name established in the Debt Service Fund pursuant to Section 5.01(a) of
the Bond Indenture.

 

“Redemption
Date” means a date on which 2019 Bonds are subject to redemption pursuant to the terms of the Bond Indenture.

 

“Refinance”
has the meaning assigned in the definition of “Refinancing Indebtedness” and “Refinancing”
and “Refinanced” have meanings correlative to the foregoing.

 

“Refinanced Debt” has the meaning
assigned to such term in the definition of “Refinancing Indebtedness”.

 

“Refinancing Indebtedness”
means (x) Indebtedness incurred by the Company or any Restricted Subsidiary, (y) Disqualified Stock issued by the
Company or any Restricted Subsidiary or (z) Preferred Stock issued by any Restricted Subsidiary which, in each case,
serves to extend, replace, refund, refinance, renew or defease (“Refinance”) any Indebtedness,
Disqualified Stock or Preferred Stock, including Refinancing Indebtedness, so long as: (1) the principal amount (or
accreted value, if applicable) of such new Indebtedness, the amount of such new Preferred Stock or the liquidation preference
of such new Disqualified Stock does not exceed (a) the principal amount of (or accreted value, if applicable) the
Indebtedness, the amount of the Preferred Stock or the liquidation preference of the Disqualified Stock being so extended,
replaced, refunded, refinanced, renewed or defeased (such Indebtedness, Disqualified Stock or Preferred Stock, the
 “Refinanced Debt”), plus (b) any accrued and unpaid interest on, or any accrued and unpaid
dividends on, such Refinanced Debt, plus (c) the amount of any tender premium or penalty or premium required to
be paid under the terms of the instrument or documents governing such Refinanced Debt and any defeasance costs and any fees
and expenses (including original issue discount, upfront fees or similar fees) incurred in connection with the issuance of
such new Indebtedness, Preferred Stock or Disqualified Stock or to Refinance such Refinanced Debt (such amounts in clause
(b) and (c), the “Incremental Amounts”); (2) such Refinancing Indebtedness has a:
(a) Weighted Average Life to Maturity at the time such Refinancing Indebtedness is incurred that is not less than the
remaining Weighted Average Life to Maturity of the applicable Refinanced Debt; (b) final scheduled maturity date equal
to or later than the final scheduled maturity date of the Refinanced Debt (or, if earlier, the date that is 91 days after the
maturity date of the Bonds); and (3) to the extent such Refinancing Indebtedness Refinances (i) Subordinated
Indebtedness (other than Subordinated Indebtedness assumed or acquired in an acquisition and not created in contemplation
thereof), unless such Refinancing constitutes a Restricted Payment permitted by Section 6.01 of the Bond Financing
Agreement and the covenant described in the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT
PROJECT—Bond Financing Agreement—Covenants of the Company—Limitation on Restricted Payments,”
such Refinancing Indebtedness is subordinated to the Bonds or the Guarantee thereof at least to the same extent as the
applicable Refinanced Debt or (ii) Disqualified Stock or Preferred Stock, such Refinancing Indebtedness must be
Disqualified Stock or Preferred Stock, respectively. Refinancing Indebtedness will not include: (a) Indebtedness,
Disqualified Stock or Preferred Stock of a Subsidiary of the Company that is not a Subsidiary Guarantor that refinances
Indebtedness or Disqualified Stock of the Company; (b) Indebtedness, Disqualified Stock or Preferred Stock of a
Subsidiary of the Company that is not a Subsidiary Guarantor that refinances Indebtedness, Disqualified Stock or Preferred
Stock of a Guarantor; or (c) Indebtedness or Disqualified Stock of the Company or Indebtedness, Disqualified Stock or
Preferred Stock of a Restricted Subsidiary that refinances Indebtedness, Disqualified Stock or Preferred Stock of an
Unrestricted Subsidiary; and, provided, further that (x) clause (2) of this definition will not apply
to any Refinancing of any Indebtedness other than Indebtedness incurred under Section 6.03(b)(3) of the Bond
Financing Agreement and clause (3) of the second paragraph of the covenant described in the Limited Offering Memorandum
under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants of the
Company—Limitation on Incurrence of Indebtedness and Issuance of Disqualified Stock and Preferred Stock,” any
Subordinated Indebtedness (other than Subordinated Indebtedness assumed or acquired in an Investment or acquisition and not
created in contemplation thereof), Disqualified Stock and Preferred Stock and (y) Refinancing Indebtedness may be
incurred in the form of a bridge or other interim credit facility intended to be Refinanced with long-term indebtedness (and
such bridge or other interim credit facility shall be deemed to satisfy clause (2) of this definition so long as
(x) such credit facility includes customary “rollover” provisions and (y) assuming such credit facility
were to be extended pursuant to such “rollover” provisions, such extended credit facility would comply with
clause (2) of this definition).

 

    55

     

    

 

“Register”
means the books kept and maintained by the Registrar for registration and transfer of Bonds pursuant to the Bond Indenture.

 

“Registrar”
means the Trustee, or any successor Registrar which shall have become such pursuant to applicable provisions of the Bond Indenture.

 

“Regular Record Date” means the
close of business on the fifteenth day preceding each Interest Payment Date.

 

“Regulations” means Treasury Regulations
promulgated pursuant to the Code.

 

“Related Business
Assets” means assets (other than Cash Equivalents) used or useful in a Similar Business; provided that any assets
received by the Company or a Restricted Subsidiary in exchange for assets transferred by the Company or a Restricted Subsidiary
will not be deemed to be Related Business Assets if they consist of securities of a Person, unless upon receipt of the securities
of such Person, such Person is or would become a Restricted Subsidiary.

 

“Required
Term Lenders” means the “Required Lenders” (or an equivalent term with substantially similar meaning)
under and as defined in the Term Loan Credit Agreement.

 

“Required
Delayed Draw Term Lenders” means the “Required Senior Term Lenders” (or an equivalent term with substantially
similar meaning as the meaning of such term in the Original KfW Credit Agreement) under and as defined in the Specified Pari Passu
Lien Debt Documents.

 

“Responsible
Officer” means, with respect to a Person, the chief executive officer, chief operating officer, president, executive
vice president, director of finance, chief financial officer, treasurer or assistant treasurer or other similar officer or Person
performing similar functions, of such Person. Unless otherwise specified, all references to a “Responsible Officer”
shall refer to a Responsible Officer of the Company.

 

“Restricted Investment” means an
Investment other than a Permitted Investment.

 

“Restricted
Subsidiary” means, at any time, any direct or indirect Subsidiary of the Company (including any Foreign Subsidiary
and BRS Finance Corp.) that is not then an Unrestricted Subsidiary; provided that upon the occurrence of an
Unrestricted Subsidiary ceasing to be an Unrestricted Subsidiary, such Subsidiary will be included in the definition of
 “Restricted Subsidiary”. Wherever the term “Restricted Subsidiary” is used with respect to any
Subsidiary of a referenced Person that is not the Company, then it will be construed to mean a Person that would be a
Restricted Subsidiary of the Company on a pro forma basis following consummation of one or a series of related
transactions involving such referenced Person and the Company (unless such transactions would include a designation of a
Subsidiary of such Person as an Unrestricted Subsidiary on a pro forma basis in accordance with the Bond Financing
Agreement).

 

    56

     

    

 

 

“Revenue Account”
means the account entitled the “Revenue Account” held by the Depository Bank under the Deposit Agreement.

 

“S&P”
means Standard & Poor’s, a division of The McGraw-Hill Companies, Inc., and any successor to its rating agency
business.

 

“Sale and
Lease- Back Transaction” means any arrangement providing for the leasing by the Company or any Restricted Subsidiary
of any real or tangible personal property, which property has been or is to be sold or transferred by the Company or such Restricted
Subsidiary to a third Person in contemplation of such leasing. The net proceeds of any Sale and Lease-Back Transaction will be
determined giving effect to transaction expenses and the tax effect of such transactions (including taxes paid or payable and tax
attributes used as a result of such transactions).

 

“Sanctions”
means any sanctions administered or enforced by the U.S. Government, including, without limitation, the Office of Foreign Assets
Control of the U.S. Department of the Treasury, or the U.S. Department of State and including, without limitation, the designation
as a “specially designated national” or “blocked person,” the European Union, Her Majesty’s Treasury,
the United Nations Security Council, or other relevant sanctions authority.

 

“SCF” means Stonebriar Commercial
Finance LLC, a Delaware limited liability company.

 

“SEC”
means the U.S. Securities and Exchange Commission or any governmental authority succeeding to any of its principal functions.

 

“Second Specified
Pari Passu Lien Debt Threshold Date” means the date, after the occurrence of the First Specified Pari Passu Lien Debt
Threshold Date, on which the sum of (1) the outstanding principal amount of the term loans under the Specified Pari Passu
Lien Debt Documents plus (2) from and after the occurrence of the Initial Funding Date, the commitments under the Specified
Pari Passu Lien Debt Documents subject to the Specified Commitment Condition is less than 50% of the aggregate outstanding principal
amount of all Pari Passu Lien Debt or less than the aggregate outstanding principal amount of the largest Series of Pari Passu
Lien Debt other than the Pari Passu Lien Debt incurred under the Specified Pari Passu Lien Debt Documents.

 

“Secured Hedging
Obligations” means any Hedging Obligations under a Hedge Agreement entered into between the Company or another Grantor
and a Hedge Bank or any guarantee thereof by the Company or another Grantor.

 

“Secured Indebtedness” means any
Indebtedness of the Company or any Restricted Subsidiary secured by a Lien.

 

“Secured Parties”
means (a) the Collateral Agent, (b) each Holder, (c) the Trustee, (d) each other Pari Passu Lien Secured Party
and (e) the successors, replacements and assigns of each of the foregoing, and shall include, without limitation, all former
Collateral Agent, Holder, Trustee and the Pari Passu Lien Secured Party to the extent that any Obligations owing to such Persons
were incurred while such Persons were Collateral Agent, Holder, Trustee or Pari Passu Lien Secured Party and such Obligations have
not been paid or satisfied in full.

 

“Securities
Act” means the Securities Act of 1933, as amended, and the rules and regulations of the SEC promulgated thereunder.

 

    57

     

    

 

“Securitization
Assets” means (a) the accounts receivable, royalty or other revenue streams and other rights to payment and
other assets related thereto subject to a Qualified Securitization Facility and the proceeds thereof and (b) contract
rights, lockbox accounts and records with respect to such accounts receivable and any other assets customarily transferred
together with accounts receivable in a securitization financing.

 

“Securitization
Facility” means any transaction or series of securitization financings that may be entered into by the Company or any
Restricted Subsidiary pursuant to which the Company or any such Restricted Subsidiary may sell, convey or otherwise transfer, or
may grant a security interest in, Securitization Assets to either (a) a Person that is not the Company or a Restricted Subsidiary
or (b) a Securitization Subsidiary that in turn sells such Securitization Assets to a Person that is not the Company or a
Restricted Subsidiary, or may grant a security interest in, any Securitization Assets of the Company or any of its Subsidiaries.

 

“Securitization
Fees” means distributions or payments made directly or by means of discounts with respect to any participation interest
issued or sold in connection with, and other fees and expenses (including reasonable fees and expenses of legal counsel) paid to
a Person that is not a Securitization Subsidiary in connection with, any Qualified Securitization Facility.

 

“Securitization
Subsidiary” means any Subsidiary formed for the purpose of, and that solely engages only in one or more Qualified Securitization
Facilities and other activities reasonably related thereto.

 

“Security
Documents” means the Collateral Trust Agreement, each Additional Pari Passu Lien Debt Designation, each of the other
Pari Passu Lien Security Documents, each of the other security agreements, pledge agreements, mortgages, deeds of trust, collateral
assignments, agreements creating a security interest, charge or encumbrance of any kind, and related agreements, as amended, supplemented,
restated, renewed, refunded, replaced, restructured, repaid, refinanced or otherwise modified from time to time, creating the security
interests in the Collateral as contemplated by the Collateral Trust Agreement.

 

“Senior Indebtedness” means:

 

(1) all
Indebtedness of the Company or BRS Finance Corp. or any Subsidiary Guarantor outstanding under the Term Loan Credit
Agreement, the Notes Indenture, the ABL Facility and the Bond Financing Agreement and related Guarantees (including interest
accruing on or after the filing of any petition in bankruptcy or similar proceeding or for reorganization of the Company or
BRS Finance Corp. or any Subsidiary Guarantor (at the rate provided for in the documentation with respect thereto, regardless
of whether or not a claim for post-filing interest is allowed in such proceedings)), and any and all other fees, expense
reimbursement obligations, indemnification amounts, penalties, and other amounts and all obligations of the Company or BRS
Finance Corp. or any Subsidiary Guarantor to reimburse any bank or other Person in respect of amounts paid under letters of
credit, acceptances or other similar instruments;

 

(2) all
(a) Hedging Obligations (and guarantees thereof) and (b) obligations in respect of Cash Management Services (and
guarantees thereof), in the case of each of clauses (a) and (b), owing to a lender under the Term Loan Credit Agreement,
the ABL Facility or any Affiliate of such lender (or any Person that was a lender or an Affiliate of such lender at the time
the applicable agreement giving rise to such Hedging Obligation or Cash Management Obligations was entered into); provided
that such Hedging Obligations and obligations in respect of Cash Management Services, as the case may be, are permitted to be
incurred under the terms of the Bond Financing Agreement;

 

(3) any
other Indebtedness of the Company or BRS Finance or any Subsidiary Guarantor permitted to be incurred under the terms of the
Bond Financing Agreement, unless the instrument under which such Indebtedness is incurred expressly provides that it is
subordinated in right of payment to the Obligations under the Bond Financing Agreement or any related Guarantee; and

 

    58

     

    

 

(4) all
Obligations with respect to the items listed in the preceding clauses (1), (2) and (3); provided that Senior
Indebtedness will not include: (a) any obligation of such Person to the Company or any of its Subsidiaries; (b) any
liability for federal, state, local or other taxes owed or owing by such Person; (c) any accounts payable or other liability
to trade creditors arising in the ordinary course of business or consistent with industry practice; (d) any Indebtedness or
other Obligation of such Person which is subordinate or junior in any respect to any other Indebtedness or other Obligation
of such Person; or (e) that portion of any Indebtedness which at the time of incurrence is incurred in violation of the
Bond Financing Agreement.

 

“Senior Secured
Net Leverage Ratio” means, with respect to any Test Period, the ratio of (a) Consolidated Secured Debt outstanding
on the last day of such Test Period minus the aggregate amount of cash and Cash Equivalents of the Company and the Restricted
Subsidiaries on such date that (x) would not appear as “restricted” on a consolidated balance sheet of the Company
and the Restricted Subsidiaries or (y) are restricted in favor of the lenders or investors under the Term Loan Credit Agreement,
the ABL Facility, or Other Pari Passu Lien Obligations, to (b) Consolidated EBITDA of the Company for such Test Period, in
each case on a pro forma basis with such pro forma adjustments as are appropriate and consistent with the pro
forma provisions set forth in the definition of Fixed Charge Coverage Ratio.

 

“Senior Secured
Notes” means $600.0 million aggregate principal amount of 7.250% Senior Secured Notes issued by the Company and BRS Finance
Corp., as co-issuers.

 

“Series”
means Bonds identified as a separate series that are authenticated and delivered on original issuance and any Bonds thereafter
authenticated and delivered in lieu of or in substitution for such Bonds pursuant to the Bond Indenture, or any Supplemental Indenture.

 

“Series 2019
Costs of Issuance Account” means the account of that name established in the Construction Fund pursuant to Section 5.01(b) of
the Bond Indenture.

 

“Series 2019
Note” means the Series 2019 Closed End Line of Credit Promissory Note, dated the Closing Date, from the Company
to the Bond Issuer, and assigned to the Trustee, issued to secure the Company’s obligations under the Bond Financing Agreement,
and any other promissory note delivered in connection with Additional Bonds.

 

“Series of
Pari Passu Lien Debt” means, severally, Funded Debt under the Term Loan Credit Agreement, the Notes Indenture, the Specified
Pari Passu Lien Debt Documents, the Bond Financing Agreement, and each other issue or series of Pari Passu Lien Debt for which
a single transfer register is maintained.

 

“Significant
Subsidiary” means any Restricted Subsidiary that would be a “significant subsidiary” as defined in Article 1,
Rule 1-02 of Regulation S-X of the SEC, as such regulation is in effect on the Closing Date; provided that notwithstanding
the foregoing, in no event will any Securitization Subsidiary be considered a Significant Subsidiary for purposes of Sections 7.05,
7.06 and 7.07 of the Bond Financing Agreement and clauses (e), (f) and (g) of the provisions described in the Limited
Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Events of
Default.”

 

“Similar Business”
means (1) any business conducted or proposed to be conducted by the Company or any Restricted Subsidiary on the Closing Date
or (2) any business or other activities that are reasonably similar, ancillary, incidental, complementary or related to (including
non-core incidental businesses acquired in connection with any Permitted Investment), or a reasonable extension, development or
expansion of, the businesses which the Company and its Restricted Subsidiaries conduct or propose to conduct as of the Closing
Date.

 

“Sinking Fund
Installment Payment Subaccount” means the subaccount of that name established in the Principal Account within the Debt
Service Fund pursuant to the Bond Indenture.

 

“Sinking Fund
Installments” mean installment payments in amounts sufficient to redeem the principal amount of 2019 Bonds subject to
mandatory redemption on the applicable redemption date in accordance with the mandatory sinking fund redemption provisions relating
thereto set forth in the Bond Indenture.

 

    59

     

    

 

“SMS Direct Agreement”
means that certain direct agreement (if any) dated as of the Closing Date by and among the Borrower, SMS Site Services Inc., SMS
Group GMBH and the Collateral Agent.

 

“Solvent” and “Solvency”
mean, with respect to any Person on any date of determination, that on such date:

 

(1)            the fair value of the assets of such
Person exceeds its debts and liabilities, subordinated, contingent or otherwise,

 

(2)           the
present fair saleable value of the property of such Person is greater than the amount that will be required to pay the probable
liability of its debts and other liabilities, subordinated, contingent or otherwise, as such debts and other liabilities become
absolute and matured,

 

(3)            such
Person is able to pay its debts and liabilities, subordinated, contingent or otherwise, as such liabilities become absolute and
matured and

 

(4)            such
Person is not engaged in, and is not about to engage in, business for which it has unreasonably small capital.

 

The amount of any contingent
liability at any time shall be computed as the amount that would reasonably be expected to become an actual and matured liability.

 

“Special Record
Date” means, with respect to any Bond, the date established by the Trustee in connection with the payment of overdue
interest on that Bond pursuant to the Bond Indenture.

 

“Specified
Access Period” means for the Commercial Building Collateral or the Equipment Lease Collateral, as the case may
be, the period, which begins on the earlier of (i) the day on which the ABL Agent provides the Commercial Building Lender
or the Equipment Lessor, as the case may be, with an enforcement notice described in the Intercreditor Agreement and as described
in the Limited Offering Memorandum under the heading “SECURITY AND SOURCES OF PAYMENT FOR THE 2019 BONDS AND OTHER PARI PASSU
LIEN DEBT—Intercreditor Agreement;” and (ii) the date on which the Commercial Building Lender or SCF, as the case
may be, provides the ABL Agent with the notice required pursuant to the Intercreditor Agreement and as described in the Limited
Offering Memorandum under the heading “SECURITY AND SOURCES OF PAYMENT FOR THE 2019 BONDS AND OTHER PARI PASSU LIEN DEBT—Intercreditor
Agreement that the Commercial Building Lender or the Equipment Lessor (or any of their agents), as the case may be, has either
obtained possession or control of such Commercial Building Collateral or Equipment Lease Collateral, as applicable, or sold or
otherwise disposed of such Commercial Building Collateral or Equipment Lease Collateral, as applicable, and ends on the earliest
of (A) the 180th day after such date; (B) the date on which all or substantially all of the ABL Priority Collateral located
on the Commercial Building Collateral and the Equipment Lease Collateral is sold, collected or liquidated; and (C) the Discharge
of ABL Obligations.

 

“Specified Commitment Condition”
has the meaning specified in the definition of Initial Funding Date.

 

“Specified
Pari Passu Lien Debt Representative” means KfW IPEX-Bank GmbH, whether acting in its own capacity or as agent to the
lenders under any Specified Pari Passu Lien Debt Document or any of its Affiliates, or any other such representative that has been
designated as “Specified Pari Passu Lien Debt Representative” by the Company in accordance with the Collateral Trust
Agreement, that delivers a Collateral Trust Joinder in the form of Exhibit B to the Collateral Trust Agreement.

 

“Specified
Pari Passu Lien Debt” means the Indebtedness incurred pursuant to the Specified Pari Passu Lien Debt Documents.

 

    60

     

    

 

“Specified
Pari Passu Lien Debt Documents” means (a) any credit agreement described in the Collateral Trust Joinder
delivered by the Specified Pari Passu Lien Debt Representative governing Funded Debt that is designated by the Company as
 “Pari Passu Lien Debt” for the purposes of the Pari Passu Lien Debt Documents in an Additional Pari Passu Lien
Debt Designation executed and delivered in accordance with the Collateral Trust Agreement and (b) any other credit
agreement entered into subsequent to the delivery of the Collateral Trust Joinder described in clause (a) above
governing another Series of Pari Passu Lien Debt for which the Specified Pari Passu Lien Debt Representative maintains
the transfer register and is appointed as a representative of the Pari Passu Lien Debt (for purposes related to the
administration of the Pari Passu Lien Security Documents) pursuant to such credit agreement or other agreement and which
governs Funded Debt that is designated by the Company as “Pari Passu Lien Debt” for the purposes of the Pari
Passu Lien Debt Documents in an Additional Pari Passu Lien Debt Designation executed and delivered in accordance with the
Collateral Trust Agreement; provided, however, that no credit agreement may be designated as, or deemed to be, a
 “Specified Pari Passu Lien Debt Document” if such credit agreement provides for any of the following:
(i) payment of interest in cash rather than solely in kind during a Specified SPOC Period, (ii) scheduled
amortization payments of principal or other repayments of principal during a Specified SPOC Period (it being understood that
such credit agreement will have scheduled amortization payments of principal following the expiration of the Specified SPOC
Period and that none of the foregoing shall prohibit the payment of interest in cash or payment of principal during the
Specified SPOC Period as long as such payment is in each case funded solely with the proceeds of Qualified Capital
Contributions), or (iii) the scheduled final maturity of the Funded Debt evidenced thereby that is prior to the
scheduled final maturity of the Senior Secured Notes.

 

“Specified
Sale and Lease-Back Transaction” means any arrangement providing for the leasing by the Company or any Restricted Subsidiary
of any real or tangible personal property, which property has been or is to be sold or transferred by the Company or such Restricted
Subsidiary to a Governmental Authority in contemplation of such leasing, and which is in connection with the purchase by the Company
or an Affiliate of industrial development revenue bonds, or similar instruments, of a Governmental Authority and pursuant to which
payments of principal, premiums and interest thereon are payable solely from income derived by such Governmental Authority from
such leasing arrangement, including the arrangement contemplated by the Act 9 Bond Documents solely to the extent that parties
under the Act 9 Bond Documents “net settle” any and all payments under such arrangement pursuant to the terms thereof,
including pursuant to the Home Office Payment Agreement, dated as of April 28, 2015.

 

“Specified
SPOC Period” means a period after the Initial Funding Date ending on the earlier to occur of (i) 6 months following
SPOC and (ii) 30 months following the Initial Funding Date.

 

“Specified
Transaction” means (i) solely for the purposes of determining the applicable cash balance, any contribution of capital,
including as a result of an Equity Offering, to the Company, in each case, in connection with an acquisition or Investment, (ii) any
designation of operations or assets of the Company or a Restricted Subsidiary as discontinued operations (as defined under GAAP),
(iii) any Investment that results in a Person becoming a Restricted Subsidiary, (iv) any designation of a Subsidiary
as a Restricted Subsidiary or an Unrestricted Subsidiary in compliance with the Bond Financing Agreement (v) any purchase
or other acquisition of a business of any Person, or assets constituting a business unit, line of business or division of any Person,
(vi) any Asset Sale (without regard to any de minimis thresholds set forth therein) (a) that results in a Restricted
Subsidiary ceasing to be a Subsidiary of the Company or (b) of a business, business unit, line of business or division of
the Company or a Restricted Subsidiary, in each case whether by merger, amalgamation, consolidation or otherwise, (vii) any
operational changes identified by the Company that have been made by the Company or any Restricted Subsidiary during the Test Period
or (viii) any Restricted Payment or other transaction that by the terms of the Bond Financing Agreement requires a financial
ratio to be calculated on a pro forma basis.

 

“SPOC”
means the “starting point of credit” as determined pursuant and in accordance with the OECD Rules and any then
applicable policies and regulations of any relevant export credit agency.

 

“Standstill Commencement Date”
has the meaning set forth in the definition of “CTA Parties Standstill Period.”

 

“Subordinated
Indebtedness” means, with respect to the Obligations under the Bond Financing Agreement and the Series 2019 Note,
(1) any Indebtedness of the Company that is by its terms subordinated in right of payment thereto, and (2) any Indebtedness
of any Guarantor that is by its terms subordinated in right of payment to the Guarantee of such entity of the Obligations under
the Bonds Financing Agreement and the Series 2019 Note.

 

    61

     

    

 

“Subsidiary” means, with respect
to any Person:

 

(1) any
corporation, association, or other business entity (other than a partnership, joint venture, limited liability company or
similar entity) of which more than 50.00% of the total voting power of Equity Interests entitled (without regard to the
occurrence of any contingency) to vote in the election of directors, members of management or trustees thereof is at the time
of determination owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of that
Person or a combination thereof; and

 

(2) any
partnership, joint venture, limited liability company or similar entity of which: (i) more than 50.00% of the capital
accounts, distribution rights, total equity and voting interests or general or limited partnership interests, as applicable,
are owned or controlled, directly or indirectly, by such Person or one or more of the other Subsidiaries of that Person or a
combination thereof whether in the form of membership, general, special or limited partnership or otherwise, and
(ii) such Person or any Restricted Subsidiary of such Person is a controlling general partner or otherwise controls such
entity. Unless otherwise specified, all references herein to a “Subsidiary” or to “Subsidiaries”
refer to a Subsidiary or Subsidiaries of the Company.

 

“Subsidiary Guarantee” means the
Guarantee of a Subsidiary Guarantor.

 

“Subsidiary
Guarantor” means each Restricted Subsidiary of the Company, if any, that Guarantees the Obligations under the Bond Financing
Agreement in accordance with the terms of the Guarantee (excluding any Parent Company that provides any such guarantees).

 

“Supplemental
Indenture” means any indenture supplemental to the Bond Indenture entered into by and between the Issuer and the Trustee
in accordance with Article VIII of the Bond Indenture.

 

“Tax-Exempt
Bonds” means any Bonds, the interest on which is (i) excludable from gross income for federal income tax purposes,
except with respect to interest on any such Bond for any period during which such Bond is held by a person who, within the meaning
of Section 147(a) of the Code, is a “substantial user” or a “related person” to such a “substantial
user” of the facilities financed or refinanced with the proceeds of such Bond, and (ii) an item of tax preference that
is includable in alternative minimum taxable income for purposes of determining the alternative minimum tax.

 

“Tax-Exempt
Obligation” means (a) any obligation the interest on which is excludable from gross income under Section 103(a) of
the Code and which is rated at least “AA” or its equivalent by at least one Rating Agency and is not a “specified
private activity bond” within the meaning of Section 57(a)(5)(C) of the Code, or (b) any interest in a regulated
investment company, the income of which is at least 95% excludable to the holder under Section 103(a) of the Code, and
which invests all its invested assets in obligations described in clause (a) hereof and is rated “Aam” or “AAm-G”
or its equivalent by a Rating Agency.

 

“Tax-Exempt Project” has the meaning
ascribed to such term in the Bond Financing Agreement.

 

“Tax-Exempt
Project Costs” means any and all costs incurred by the Bond Issuer or the Company in connection with the acquisition,
construction, and equipping, as the case may be, of the Tax Exempt Project, and all other costs permitted by the Act and the Code
to be paid or reimbursed from the proceeds of the 2019 Bonds including, but not limited to, the following:

 

(i)            (a)
the cost of the preparation of plans and specifications (including any preliminary study or planning thereof or any aspect
thereof), (b) the cost of acquisition and construction thereof and all construction, acquisition, and installation
expenses required to provide utility services or other facilities and all real or personal properties deemed necessary in
connection therewith (including development, architectural, engineering, and supervisory services with respect to any of the
foregoing), and (c) any other costs and expenses relating to the acquisition, construction, and placing in service
thereof;

 

    62

     

    

 

(ii)           the
purchase price of the equipment in connection therewith, including all costs incident thereto, payment for labor, services,
materials, and supplies used or furnished in site improvement and in the construction thereof, including all costs incident
thereto, payment for the cost of the construction, acquisition, and installation of utility services or other facilities in
connection therewith, payment for all real and personal property deemed necessary in connection therewith, payment of
consulting and development fees in connection therewith, and payment for the miscellaneous expenses incidental to any of the
foregoing items including the premium on any surety bond;

 

(iii)          the
fees or out-of-pocket expenses, if any, of those providing services with respect thereto, including, but not limited to, architectural,
engineering, development and supervisory services;

 

(iv)          any
other costs and expenses relating to the Tax Exempt Project, including, without limitation, interest expense, that constitute costs
or expenses for which the Company may expend 2019 Bond proceeds under the Act, but other than costs of issuance of the Bonds; and

 

(v)           reimbursement
to the Company for any costs described above paid by the it, whether before or after the execution of the Bond Financing Agreement;
provided, however, that reimbursement for any expenditures made prior to the execution of the Bond Financing Agreement, as applicable,
from the Construction Fund shall only be permitted for expenditures meeting the requirements of the Regulations, including but
not limited to, §1.150-2 of the Regulations.

 

“Term Loan Administrative Agent”
means Goldman Sachs Bank USA.

 

“Term Bonds”
means 2019 Bonds that are payable on or before their specified maturity dates from Sinking Fund Installments.

 

“Term
Loan” means the loan of the proceeds of the Term Loan Credit Agreement from the lenders and other entities party
thereto to the Company, pursuant to the Term Loan Credit Agreement.

 

“Term Loan
Credit Agreement” means the first lien secured term loan credit agreement, dated as of August 23, 2017, by and among
the Company, Parent, Goldman Sachs Bank USA, as the administrative agent, and the lenders and other entities party thereto, as
amended, restated, amended and restated, supplemented or otherwise modified from time to time, including any replacement thereof
if such replacement thereof which has been designated as Additional Pari Passu Lien Debt under the Collateral Trust Agreement.

 

“Test Period”
in effect at any time means the Company’s most recently ended four consecutive fiscal quarters for which internal financial
statements are available (as determined in good faith by the Company).

 

“Top Parent” means Big River Steel
Parent LLC and any successor thereof.

 

“Total Net
Leverage Ratio” means, with respect to any Test Period, the ratio of (a) Consolidated Total Debt outstanding on
the last day of such Test Period minus the aggregate amount of cash and Cash Equivalents of the Company and the Restricted
Subsidiaries on such date that (x) would not appear as “restricted” on a consolidated balance sheet of the Company
or (y) are restricted in favor of the Term Loan Credit Agreement, the ABL Facility or Other Pari Passu Lien Obligations to
(b) Consolidated EBITDA of the Company for such Test Period, in each case on a pro forma basis with such pro forma
adjustments as are appropriate and consistent with the pro forma adjustment provisions set forth in the definition of Fixed
Charge Coverage Ratio.

 

“Trust Estate” has the meaning
given to such term in the Bonds Indenture.

 

“Trust Estate
Revenues” means (a) the Bond Financing Payments, (b) all of the moneys received or to be received by the Bond
Issuer or the Trustee in respect of payment of the amounts owing under the Bond Financing Agreement, (c) all moneys and investments
in the Debt Service Fund (created and held under the Bond Indenture), (d) with regard to a Series of Bonds, the proceeds
of such Series and investments thereof in the Construction Fund (or in any account or subaccount therein relating to such
Series) created and held by the Trustee for the benefit of the Bond Issuer and the holders of the Bonds until expended, (e) with
regard to any other Series of Bonds, all amounts on deposit in a debt service reserve fund (if any) held for the benefit
of the holders of such Series of Bonds, and (f) all income and profit from the investment of the foregoing moneys. For the
avoidance of doubt, with regard to (d) herein, any proceeds of a Series of Bonds constitute “Trust Estate Revenues”
only for the Series from which such proceeds were derived and for no other Series of Bonds.

 

    63

     

    

 

“Trustee”
means the Trustee at the time acting on behalf of itself and the owners of the Bonds under the Bond Indenture, originally U.S.
Bank National Association, as Trustee, and any successor Trustee as determined or designated under or pursuant to the Bond Indenture.

 

“Trust Indenture Act” means the
Trust Indenture Act of 1939, as amended (15 U.S.C. §§ 77aaa- 777bbbb).

 

“Unassigned Issuer’s Rights”
shall have the meaning ascribed thereto in the Bond Financing Agreement.

 

“Underwriter”
means, collectively, Goldman Sachs & Co. LLC, Crews & Associates, Inc. and SunTrust Robinson Humphrey, Inc.

 

“Uniform Commercial
Code” or “UCC” means the Uniform Commercial Code or any successor provision thereof as the same may
from time to time be in effect in the State of New York; provided, however, that in the event that, by reason of mandatory provisions
of law, any or all of the perfection or priority of, or remedies with respect to, any Collateral is governed by the Uniform Commercial
Code as enacted and in effect in a jurisdiction other than the State of New York, the term “UCC” shall mean the Uniform
Commercial Code as enacted and in effect in such other jurisdiction solely for purposes of the provisions of the Pari Passu Lien
Security Documents relating to such perfection, priority or remedies.

 

“Unrestricted Subsidiary” means:

 

(1) any
Subsidiary of the Company which at the time of determination is an Unrestricted Subsidiary (as designated by the Company, as
provided below); and

 

(2) any Subsidiary of an Unrestricted
Subsidiary.

 

The Company
may designate any Subsidiary of the Company (including any existing Subsidiary and any newly acquired or newly formed Subsidiary)
to be an Unrestricted Subsidiary unless such Subsidiary or any of its Subsidiaries owns any Equity Interests or Indebtedness of,
or owns or holds any Lien on, any property of, the Company or any Subsidiary of the Company (other than solely any Subsidiary of
the Subsidiary to be so designated);

 

provided:

 

(1)
such designation complies with Section 6.01 of the Bond Financing Agreement and as described in the covenant described
in the Limited Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing
Agreement—Covenants of the Company—Limitation on Restricted Payments;” and

 

(2) each
of (a) the Subsidiary to be so designated and (b) its Subsidiaries has not at the time of designation, and does not
thereafter, create, incur, issue, assume, guarantee or otherwise become directly or indirectly liable with respect to any Indebtedness
pursuant to which the lender has recourse to any of the assets of the Company or any Restricted Subsidiary (other than Equity
Interests in an Unrestricted Subsidiary). The Company may designate any Unrestricted Subsidiary to be a Restricted Subsidiary;
provided that immediately after giving effect to such designation, no Event of Default will have occurred and be continuing
and the Company could incur at least $1.00 of additional Indebtedness pursuant to the Fixed Charge Coverage Ratio test set forth
in the Section 6.03(a) of the Bond Financing Agreement and of the first paragraph of the covenant described in the Limited
Offering Memorandum under the heading “FINANCING FOR THE TAX-EXEMPT PROJECT—Bond Financing Agreement—Covenants
of the Company—Limitation on Incurrence of Indebtedness and Issuance of Disqualified Stock and Preferred Stock;” and.
Any such designation by the Company will be notified by the Company to the Trustee by promptly filing with the Trustee a copy
of the resolution of the Board of Directors or any committee thereof giving effect to such designation and an Officer’s
Certificate certifying that such designation complied with the foregoing provisions.

 

    64

     

    

 

“Use of Proceeds
Certificate” means the Use of Proceeds Certificate and Agreement, dated the Closing Date, between the Bond Issuer and
the Company, as amended from time to time pursuant to the terms thereof.

 

“Voting Stock”
of any Person as of any date means the Capital Stock of such Person that is at the time entitled to vote in the election of the
Board of Directors of such Person.

 

“Weighted
Average Life to Maturity” means, when applied to any Indebtedness, Disqualified Stock or Preferred Stock, as the case
may be, at any date, the quotient obtained by dividing: (1) the sum of the products of the number of years (calculated to
the nearest one-twenty-fifth) from the date of determination to the date of each successive scheduled principal payment of such
Indebtedness or redemption or similar payment with respect to such Disqualified Stock or Preferred Stock, multiplied by
the amount of such payment; by (2) the sum of all such payments; provided that for purposes of determining the Weighted
Average Life to Maturity of any Indebtedness that is being Refinanced (the “Applicable Indebtedness”), the effects
of any amortization or prepayments made on such Applicable Indebtedness prior to the date of the applicable Refinancing will be
disregarded.

 

“Wholly-Owned
Subsidiary” of any Person means a Subsidiary of such Person, 100.00% of the outstanding Equity Interests of which (other
than directors’ qualifying shares and shares of Capital Stock of Foreign Subsidiaries issued to foreign nationals as required
under applicable law) is at the time owned by such Person and/or by one or more Wholly-Owned Subsidiaries of such Person.

 

“Wholly-Owned Restricted Subsidiary”
is any Wholly-Owned Subsidiary that is a Restricted Subsidiary.

 

    65Exhibit 10.11

 

*** CERTAIN MATERIAL (INDICATED BY THREE ASTERISKS IN BRACKETS) HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH (1) NOT MATERIAL AND (2) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.

 

CONFIDENTIAL

 

MATERIAL TRANSFER AND COLLABORATION AGREEMENT

 

This Material Transfer and Option Agreement (“Agreement”), is made on April 11, 2019 (“Effective Date”) and is entered into by and between ADC THERAPEUTICS SA, a company having an address at Route de la Corniche 3B, 1066 Epalinges, Switzerland (“ADCT”), ADAGENE Inc., a Cayman company having an address at Grand Pavilion, Hibiscus Way, 802 West Bay Road, P.O. Box 31119, KY1-1205, Cayman Islands, (“ADAGENE”), ADAGENE also acting on behalf and for the account of its affiliated companies, including in the USA and in PRC, as listed in Annex 7 (individually “ADAGENE Affiliate” and collectively as “ADAGENE Affiliates”). ADCT and ADAGENE are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”

 

RECITALS

 

WHEREAS, ADCT has expertise and proprietary Intellectual Property (as defined below) in the field of antibody drug conjugates (“ADC”) and cancer cell destroying warheads known as [***] and

 

WHEREAS, ADAGENE has expertise and proprietary Intellectual Property in the field of antibody engineering known as SAFEbodyTM (“SAFEbody Technology”).

 

WHEREAS, ADCT wishes ADAGENE, who agrees, to engineer certain antibodies selected by ADCT using the SAFEbody Technology to be used by ADCT for the research, development, manufacturing and potential commercialization of certain ADCs, in accordance with the terms and conditions of this Agreement and of the License Agreement (as defined below).

 

WHEREAS, should ADCT exercise its option for the License Agreement for the [***] SAFEbody ADC (as defined below), ADCT is willing to grant to ADAGENE a license to the [***] SAFEbody ADC in the territory of China as specified in the License Agreement.

 

NOW THEREFORE, in consideration of the mutual covenants contained herein, the Parties agree as follows:

 

1.                                      DEFINITIONS

 

Capitalized terms used in this Agreement, whether used in the singular or plural, shall have the meanings specified in this Section.

 

1.1          “ADAGENE Background IP” means Background IP owned or controlled, in whole or in part, by ADAGENE or any of its Affiliates, on the Effective Date of this Agreement, including the SAFEbody Technology and the [***] SAFEbody and the ADAGENE library of blocking peptides.

 

1

 

1.2                               “ADAGENE Final Report” shall have the meaning given in Section 2.5.

 

1.3          “ADAGENE Know-How” means any and all Know-How owned or controlled by ADAGENE or any of its Affiliates at any time relating to the SAFEbody Technology and any improvements thereof.

 

1.4          “ADAGENE Materials” means the [***] SAFEbody, including genetic sequences, and related Confidential Information, as supplied by ADAGENE to ADCT for the purpose of and for use in the Development Plan.

 

1.5          “ADAGENE New IP” means any improvements to the SAFEbody Technology and ADAGENE Background IP developed by ADAGENE or any of its Affiliates under this Agreement, the ADAGENE Platform Improvements and the ADAGENE library of peptides, including Results that are specific to such improvements and that are not specific to the [***] SAFEbody, the [***] SAFEbody (if any), any Conjugated Materials, the [***] SAFEbody Panel, or the [***] SAFEbody Panel, with the express exclusion of the [***] SAFEbody Panel, the [***] SAFEbody Panel, the ADCT New IP, the ADCT Platform Improvements, the Conjugated Materials and any ADC including the [***] SAFEbody, a [***] SAFEbody or the [***] SAFEbody.

 

1.6          “ADAGENE Patents” means any Patents and Patents Applications owned or controlled by ADAGENE or any of its Affiliates, necessary or useful to practice the SAFEbody Technology.

 

1.7          “ADAGENE Platform Improvements” means IP that is developed under this Agreement that specifically relates to ADAGENE’s proprietary SAFEbody Technology, and that is not specific to [***] SAFEbodies, [***] SAFEbodies, ADCs or ADCT’s proprietary [***] toxic molecules, or linkers, the ADCT Platform Improvements or the ADCT New IP.

 

1.8          “ADC” means an antibody drug conjugate in any form, as selected by ADCT in its sole discretion, containing any cytotoxic payload, such as a [***] or any other toxic molecule, linkers and/or other tangible material, as well as an antibody in any form (including the [***] SAFEbody, a [***] SAFEbody or the [***] SAFEbody, in each case as may be modified by ADCT as needed to facilitate its conjugation).

 

1.9          “ADCT Background IP” means Background IP owned or controlled, in whole or in part, by ADCT, including PBDs, or any other toxic molecules, linkers and/or other tangible materials, ADCs, the [***] and any IP related thereto.

 

1.10        “ADCT Platform Improvements” means IP that is developed under this Agreement that specifically relates to ADCT’s proprietary [***] toxic molecules, or linkers, used alone or in conjugation with the SAFEbody Technology.

 

2

 

1.11        “ADCT Final Report” shall have the meaning given in Section 2.5.

 

1.12        “ADCT Material” means any cytotoxic compounds, linkers and or other tangible material, including [***] the [***] SAFEbody and the [***] SAFEbody.

 

1.13        “ADCT New IP” means IP Rights covering the composition, the manufacturing, selling or use of the [***] SAFEbody, the [***] SAFEbody (if any), any Conjugated Materials, the [***] SAFEbody Panel, the [***] SAFEbody Panel, the Results (other than Results that are specific to improvements to the SAFEbody Technology and ADAGENE Background IP developed by ADAGENE or any of its Affiliates under this Agreement, the ADAGENE Platform Improvements and the ADAGENE library of peptides, in each case that are not specific to the [***] SAFEbody, the [***] SAFEbody (if any), any Conjugated Materials, the [***] SAFEbody Panel, or the [***] SAFEbody Panel), and any improvements to the ADCT Background IP developed under this Agreement. ADCT New IP expressly excludes the ADAGENE New IP.

 

1.14        “Affiliate” means any person, company or other entity that, directly or indirectly (through one or more intermediaries) controls, is controlled by, or is under common control with a Party. For purposes of this Article 1.2, “control” means (i) the direct or indirect ownership of greater than fifty percent (50%) of the voting stock or other voting interests or interest in the profits of the Party, or (ii) the ability to otherwise control or direct the decisions of board of directors or equivalent governing body thereof.

 

1.15        “Background IP” means any IP that is owned or controlled (including through a license, sublicense or other right to exploit) by a Party or its Affiliates and that (a) exists as of and/or was conceived prior to the Effective Date of this Agreement or (b) is generated, conceived, obtained or otherwise acquired by a Party after the Effective Date independently of this Agreement without the use of the other Party’s Confidential Information or IP.

 

1.16        “BLA” means a biologies license application (“BLA”) filed with the U.S. Food and Drug Administration or any successor application thereto for approval to sell a biological product and any foreign equivalent of any such BLA application filed with a regulatory authority in any other country.

 

1.17        “Chinese Territory License” shall have the meaning given in Section 6.

 

1.18        “Commercially Reasonable Efforts” means, with respect to the performance of the Development Plan by a Party, the carrying out of such activities using efforts and resources that a biopharmaceutical company of similar size would typically devote to compounds or products of similar market potential at a similar stage in development or product life, taking into account all scientific, commercial and other factors that the Party would take into account, including issues of safety and efficacy, expected and actual cost and time to develop, expected and actual profitability (including payments required hereunder), expected and actual competitiveness of alternative Third Party products (including generic products) in the marketplace, the nature and extent of expected and actual market exclusivity (including Patent coverage and regulatory exclusivity), the expected likelihood of regulatory approval, the expected and actual labeling, the expected and actual reimbursability and pricing and the expected and actual amounts of marketing and promotional expenditures required.

 

3

 

1.19        “Confidential Information’’ means any non-public information proprietary to or controlled by a Party (“Disclosing Party”) and (i) disclosed in connection with this Agreement to the other Party (“Receiving Party”) in writing, orally or visually and which is identified as “confidential” or which should be considered confidential given the nature and circumstances of disclosure by a reasonable person working in the industry, or (ii) created by, or on behalf of, either Party and provided to the other Party, or created jointly by the Parties, in the course of this Agreement. Confidential Information may include but is not limited to technology, Know-How, methods, test results, data, protocols, product information, and other information relating to research, development, clinical, manufacturing, marketing, commercialization or regulatory related activities, business plans or financial information, and the Materials, Conjugated Materials or any other tangible materials and deliverables provided by one Party to the other Party. For clarity, proprietary information corresponding to IP owned by a Part}’ shall be deemed such Party’s Confidential Information, such Party shall be deemed the Disclosing Party and the other Party shall be deemed the Receiving Party, regardless of which Party actually disclosed or generated such information.

 

1.20        “Conjugated Materials” means the ADCs generated by ADCT by conjugating certain ADCT Materials to the [***] SAFEbody, the [***] SAFEbody or the [***] SAFEbody.

 

1.21        “Criteria” means a [***] SAFEbody and a [***] SAFEbody that exhibits a masking efficiency equal to or greater than [***] fold as compared to the corresponding native antibody, while the masking efficiency should approximately be one (1) or less than one (1) after proteolytical removal of the masking peptide. Masking efficiency is calculated as: EC50 (SAFEbody)/EC50 (corresponding native antibody).

 

1.22        “Development Plan” means the research program consisting of up to three proof of concepts research programs, namely the [***], [***] and [***] as detailed and defined in Annex 1.

 

1.23        “Exclusivity Fee” shall have the meaning given in Section 3.3.

 

1.24        “Field” means the use of ADCs for human therapeutics and related diagnostics.

 

1.25        “IND Application” means investigational new drug application filed with the U.S. Food and Drug Administration or any successor application thereto and any foreign equivalent of any such application filed with the applicable regulatory authority.

 

1.26        “Intellectual Property” or “IP” means all proprietary algorithms, apparatus, assay components, biological materials, cell lines, chemical compositions or structures, clinical trial designs, plans for obtaining regulatory approval, concepts, Confidential Information, Results, designs, diagrams, documentation, drawings, flow charts, formulae, ideas and inventions (whether or not patentable or reduced in practice), Patents, Know-How, trade secrets, marks (including brand names, trademarks, product names, logos, and slogans), methods, models, procedures, processes, protocols, specifications, techniques, tools, user interfaces, works of authorship, copyright, or other forms of IP.

 

4

 

1.27        “Intellectual Property Rights” or “IP Rights” means all past, present and future rights, which may exist or be created under the laws of any jurisdiction in the world, in Intellectual Property of every kind and nature.

 

1.28        “JSC” shall have the meaning set forth in Section 2.4.

 

1.29        “Know-How” means technical and other information which is not in the public domain including, ideas, concepts, inventions (whether or not patentable), discoveries, data, formulae, cell-line libraries, antibody libraries, algorithms, improvements, practices, trade secrets, techniques, methods, specifications, knowledge, clinical data, procedures for experiments and tests, results of experimentation and testing, results of research and development (including laboratory records and data analysis, pharmacological, toxicological, pharmacokinetic, pre-clinical and clinical study results, related reports, structure-activity relationship data and statistical analysis) regarding, without limitation, discovery, research, development, manufacturing, marketing, pricing, distribution, costs and sales relating to the SAFEbody Technology. Information in a compilation or a compilation of information may be Know-How notwithstanding that some or all of its individual elements are in the public domain. Know-How excludes any Patents and constitutes Confidential Information.

 

1.30        “License Agreement” means the license agreement executed between ADCT and ADAGENE and herein attached as Annex 2, by which ADAGENE will grant to ADCT after exercise of the [***] Option and/or [***] License Option, an exclusive, irrevocable (except as expressly set forth in the termination provisions of the License Agreement), worldwide, sub-licensable license under the Licensed IP to research, develop, manufacture, make, use, sell, offer for sale, market, commercialize, distribute and import, and have researched, developed, manufactured, made, used, sold, offered for sale, marketed, commercialized, distributed, or imported, ADCs in the Field. The License Agreement shall only become effective with respect to the [***] program if and when ADCT exercises its [***] Option in accordance with the procedure set forth in Section 5 below. The License Agreement shall only become effective with respect to the [***] program if and when ADCT exercises its [***] License Option in accordance with the procedure set forth in Section 5 below.

 

1.31        “Licensed IP” or “Licensed Intellectual Property” means any and all IP Rights owned or controlled by ADAGENE or any of its Affiliates at any time relating to the SAFEbody Technology, including the ADAGENE Background IP, the ADAGENE Patents if any, the ADAGENE Know-How and any other ADAGENE IP Rights relating thereto, and any improvements thereof.

 

5

 

1.32        “Materials” means the ADCT Materials, the Conjugated Materials, the ADAGENE Materials and any Confidential Information relating thereto.

 

1.33        “[***]  Antibody” means a chimeric or humanized antibody which binds to the [***] Target, as selected and supplied by ADCT to ADAGENE for the purpose of ADAGEN engineering such antibody using the SAFEbody Technology and thus generating a [***] SAFEbody.

 

1.34        “[***]  Option” shall have the meaning given in Section 5.1.

 

1.35        “[***] Option Period” means a period from the Effective Date of this Agreement until the earlier of: (i) twenty four (24) months from the date ADCT receives the [***] SAFEbody Panel from ADAGENE; or (ii) IND filing of the [***] SAFEbody ADC.

 

1.36        “[***]  PoC”means the PoC for the [***] SAFEbody, the [***] SAFEbody Panel and the [***] SAFEbody ADCs, as further defined in the Development Plan.

 

1.37        “[***]  PoC Initiation Notice” shall have the meaning given in Section 2.1.2.

 

1.38        “[***]  SAFEbody” means the [***] Antibody supplied by ADCT and comprising a masking peptide identified using the SAFEbody Technology.

 

1.39        “[***] SAFEbody ADC” means an ADC containing a [***] SAFEbody.

 

1.40        “[***]  SAFEbody Panel” means a panel of at least [***] SAFEbody versions of the [***] Antibody, as selected by the JSC. In the event there are more than [***] SAFEbody versions arising from ADAGENE’s activities under this Agreement that meet the Criteria, then the Parties shall discuss in good faith as to determine if the [***] SAFEbody Panel shall include more than [***] SAFEbody versions.

 

1.41        “[***]  Target” means a Target that binds to [***], as exclusively reserved by ADAGENE to ADCT.

 

1.42        “Patents” means any patent applications, patents, author certificates, inventor certificates, utility models, and all foreign counterparts of them and includes all divisionals, renewals, continuations, continuations-in-part, extensions, reissues, substitutions, confirmations, registrations, revalidations and additions of or to them, as well as any supplementary protection certificate, or any like form of protection.

 

6

 

1.43        [***] means a compound containing the following atomic framework:

 

[***]

 

For the avoidance of doubt, such compounds may include additional unsaturation, be substituted on any position, or be fused to another structure.

 

1.44        “PoC” means Proof of Concept as further defined in the Development Plan.

 

1.45        “[***]” means the PoC for the development of [***] SAFEbody, [***] SAFEbody Panel and [***] SAFEbody ADCs, as further defined in the Development Plan.

 

1.46        “[***]  Alternative Target” shall have the meaning given in Section 2.1.4 (b).

 

1.47        “[***]  Antibody” means a chimeric or humanized antibody which binds to the [***] Target, as selected and supplied by ADCT to ADAGENE for the purpose of ADAGENE engineering such antibody using the SAFEbody Technology and thus generating a [***] SAFEbody.

 

1.48        “[***]  Initiation Notice” shall have the meaning given in Section 2.1.4.

 

1.49        “[***]  License” shall have the meaning given in Section 5.3.

 

1.50        “[***]  License Option” shall have the meaning given in Section 5.4.

 

1.51        “[***]  Option Period” means a period from the Effective Date of this Agreement until the earlier of: (i) twenty (24) months from the date ADCT receives the [***] SAFEbody Panel from ADAGENE; and (ii) IND filing the [***] SAFEbody ADC.

 

1.52        “[***]  Reserved Targets” means the Targets identified in Annex 4, which are exclusively reserved by ADAGENE to ADCT in accordance with the terms and conditions of this Agreement.

 

1.53        “[***]  SAFEbody” means the antibody sequence against the [***] Target selected and provided by ADCT for the purpose of the [***] and comprising a masking peptide identified using the SAFEbody Technology under [***].

 

1.54        “[***]  SAFEbody ADCs” means an ADC containing a [***] SAFEbody.

 

1.55        “[***]  SAFEbody Panel” means a panel of at least [***] SAFEbodies versions of the [***] Target based on an antibody sequence provioed by ADCT for the purpose of the [***] as selected by the JSC. In the event there are more than [***] SAFEbody versions arising from ADAGENE’s activities under this Agreement that meet the Criteria, then the Parties shall discuss in good faith as to determine if the [***] SAFEbody Panel shall include more than [***] SAFEbody versions.

 

7

 

1.56        “[***]  Target” means the Target selected by ADCT in accordance with Section 2.1.4 for the purpose of [***] and against which ADAGENE shall generate the [***] SAFEbody Panel using the SAFEbody Technology based on the antibody sequence of [***] Antibody.

 

1.57        “Representatives” means the directors, officers, employees, agents, advisors, contractors of a Party or of its Affiliates.

 

1.58        “Reservation Fee” shall have the meaning given in Section 3.4.

 

1.59        “Results” means any and all data, information, Know-How, analysis, results, inventions, cell bank library, antibody library, [***] SAFEbody Panel, [***] SAFEbody Panel, whether patentable or not, which are generated, developed, or otherwise discovered pursuant to this Agreement by either Party (alone or with others) or by the Parties jointly, and which specifically relate to the [***] SAFEbody or [***] SAFEbody or ADC. For clarity, Results does not include ADAGENE’s existing masking peptide library.

 

1.60        “SAFEbody Technology” means ADAGENE’s proprietary antibody engineering technology performed by ADAGENE which enables an antibody to bind its target specifically only after conditional activation of the antibody, including but not limited to cleavage of a protecting group in the vicinity of a cancer cell, including as covered by the ADAGENE Patents and other ADAGENE Know-How described in Annex 5. Such protecting group is referred to herein as a “masking peptide” (such masking peptide may also include a portion which is cleaved).

 

1.61        ‘‘Successful Completion of GLP Toxicology Studies” means with respect to the [***] SAFEbody ADC and the [***] SAFEbody ADC a final report stating, in ADCT’s sole discretion, that the available results from GLP toxicology studies confirm the adequate safety profile of the [***] SAFEbody ADC or [***] SAFEbody ADC, as applicable, to support an IND filing.

 

1.62        “Target” means an antigen or protein described by a unique UniprotKB/Swiss Prot accession number (and all fragments, mutations, splice variants and isoforms thereof having the biological activity of such protein) against which ADCT intends to develop a [***] SAFEbody and/or the [***] SAFEbody.

 

1.63        “Term” shall have the meaning set forth in Section 9.1 to this Agreement.

 

1.64        “Territory” means People’s Republic of China, Macao, Hong-Kong and Taiwan.

 

1.65                        “Third Party” means any person other than ADCT, ADAGENE and their respective Affiliates.

 

8

 

1.66        “[***]  PoC” means the PoC for the [***] SAFEbody as further defined in the Development Plan.

 

1.67        “[***]  SAFEbody” means the ADAGENE proprietary [***] antibody that binds to [***] as engineered by ADAGENE using the SAFEbody Technology.

 

2.             DEVELOPMENT PLAN

 

2.1          ADCT and ADAGENE agree to conduct the Development Plan as set forth in Annex 1 and in accordance with the terms and conditions of this Agreement. The Parties acknowledge and agree that the Development Plan shall divided in up to three proof of concept development programs, namely the [***] PoC, the [***] PoC and [***], as detailed in Annex 1. Prom time to time during the Term, ADCT shall have the right to modify the Development Plan by written notice to ADAGENE, provided that any such modification that would result in a material increase of ADAGENE’s obligations (including unreimbursed expenses from ADCT) under the Development Plan shall require ADAGENE’s prior written consent.

 

2.1.1                     The Parties agree to initiate the [***] PoC upon the Effective Date of this Agreement. ADAGENE shall supply 150 mg of [***] SAFEbody at no cost to ADCT at such date as specified in Annex 1.

 

2.1.2                     ADCT may notify ADAGENE in writing of its desire to initiate the [***] PoC at any time during the [***] Option Period but at the latest within sixty (60) days of completion of [***] PoC (“[***] PoC Initiation Notice”). [***] Antibody is hereby exclusively reserved for ADCT in accordance with Section 2.2.1. For the avoidance of doubt, ADCT is under no obligation to initiate the [***] PoC under this Agreement.

 

2.1.3                     Within [***] from the date of the [***] PoC Initiation Notice, ADAGENE shall generate and select [***] SAFEbodies meeting the Criteria, and supply to ADCT the amino acid sequences of the corresponding masking peptides, and such information shall be deemed Confidential Information of ADCT. For this purpose, ADAGENE shall select those [***] SAFEbodies within a library of antibodies, that, in its reasonable experience, Know-How, and considering ADCT’s input as well, will present the best engineered structure to successfully enable conjugation with the ADCT Materials. During this process, ADAGENE shall fully collaborate with ADCT and work in full transparency with ADCT in order to elect the best [***] SAFEbodies to be the [***] SAFEbody Panel. Final decision relating to the selection of the [***] SAFEbody Panel shall be made by the JSC. ADCT acknowledges that the generation and selection of biomolecules is unpredictable and that the timeline for generation and selection of the masking peptides may be delayed, and the [***] period will be extended by any reasonable delay outside of ADAGENE’s control.

 

9

 

2.1.4                     [***] initiation.

 

a)             In addition, at any time during the [***] Option Period, ADCT may elect to initiate [***] by sending written notice to ADAGENE identifying the [***] Target elected by ADCT, such elected [***] Target being either from the list of the [***] Reserved Targets or a [***] Alternative Target (as sot forth in Section 2.1.4 (b) below) (“[***] Initiation Notice”), it being however understood and agreed that ADCT is under no obligation to initiate the [***] under this Agreement.

 

b)             For the purpose of [***] Target election, no later than [***] days before the expiry date of the [***] Option Period, ADCT may ask ADAGENE in writing (including by email) to confirm if a certain Target named by ADCT, other than the [***] Reserved Targets, (the “[***] Alternative Target”), is available and can be elected by ADCT as a [***] Target under this Agreement. Within [***] business days from the date of ADCT’s request. ADAGENE shall confirm if the [***] Alternative Target is available or not as an Target to the sole and exclusive benefit of ADCT. The [***] Alternative Target shall be deemed available if ADAGENE has not, prior to ADCT’s notice hereunder and as supported by written evidence as set forth below, either (i) already granted exclusive development and commercial rights to the [***] Alternative Target to a Third Party; or (ii) has agreed to a bona fide term sheet and is in preparation or negotiations for a definitive agreement to grant exclusive development and commercial rights to the [***] Alternative Target to a Third Party, provided that in such event, if ADAGENE does not enter into such definitive agreement with such Third Party prior to the expiration of the [***] Option Period, then ADCT shall have the right to elect such Target as the [***] Target under Section 2.1.4(a); or (iii) elected to retain the exclusive rights itself to such [***] Alternative Target and is actively developing its SAFEbody Technology agains such [***] Alternative Target. If ADAGENE claims that the [***] Alternative Target is not available, ADAGENE shall provide ADCT’s outside counsel in confidence with a copy of the exclusive reservation agreement with such Third Party (provided that the financial terms of said agreement might be redacted) or provide ADCT with written evidence that the [***] Alternative Target is being actively developed by ADAGENE as supported by dated pre-clinical or clinical data. If the requested [***] Alternative Target is available, ADAGENE shall immediately notify ADCTand ADCT shall have the right, but not the obligation, to elect such [***] Alternative Target as the [***] Target in lieu of either Reserved Target in accordance with Section 2.1.4 (a) above prior to the expiration of the [***] Option Period.

 

10

 

c)              Upon election of the [***] Target as stated in the [***] Initiation Notice, ADAGENE shall be free to release the exclusive reservation to the other Target(s) not-elected for the purpose of the [***] (i.e. either one or both [***] Reserved Target(s) or the [***] Alternative Target as the case may be), and ADAGENE shall be free to develop those other Targets which have not been elected for the [***] as it deems appropriate.

 

2.1.5                                             Within [***] months from the date of the [***] Initiation Notice, ADAGENE shall generate and select [***] SAFEbodies meeting the Criteria, and supply to ADCT the amino acid sequences of the corresponding masking peptides, and such information shall be deemed Confidential Information of ADCT. For this purpose, ADAGENE shall select those [***] SAFEbodies within a library of antibodies, that, in its reasonable experience, Know-How, and considering ADCT’s input as well, will present the best engineered structure to successfully enable conjugation with the ADCT Materials. During this process, ADAGENE shall fully collaborate with ADCT and work in full transparency with ADCT in order to elect the best [***] SAFEbodies to be the [***] SAFEbody Panel. Final decision relating to the selection of the [***] SAFEbody Panel shall be made by the JSC. ADCT acknowledges that the generation and selection of biomolecules is unpredictable and that the timeline for generation and selection of the masking peptides may be delayed, and the [***] period will be extended by any reasonable delay outside of ADAGENE’s control.

 

2.2          Exclusivity and non-compete obligations.

 

2.2.1                     (A) Effective from the Effective Date, ADAGENE agrees to exclusively reserve the [***] Target and to exclusively develop a [***] SAFEbody for the sole benefit of ADCT. (B) Further, ADAGENE shall refrain from (i) developing for itself or for or with any Third Party a [***] SAFEbody or any other antibody or antibody drug conjugate that binds to the [***] Target, regardless of whether (a) it uses the SAFEbody Technology or not; or (b) it is selected from the ADAGENE proprietary antibody library or not; and (ii) granting to a Third Party any rights to ADAGENE’s Intellectual Property Rights necessary or useful for the Development Plan or which would preclude ADAGENE from granting the License Agreement under Section 5; and (iii) taking any actions which would result in infringing any of ADCT’s IP Rights in the ADCT New IP. The obligations under this section 2.21 (A) and 2.2.1 (B)(i) and (ii) shall terminate immediately if the [***] PoC is never initiated by ADCT, or [***] PoC is initiated but the [***] Option is not exercised by ADCT in the [***] Option Period, in which case the obligations under this Section 2.2.1 (i) and (ii) shall terminate at the end of the [***] Option Period or, if earlier, on the effective date of termination of this Agreement. Unless terminated as provided in this Section 2.2.1, the obligations under this Section 2.2.1 shall survive the expiration of this Agreement.

 

11

 

2.2.2                     (A) Effective from the Effective Date of this Agreement, ADAGENE agrees to exclusively reserve the [***] Reserved Targets and to exclusively develop SAFEbody versions of the [***] Reserved Targets for the exclusive benefit of ADCT. ADAGENE shall also exclusively reserve [***] Alternative Target as soon as its availability is confirmed in accordance with Section 2.1.4 (b) and exclusively develop SAFEbody versions of the [***] Alternative Target for the exclusive benefit of ADCT. (B) Further, ADAGENE shall refrain from (i) developing for itself or for or with any Third Party a [***] SAFEbody or any other antibody or antibody drug conjugate that binds to the [***] Reserved Targets or [***] Alternative Target, regardless of whether (a) it uses the SAFEbody Technology or not; or (b) it is selected from the ADAGENE proprietary antibody library or not; and (ii) granting to a Third Party any rights to ADAGENE’s Intellectual Property Rights necessary or useful for the Development Plan or which would preclude ADAGENE from granting the [***] License under Section 5; and (iii) from taking any actions which would result in infringing any of ADCT’s IP Rights in the ADCT New IP. ADAGENE shall be released from its obligations under this section 2.2.2 (A) and 2.2.2 (B) (i) and (ii) as follows:

 

·                  if [***] is never initiated by ADCT, or if ADCT elects the [***] Alternative Target for [***] in accordance with Section 2.1.4, then both [***] Reserved targets shall be released from the [***] Initiation Notice date, or

 

·                  if ADCT elects one of the two [***] Reserved Targets for the purpose of the [***] in accordance with Section 2.1.4, then the [***] Reserved Target and the [***] Alternative Target if any which has not been elected for [***] shall be released from the [***] Initiation Notice date; or 

 

·                  if [***] is initiated with any [***] Targets but the [***] Option is not exercised by ADCT within the [***] Option Period, then the [***] Target elected for [***] shall be released at expiry of the [***] Option Period, or, if earlier, on the effective date of termination of this Agreement.

 

Unless terminated as provided in this Section 2.2.2, the obligations under this Section 2.2.2 shall survive the expiration of this Agreement.

 

2.3          Each Party shall use its Commercially Reasonable Efforts to achieve the objectives of the Development Plan. Both Parties shall fully collaborate and assist the other as necessary and shall allocate sufficient time, effort, equipment, facilities and personnel with sufficient skills, training and experience to conduct the activities under the Development Plan and accomplish the objectives of the Development Plan.

 

12

 

2.4          JSC. Promptly, but in no event later than ten (10) days from the Effective Date, the Parties shall establish a joint steering committee (“JSC”) which shall consist of two (2) Representatives from each of the Parties, with each Representative (including replacements) having the requisite experience and seniority to enable such person to make decision on behalf of the Parties with respect to the issues falling within the jurisdiction of the JSC. The Parties may substitute at any time, any of its Representatives on written notice to the other Party. ADCT shall select from its Representatives the chairperson for the JSC. The JSC shall:

 

2.4.1                     Meet at least once a quarter in person or by telephone or as otherwise agreed to by the Parties;

2.4.2                     Be responsible for the oversight of the progress of the activities of each Party under the Development Plan;

2.4.3                     Select the [***] SAFEbody Panel and the [***] SAFEbody Panel;

2.4.4                     Review the Periodic Development Reports and Final Reports for each PoC (as defined in Section 2.5);

2.4.5                     Discuss and seek resolution of issues around the execution and completion of the Development Plan.

 

2.5          JSC Decisions. Decisions of the JSC shall be by consensus. If no consensus can be reached by the JSC members within ten (10) days of a matter being raised at the JSC level, the matter of disagreement shall be escalated to the CEOs (or its designee as advised by the CEO) of both Parties for a final good faith resolution of the issue, to be made within (7) days of its escalation to the CEOs. If no agreement can be found, ADCT shall have a casting vote. No decisions of the JSC will (i) require either Party to violate any applicable laws or any agreement it may have with any Third Party or (ii) amend the terms and conditions of this Agreement.

 

2.6          Each Party shall ensure that the other Party is kept fully informed in writing on a monthly basis of the progress of its activities under the Development Plan and of the Results (“Periodic Development Reports”). Within thirty (30) days of completion of its respective activities under each PoC under the Development Plan, ADAGENE shall provide ADCT with a final written report describing the work conducted by it under the Development Plan and all Results related to the [***] SAFEbody, the [***] SAFEbody Panel or the [***] SAFEbody Panel (“ADAGENE Final Report”). In addition, at the latest (i) within twelve (12) months of receipt by ADCT of the [***] SAFEbody and (ii) eighteen (18) months from receipt by ADCT of the respective [***] SAFEbody Panel and of the [***] SAFEbody Panel, ADCT shall provide ADAGENE with a final written report describing the work conducted by it under the relevant PoC and all Results relating thereto (“ADCT Final Report”).

 

2.7          Unless otherwise agreed to in writing by the Parties or unless authorized under the License Agreement, the [***] License or the Chinese Territory License, each Party agrees to use the Confidential Information and the materials supplied by the other Party solely for the purpose of performing the Development Plan.

 

13

 

2.8          Neither Party shall use the other Party’s Materials for the purposes of the diagnosis, treatment or any other activity in humans.

 

2.9          Neither Parry shall transfer the Materials of the other Party or their compositions, sequences or structural characteristics to any third party, except that ADCT is entitled to subcontract any of its activities assigned to it under the Development Plan to third parties, provided that such third parties shall be subject to obligations relating to IP Rights, confidentiality and non-use no less restrictive than the obligations of ADCT pursuant to this Agreement.

 

2.10        Each Party shall comply with all applicable laws, regulations and codes of practice in the performance of the Development Plan, including, but not limited to, good laboratory practices, animal welfare laws and regulations and will obtain all necessary certifications, licenses and approvals necessary to allow it to carry out its activities under the Development Plan.

 

3.             COSTS

 

3.1          For the purpose of [***] PoC of the Development Plan, ADAGENE shall supply [***] SAFEbody to ADCT at no charge. For the avoidance of doubt, no payment shall be due by ADCT to ADAGENE under the [***] POC.

 

3.2          ADCT shall bear its own costs and expenses associated with its activities under the Development Plan. In addition, (i) for the purpose of the [***] PoC, ADCT shall supply the [***] Antibody to ADAGENE at no cost to ADAGENE; and (ii) for the purpose of [***] of the Development Plan, ADCT shall also supply the Antibody to ADAGENE at no cost to ADAGENE.

 

3.3          In consideration of the exclusivity rights granted to ADCT under this Agreement, ADCT will pay to ADAGENE a one-time milestone payment of [***] US Dollars ($[***] payable within [***] days after successful outcome of the first in vivo study with the [***] SAFEbody ADC (‘‘Exclusivity Fee”).

 

3.4          In consideration of the exclusive reservation of the [***] Reserved Targets under this Agreement in accordance with Section 2.2.2, ADCT shall pay to ADAGENE a reservation fee of: (a) [***] US Dollars ($ [***] ), within thirty (30) days after the Effective Date of this Agreement after receiving an invoice thereof from ADAGENE; and (b) in the event ADCT wishes to maintain the Reserved Target for a second year, [***] US Dollars ($ [***] ), within [***] days the first (1st) anniversary of this Agreement after receiving an invoice thereof from ADAGENE.

 

14

 

3.5          In the event ADCT elects to proceed with the [***] PoC under the Development Plan, ADAGENE shall be entitled to the following payments as a compensation for the development and manufacturing and supply of the [***] SAFEbody Panel:

 

3.5.1       [***] US Dollars ($[***])to be by ADAGENE upon receipt of the [***] Antibody from ADCT; and

 

3.5.2       [***] US Dollars ($[***]) to be by ADAGENE once ADAGENE has delivered to ADCT the amino acid sequence of the corresponding masking peptides and [***] of necessary quality of each [***] SAFEbody among the [***] SAFEbody Panel that meet the Criteria and which have been elected by the JSC to allow ADCT to conduct the [***] PoC. In the event the quantity or quality of the supplied [***] SAFEbody Panel is insufficient to ADCT’s sole discretion, ADCT shall inform ADAGENE with no delay and ADAGENE shall supply additional quantities of the relevant [***] SAFEbody to ADCT at no additional cost.

 

3.6          In the event ADCT elects to proceed with [***] under the Development Plan, ADAGENE shall be entitled to the following payments as a compensation for the development and manufacturing of the [***] SAFEbody Panel:

 

3.6.1       $[***] US Dollars) to be invoiced by ADAGENE upon receipt of the Antibody from ADCT; and

 

3.6.2       $[***] US Dollars) to be invoiced by ADAGENE once ADAGENE has delivered to ADCT the amino acid sequence of the corresponding masking peptides and [***] of necessary quality of each [***] SAFEbody among the [***] SAFEbody Panel that meet the Criteria and which have been elected by JSC to allow ADCT to conduct the [***] PoC. In the event the quantity or quality of the supplied [***] SAFEbody Panel is insufficient to ADCT.s sole discretion, ADCT shall inform ADAGENE with no delay and ADAGENE shall supply additional quantities of the relevant [***] SAFEbody to ADCT at no additional cost.

 

3.7          Undisputed invoices shall be payable by ADCT within thirty (30) day of receipt of the invoice, to the bank account of ADAGENE:

 

	
Account Name:
    	
[***]
    
	
Bank Name:
    	
[***]
    
	
Bank Address:
    	
[***]
    
	
Central, Hong   Kong.
    	
 
    
	
Account Number:
    	
[***]
    
	
SWIFT Number:
    	
[***]
    

 

or if specified on the invoice, the bank account indicated on the invoice. Invoices shall be issued in ADCT’s name and address and shall contain ADCT’s PO number (as provided by ADCT), product name, ADCT’s contact name, description of the invoiced services, bank account number, routing/swift code number. Invoices shall be sent by email to: Accounts.Payable@adctherapeutics.com

 

15

 

4.             INTELLECTUAL PROPERTY AND RESULTS

 

4.1          Background IP. Except as explicitly set forth in this Agreement, each Party will retain all its right, title, and interest in and to its Confidential Information, Materials and Background IP. For the avoidance of doubt, ADCT and/or its Affiliates or designees have and retain all right, title and/or interest in the PBDs and all ADCT Background IP specifically related to PBDs and ADCT Materials.

 

4.2          No implied licenses. Neither Party transfers or grants any rights or licenses to the other Party under its respective Materials, Confidential Information and IP or other IP Rights owned or controlled by that Party except for the right to use the same solely for the purpose of the Development Plan.

 

4.3          ADCT New IP. ADCT and/or its designee shall own (alone or jointly with its Third Party licensor(s)) all ADCT New IP. ADAGENE acknowledges and agrees that the ADCT New IP may as the case may be, be owned solely by ADCT or jointly by ADCT and ADCT’s Third Party licensor(s) or solely by ADCT’s Third Party licensor(s), including in particular with regards to any IP relating to PBDs and ADCs, including the Conjugated Materials. With respect to the Results included in the ADCT New IP, ADAGENE retains the right to use the Results for the improvement of its SAFEbody Technology platform, including for use of the SAFEbody Technology with its bona fide collaborators; provided that (i) ADAGENE shall not use the Results included in the ADCT New IP with Third Parties until ADCT has filed Patents on the ADCT New IP, and (ii) ADAGENE shall not use the Results in breach of its obligations under Section 2.2 herein and (iii) the Results that are not ADAGENE New IP will remain the Confidential Information of ADCT.

 

4.4          ADAGENE New IP. ADAGENE or its designee shall solely own all ADAGENE New IP.

 

4.5          IP assignments.

 

4.5.1               ADAGENE agrees to assign and hereby assigns all IP in the ADCT New IP and the ADCT Platform Improvements (in each case together with all IP Rights therein) to ADCT or its designee and will provide all necessary assistance and execute any IP assignment document, or other document, reasonably requested by ADCT, at ADCT’s cost, in each case that is reasonably necessary to give effect to Sections 4.3. ADAGENE acknowledges and agrees that ADCT may be bound by certain IP assignment obligations towards ADCT’s Third Party licensor(s), including in particular with regards to any IP relating to PBDs and ADCs, including the Conjugated Materials, and ADAGENE agrees to not take any action which would prevent ADCT from complying with its assignment obligations thereto.

 

16

 

4.5.2               ADCT agrees to assign and hereby assigns all IP in the ADAGENE Platform Improvements to ADAGENE or its designee and will provide all necessary assistance and execute any IP assignment document, or other document, reasonably requested by ADAGENE, at ADAGENE’s cost, in each case that is reasonably necessary to give effect to Sections 43. ADAGENE acknowledges and agrees that ADCT may be bound by certain IP assignment obligations towards ADCT’s Third Party licensor(s), including in particular with regards to any IP relating to PBDs and ADCs, including the Conjugated Materials, and ADAGENE agrees to not take any action which would prevent ADCT from complying with its assignment obligations thereto.

 

4.6          ADAGENE Patents’ prosecution and maintenance. Subject to Section 4.8, ADAGENE shall, at its sole cost, have the sole right to prosecute and maintain worldwide Patents and Patent applications relating to ADAGENE Background IP and ADAGENE New IP. ADAGENE shall not abandon any of the ADAGENE Key IP (as defined below). ADAGENE shall timely, and at least thirty (30) days in advance, inform and consult ADCT on Patent applications and prosecution relating to ADAGENE Key IP, and provide ADCT with a copy of such Patent applications for that purpose. ADCT shall review and comment thereon within thirty (30) days. ADAGENE shall reasonably consider and incorporate in good faith ADCT’s comments and requests. “ADAGENE Key IP” means all ADAGENE Patents that (a) claim composition(s) and/or method(s) used by ADAGENE to generate the [***] SAFEbody(ies) and/or [***] SAFEbody(ies) under this Agreement, (b) would reasonably expected to protect the exclusivity of ADCT’s exploitation of [***] SAFEbody(ies) and/or [***] SAFEbody(ies); and/or (c) would reasonably expected to affect the ADCT New IP.

 

4.7          ADCT Patents’ prosecution and maintenance. Subject to Section 4.8, ADCT shall be free at all times to prosecute and maintain (or have prosecuted and maintained) worldwide Patents and Patent applications relating to ADCT Background IP.

 

4.8          IP Standstill and New IP filing.

 

4.8.1               From the Effective Date of this Agreement and until the earlier of (A) ADCT exercising the [***] Option or the [***] License Option respectively, or (B) the Parties agreeing in writing after consultation with the IP counsels of both Parties, and except as provided in the final two sentence of this Section 4.8.1, (i) neither Party shall file any patent application on any Intellectual Property claiming or covering the ADCT New IP; and (ii) ADAGENE shall not file any patent application on any Intellectual Property claiming or covering the ADAGENE New IP made in the performance of this Agreement; and (iii) neither Party shall file any IP which would create a material prior art issue for future filings of the ADCT New IP or ADAGENE New IP. When patent filing of the ADCT New IP and/or the ADAGENE New IP is authorized in accordance with the terms and conditions of this Section, the Parties agree to first consult with each other in good faith and to file any patent applications relating to their respective new IP under this Agreement on the same day and take all necessary actions to avoid any double patenting issues. For avoidance of doubt, ADCT New IP will be filed separately from ADAGENE New IP. The foregoing shall not be construed as preventing ADAGENE from filing any patent application claiming SAFEbodies against any other Target, provided that ADAGENE provide ADCT sixty (60)-day notice of its intent to make such a filing prior to such filing. Upon receiving such notice, ADCT shall have the right to file patent applications claiming or covering any and all ADCT New IP on the same day ADAGENE files such patent application, or thereafter, in which case the IP standstill provision on ADCT on ADCT New IP under this Section 4.8.1 shall be of no further effect. ADAGENE shall coordinate with ADCT to ensure that ADCT can file its patent applications (if ADCT so chooses and informs ADAGENE within 30 days of such notice) on that same day.

 

17

 

4.8.2               In addition, ADCT shall not file any patent application relating to the [***] SAFEbody and neither Party shall file any patent application relating to the [***] SAFEbody ADC, in each case made in the performance of this Agreement, and the Parties agree to keep the [***] SAFEbody ADC trade secret and confidential at all times; provided, however, that ADAGENE may disclose data, information and results that are related to the [***] SAFEbody ADC with its actual and potential investors, acquirers and collaborators under written obligations of confidentiality, provided that such data, information or results does not include the identity of ADCT or any of ADCT’s conjugation technology, including the structure or identity of the PBD or linker used. This Section shall expressly survive termination of this Agreement.

 

4.9          During the Term, ADAGENE shall refrain from (i) using, for the purpose of the Development Plan, any IP Rights pertaining to or otherwise licensed from a Third Party or exclusively licensed to a Third Party which would preclude ADAGENE from granting the License Agreement under Section 5 or ADCT to own the ADCT New IP; and/or (a) granting any rights to any Third Party for any Intellectual Property Rights necessary or useful for the Development Plan and the License Agreement in a manner that would preclude a license grant under Section 5 herein.

 

5.             OPTION RIGHT TO THE LICENSE AGREEMENT

 

5.1          The Parties have mutually agreed that, at ADCT’s sole discretion and option, and subject to the terms contained herein in Section 5.1, ADAGENE grants ADCT an exclusive option (“the [***]  Option”) to a worldwide, irrevocable (except as expressly set forth in the termination provisions of the License Agreement), sub-licensable, license under the Licensed IP to research, develop, manufacture, make, use, sell, offer for sale, market, commercialize, distribute and import, and have researched, developed, manufactured, made, used, sold, offered for sale, marketed, commercialized, distributed, or imported, ADCs containing the [***] SAFEbody in the Field, in accordance with the terms and conditions of the License Agreement.

 

5.2          For the purpose of Section 5.1, at any time during the [***] Option Period, ADCT shall have the right, but not the obligation, to activate, upon written notice to ADAGENE, the License Agreement for the [***] SAFEbody and the License Agreement shall then become effective on the date of the option notice to ADAGENE. If ADCT does not exercise the [***] Option within the [***] Option Period, (i) ADCT shall have no further rights with respect to the [***] SAFEbody (ii) the IP standstill provision under Section 4.8 shall survive, and (iii) ADAGENE shall be free to research, develop or commercialize a [***] SAFEbody targeting the [***] Target, including as an antibody drug conjugate, provided however that it is understood and agreed that ADCT does not grant any rights to ADAGENE under this Agreement to the [***] SAFEbody ADC or to PBDs or ADCs under the ADCT Background IP or the ADCT New IP in connection with ADAGENE’s development and commercialization of such [***] SAFEbodies.

 

18

 

5.3          In addition, ADAGENE hereby grants ADCT a right to elect, at any time during the [***] Option Period, a Target for the conduct of [***] in accordance with Section 2.1.4 and to opt during the [***] Option Period for an exclusive, worldwide, irrevocable (except as expressly set forth in the termination provisions of the License Agreement), sub-licensable, license under the Licensed IP to research, develop, manufacture, make, use, sell, offer for sale, market, commercialize, distribute and import, and have researched, developed, manufactured, made, used, sold, offered for sale, marketed, commercialized, distributed, or imported, ADCs containing the [***] SAFEbody in the Field on the terms and conditions contained in the License Agreement (“[***] License”).

 

5.4          For the purpose of Section 5.3, at any time during the [***] Option Period. ADCT shall have the right, but not the obligation, to exercise its option right to obtain the [***] License by notifying ADAGENE (“[***] License Option”). If ADCT does not exercise the [***] License Option, (i) ADCT shall have no further rights with respect to the [***] SAFEbody; and (ii) the IP standstill provision under Section 4.8 shall survive; and (iii) ADAGENE shall be free to research, develop or commercialize a [***] SAFEbody targeting the [***] Reserved Targets and, if applicable, the [***] Alternative Target, including as an antibody drug conjugate, provided however that it is understood and agreed that ADCT does not grant any rights to ADAGENE under this Agreement to the [***] SAFEbody ADC or to PBDs or ADCs under the ADCT Background IP or the ADCT New IP in connection with ADAGENE’s development and commercialization of such [***] SAFEbodies.

 

5.5          For clarity, no option is granted by ADAGENE to ADCT with respect to the [***] SAFEbody. ADCT acknowledges that ADCT has no right to develop or commercialize the [***] SAFEbody or any [***] SAFEbody ADC, and ADAGENE will have the sole right in its sole discretion to develop and commercialize the [***] SAFEbody.

 

6.             COMMERCIAL OPTION

 

6.1          The Parties mutually agree that should ADCT activate the License Agreement in accordance with Section 5.2 and achieve Successful Completion of the GLP Toxicology Studies for the [***] SAFFbody ADC and/or the [***] SAFEbody ADC. except if such [***] SAFEbody ADC binds to the [***] (Uniprot Code [***]) Target, ADCT would grant ADAGENE for a period of [***] starting from such Successful Completion of the GLP Toxicology Studies for the [***] SAFEbody ADC or the [***] SAFEbody ADC which does not bind to the [***] Target, as applicable, the right to obtain a license to develop, manufacture, make, use, sell, offer for sale, market, commercialize, distribute and import, and have developed, used, sold, offered for sale, marketed, commercialized, distributed, or imported, ADCs containing the [***] SAFEbody and/or the [***] SAFEbody ADC which does not bind to the [***] Target in the Field for sale in the Territory, in accordance with the terms and conditions contained in Annex 3 (“Chinese Territory License Terms”). For the sake of clarity, ADAGENE has no option to negotiate a license, in the Territory, for a [***] SAFEbody ADC that binds to the [***] Target.

 

19

 

7.             CONFIDENTIALITY

 

7.1          Non-use and non-disclosure of Confidential Information. During the Term, and for a period often (10) years thereafter, a Party shall (i) except to the extent permitted by this Agreement or otherwise agreed to in writing, keep confidential and not disclose to any Third Party any Confidential Information of the other Party; (ii) except in connection with activities permitted by this Agreement or otherwise agreed to in writing, not use for any purpose any Confidential Information of the other Party; and (iii) take all reasonable precautions to protect the Confidential Information of the other Party, including all precautions a Party employs with respect to its own confidential information of a similar nature and taking reasonable precautions to assure that no unauthorized use or disclosure is made by others to whom access to the Confidential Information of the Party is granted. ADAGENE shall further take all necessary measures to maintain confidential and to not disclose, and it shall cause its Representatives to maintain confidential and not disclose, to any Third Party not bound by any confidentiality obligation or otherwise in breach of ADCF’s rights under this Agreement, any Confidential Information relating to the SAFEbody Technology and the ADAGENE Know-How and any IP Rights relating thereto.

 

7.2          Exclusions regarding Confidential Information. Notwithstanding anything set forth to the contrary in this Article 7, the obligations of Article 7.1 above shall not apply to the extent that the Party seeking the benefit of the exclusion can demonstrate that the Confidential Information of the other Party:

 

a)            except for ADCT Confidential Information developed by ADAGENE for ADCT, was already known to the receiving Party, other than under an obligation of confidentiality, at the time of receipt by the receiving Party;

 

b)            was generally available to the public or otherwise part of the public domain at the time of its receipt by the receiving Party;

 

20

 

c)                                      became generally available to the public or otherwise part of the public domain after its receipt by the receiving Party other than through any act or omission of the receiving Party in breach of this Agreement;

 

d)                                     was received by the receiving Party without an obligation of confidentiality from a Third Party having the right to disclose such information without restriction;

 

e)                                      except for ADCT Confidential Information developed by ADAGENE for ADCT, was independently developed by or for the receiving Party without use of or reference to the Confidential Information of the other Party; or

 

f)                                       was released from the restrictions set forth in this Agreement by express prior written consent of the Party.

 

7.3                               Authorized disclosures of Confidential Information. Notwithstanding the foregoing, a Party may use and disclose the Confidential Information of the other Party as follows:

 

a)                                     if required by law or governmental regulation, provided that the Party seeking to disclose the Confidential Information of the other Party shall (i) use all reasonable efforts to inform the other Party prior to making any such disclosures and cooperate with the other Party in seeking a protective order or other appropriate remedy (including redaction) and (ii) whenever possible, request confidential treatment of such information;

 

b)                                     as reasonably necessary to obtain or maintain any regulatory approval, including to conduct preclinical studies and clinical trials and for pricing approvals, for any Licensed Product, provided, that, the disclosing Party shall take all reasonable steps to limit disclosure of the Confidential Information outside such regulatory agency and to otherwise maintain the confidentiality of the Confidential Information to the same extent to which it maintains its own confidential information; or

 

c)                                      to the extent necessary, to permitted sublicensees, licensees, collaborators, vendors, consultants, agents, attorneys, contractors and clinicians under written agreements of confidentiality at least as restrictive on those set forth in this Agreement, who have a need to know such information in connection with such Party performing its obligations or exercising its rights under this Agreement.

 

7.4                               Terms of this Agreement. The Parties agree that this Agreement and the terms hereof will be considered Confidential Information of both Parties but can be shared with potential sublicensees, banks, investors or acquirers to the extent necessary to complete the subject transaction.

 

7.5                               No License. As between the Parties, Confidential Information disclosed hereunder shall remain the property of the disclosing Party. Disclosure of Confidential Information to the other Party shall not constitute any grant, option or license to the other Party, beyond those licenses expressly granted hereunder, under any Patent, Know-How or other rights now or hereinafter held by the disclosing Party.

 

21

 

7.6                               Confidentiality Breach Remedies. The Receiving Party acknowledges that money damages may not be a sufficient remedy for any breach of this Section 7, and the Disclosing Party will be entitled to seek specific performance and injunctive relief as remedies for any such breach. Such remedies will not be deemed to be the exclusive remedies for breach of this Section 7 but will be in addition to all other remedies available at law or equity to the Disclosing Party. In addition, in the event of a Severe Confidentiality Breach (as defined below) by either Party, the other Party shall in good faith notify the first Party of the alleged and evidenced Severe Confidentiality Breach and (i) if ADCT alleges that ADAGENE has committed such Severe Confidentiality Breach, ADCT shall be entitled to suspend payment of [***] of any outstanding or future payments due to ADAGENE under this Agreement and/or the License Agreement; and (ii) if ADAGENE alleges that ADCT has committed such Severe Confidentiality Breach, ADAGENE shall be entitled to collect [***] of the future payments it would otherwise receive from ADCT under this Agreement, in each case subject to the following (each, an “Automatic Remedy”). Should the alleged breaching Party dispute the existence of a Severe Confidentiality Breach, it shall show all necessary evidence to support its position. If the evidence shown is deemed insufficient by the Party alleging such breach, the issue may be escalated by the Party alleging such breach to the CEOs of both Parties, who shall strive to find an amicable resolution of the matter within ten (10) business days from the day the issue was escalated to them. If no amicable resolution can be found, the alleged breaching Party may use the arbitration process under Section 12.2 for settlement. If the arbitration decision confirms a Severe Confidentiality Breach by a Party under this Agreement, the Automatic Remedy shall continue for the term of this Agreement and/or the License Agreement and the Party alleging breach may seek additional damages from the alleged breaching Party in accordance with this Agreement. If the arbitration decision confirms that the alleged breaching Party has not committed a Severe Confidentiality Breach, then: (a) if ADCT is the Party alleging such breach, ADCT shall be responsible for all past and future payments due under this Agreement and shall be liable for paying to ADAGENE within seven (7) days of the arbitration decision, all payments unduly suspended since the confidentiality breach notice to ADAGENE with an annual interest rate of at the Prime Rate (as quoted in the Wall Street Journal) plus two percent (2%), to be calculated from the day those payments became due until effective payment date; or (b) if ADAGENE is the Party alleging such breach, ADAGENE shall refund to ADCT within seven (7) days of the arbitration decision, all over-payments unduly collected from ADCT since the confidentiality breach notice to ADCT with an annual interest rate of at the Prime Rate (as quoted in the Wall Street Journal) plus two percent (2%), to be calculated from the day those payments became due until effective payment date. “Severe Confidentiality Breach” shall mean: (1) a breach of Section 4.8; and (2) with respect to both Parties, any disclosure of the portion of SAFEbody Technology that is strictly confidential such that such disclosure has enabled a Third Party to perform the SAFEbody Technology in a manner substantially similar to ADAGENE and resulted in ADAGENE’s competitive advantage in SAFEbody Technology, in each case without regard to the existence, validity or enforceability of any ADAGENE Patents; provided, however, that ADAGENE shall be free to disclose its SAFEbody Technology as necessary, in the ordinary course of business to seek patent protection, if permitted under Section 4.8, on the SAFEbody Technology and to disclose the SAFEbody Technology to its actual and potential bona fide acquirers and licensees under an obligation of confidentiality at least as restrictive as those confidentiality obligations contained in this License Agreement, and provided always that ADAGENE shall be and remain solely and exclusively liable towards ADCT for any Severe Confidentiality Breach by any such acquirers and licensees; and (3) in addition, with respect to ADAGENE, any disclosure regarding [***] SAFEbody ADC (including the PBD) that would implicate ADCT as in any manner having any interest or involvement with [***] SAFEbody or [***] SAFEbody ADC. In the event of a dispute of such alleged Severe Confidentiality Breach, the Party for which the dispute is finally decided against will reimburse the other Party for all internal and out-of-pocket costs and fees incurred by such other Party in connection with such dispute. Neither Party shall disclose any of its Confidential Information to the other Party that, in the event of an unintended disclosure by the receiving Party, would cause the receiving Party to commit a Severe Confidentiality Breach, unless and until first obtaining the receiving Party’s express prior written consent, and any such Confidential Information disclosed by a Party to the receiving Party without such express prior written consent shall excuse the receiving Party from its compliance obligation of this Section; provided, however, that disclosure by ADAGENE to ADCT of SAFEbodies or masking peptides that meet the Criteria in accordance with Section 2.1.3 or 2.1.5 shall not require any prior written consent.

 

22

 

8.                                      REPRESENTATIONS AND WARRANTIES

 

8.1                               Representations and warranties.

 

8.1.1                     Each Party represents and warrants to the other Party that:

 

a)             it is validly organized and in good standing under the laws of its jurisdiction of incorporation;

 

b)             it is permitted to enter into this Agreement; and

 

c)              the terms of this Agreement are not inconsistent with other contractual obligations (express or implied) it has or may have; and

 

d)             all research conducted by it under the Development Plan will comply with all applicable government laws, regulations and guidelines, including, but not limited to, those relating to good laboratory practices, good manufacturing practices if applicable, animal testing, biotechnological research and to the handling and containment of hazardous and biohazardous materials, and any other laws, regulations, practices, guidelines and the like which compliance is required in the US and EU for the purpose of (A) IND Applications or (B) a BLA application (“BLA”) filed with the U.S. Food and Drug Administration or any successor application thereto for approval to sell a biological product and any foreign equivalent of any such BLA application filed with the applicable regulatory authority; and

 

e)              it will comply at all times with all applicable laws and regulations; and

 

23

 

f)               it will comply at all times with the Bribery Act 2010 of the United Kingdom (“Bribery Act”), the Foreign Corrupt Practices Act 1977 of the United States of America (“FCPA”), and any other applicable anti-bribery and anti-corruption laws and regulations.

 

8.1.2                                             ADAGENE warrants that:

 

a)             neither ADAGENE nor any of its Affiliates has entered, or shall enter, into any agreement with any Third Party that conflicts with the rights conveyed in this Agreement and in the License Agreement to ADCT; and

 

b)             (i) to the knowledge of ADAGENE as of the Effective Date, neither practice of the SAFEbody Technology and other ADAGENE IP Rights contemplated under this Agreement nor the use or composition of the [***] SAFEbody, infringes or misappropriates any Third Party IP Rights and that (ii) to the knowledge of ADAGENE as of the date ADAGENE develops or supplies a [***] SAFEbody or a [***] SAFEbody to ADCT, ADAGENE will not develop a [***] SAFEbody and [***] SAFEbody in a manner that would infringe or misappropriate any Third Party IP Rights, or deliver to ADCT any [***] SAFEbody and [***] SAFEbody that would infringe or misappropriate any Third Party IP Rights, other than in each case such infringement or misappropriation was caused by the antibody provided by ADCT to ADAGENE;

 

c)              as of the Effective Date, ADAGENE has not filed any patent application which will create a material prior art issue under Section 4.8 except as expressly disclosed in Annex 5.

 

8.1.3                                                             ADCT warrants that: (a) as of the Effective Date, ADCT has no knowledge of any infringement of ADCT Intellectual Property by any Third Party; and (b) to the knowledge of ADCT as of the supplies a [***] Antibody or a [***] Antibody to ADAGENE, ADCT will not deliver any [***] Antibody or [***] Antibody that is proprietary to a Third Party to ADAGENE for ADAGENE’s use to generate SAFEbodies under this Agreement, without first obtaining ADAGENE’s prior written consent.

 

8.2                               No Use of Debarred Person. During the Term, each Party agrees that it will not use (and will cause its Affiliates not to use) any employee or consultant that is debarred by any regulatory authority or, to the best of such Party’s knowledge, is the subject of debarment proceedings by any regulatory authority. If either Party learns that any employee or consultant performing on its behalf (including by an Affiliate) under this Agreement has been debarred by any regulatory authority, or has become the subject of debarment proceedings by any regulatory authority, such Party will promptly notify the other Party and will prohibit such employee or consultant from performing on its behalf (including by an Affiliate) under this Agreement.

 

24

 

8.3                               Warranty Disclaimer. EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL REPRESENTATIONS OR WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED AND DOES NOT ASSUME ANY RESPONSIBILITIES WHATSOEVER WITH RESPECT TO THE USE, OR OTHER DISPOSITION OF IP AND MATERIALS BY A PARTY TO THE OTHER UNDER THIS AGREEMENT. WITHOUT LIMITING THE FOREGOING, NEITHER PARTY MAKES ANY EXPRESS OR IMPLIED WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE.

 

9.                                      PUBLICITY, PUBLICATION, USE OF NAMES

 

9.1                               Publicity.

 

9.1.1                                             The Parties have agreed to an initial press release attached as Annex 6, which will be released by the Parties within ten (10) days after the Effective Date (the “Initial Press Release”). Neither Party will make any subsequent press release or other public disclosure regarding this Agreement or the transactions contemplated hereby without the other Party’s express prior written consent, which shall not be unreasonably withheld or delayed; provided, that no consent will be required for any release of information that was already included in the Initial Press Release or any other approved release. For the purpose of this Section 9.1, if a party elects to make a public announcement, and at least ten (10) business days in advance of such planned press release or public announcement it shall provide a draft to the other Party for review. The reviewing Party shall have the right to require changes, in particular to request deletion of its Confidential Information and financial terms under this Agreement or the transactions contemplated hereunder, from the planned press release or announcement, and the other Party shall delete any Confidential Information and reasonably and in good faith consider and implement any other changes requested by the reviewing Party.

 

9.1.2                                             It is further agreed between the Parties that in the event ADCT elects to activate the License Agreement in accordance with Section 5.2, the Parties shall issue a joint press-release, which timing and content shall be agreed upon in advance and in writing between the Parties in accordance with this Section 9.1.

 

9.1.3                                             The Parties agree that they may issue future joint announcements concerning ADCT’s achievement of any significant milestones under this Agreement or the License Agreement, provided that the content of any such announcement has been mutually agreed upon in advance and in writing by the Parties.

 

25

 

9.2                               Publication. Neither Party shall publish or present the Materials or the Results without the prior written consent of the other Party. Prior to making any oral or written public presentation and/or submitting or presenting a manuscript, poster, abstract, publication, or other materials relating to the Materials or Results under this Agreement to a publisher, reviewer, or other outside person (“Publication”), the publishing Party shall provide to the other Party a copy of all such Publication in English language, and the other Party shall have thirty (30) days from receipt to review and comment. Upon the other Party’s request, the publishing Party shall (i) remove any Confidential Information; and/or (ii) discuss with the other Party and consider in good faith any of the other Party’s suggestions and amendments proposed with respect to the Publication, and the timing of the disclosure; and/or (iii) delay the Publication for a period of up to sixty (60) days from the date the other Party receives the proposed Publication, in order to allow the other Party to protect its interests in any IP Rights described in any such Publication.

 

9.3                               No Right to use names. Except as expressly provided herein, no right, express or implied, is granted by this Agreement to use in any manner the other’s Party symbol, logo or trademark of the other Party in connection with this Agreement unless authorized in writing by the other Party.

 

10.                               TERM AND TERMINATION

 

10.1                        Term. This Agreement shall commence on the Effective Date and shall continue until (i) expiry of the [***] Option Period in case [***] is not initiated by ADCT in accordance with Section 2.1.4; or (ii) expiry of the [***] Option Period in case [***] is initiated by ADCT in accordance with Section 2.1.4, unless terminated earlier in accordance with the terms and conditions of this Agreement (“Term”).

 

10.2                        Termination by ADCT. ADCT may terminate this Agreement in its entirety or on a Target-by-Target basis at any time and for any reason upon thirty (30) days prior written notice to ADAGENE.

 

10.3                        Termination by either Party. Either Party may terminate this Agreement in its entirety or on a Target-by-Target basis:

 

10.3.1              upon any other material breach (other than any confidentiality breach) by the other Party of the material terms or conditions of this Agreement, which breach cannot be, or is not cured within thirty (30) days after the breaching Party receives written notice by the non-breaching Party regarding such breach, provided that, if the other Party disputes such alleged breach, such termination shall not become effective unless and until such dispute is resolved in favor of the Party alleging such breach; or

 

10.3.2              upon immediate written notice upon the other Party becoming insolvent or bankrupt or making an assignment for the benefit of its creditors, upon appointment of a trustee or receiver for the other Party or all or substantially all of its property, or upon the filing of a voluntary or involuntary petition by or against the other Party under any bankruptcy or insolvency law, or any similar law.

 

26

 

10.4                        Consequences of termination.

 

10.4.1              Subject to Section 12.11 and except to the extent required for the execution of the License Agreement and the [***] License, upon the expiration or termination of this Agreement,

 

a)             any licenses granted hereunder pursuant to this Agreement shall immediately terminate; and

 

b)             ADCT shall (i) discontinue use of (A) the ADAGENE Materials (B) ADAGENE Background IP and other IP Rights; (C) ADAGENE’s Confidential Information, and (D) the Conjugated Materials and (ii) destroy or return to ADAGENE, as instructed by ADAGENE, ADAGENE Confidential Information and ADAGENE Materials, and (iii) destroy any remaining quantity of Conjugated Materials; and

 

c)              ADAGENE shall discontinue the use of ADCT’s Confidential Information, and destroy or return to ADCT, as instructed by ADCT, such Confidential Information; and

 

d)             If not activated yet in accordance with Section 5.2, the License Agreement shall be null and void and not enter into force; and

 

e)              If not executed yet in accordance with Section 5.4, the [***] License shall be null and void and not enter into force; and

 

f)               In case ADCT has not activated the License Agreement in accordance with Section 5.2, Section 6 shall be null and void.

 

10.4.2              In the event that: (i) ADCT does not exercise the [***] Option or the [***] License Option and (ii) the JSC had authorized ADCT to file a patent application (or any resulting patent) on the [***] SAFEbody and/or the [***] SAFEbody as the case- may be, ADCT shall (a) assign to ADAGENE or its designee any such patent application or patent specifically relating to the [***] SAFEbody Panel and/or the [***] SAFEbody Panel, (b) abandon any such patent application or patent that is not described in subsection (a) and is solely owned by ADCT; and (c) attempt in good faith to seek abandonment of any such patent application or patent that is not described in subsection (a) and is jointly owned by ADCT and its Third Party licensor(s). Prior to the its exercise of the [***] Option or the [***] License Option, ADCT will not assign any patent applications or patents on the [***] SAFEbody or [***] SAFEbody to any Third Party, except to its Third Party licensor, as required by ADCT’s written agreement with such Third Party licensor.

 

27

 

10.4.3              For clarity, any termination of this Agreement shall not termination the License Agreement with respect to the License Agreement that is already effective as of the date of the termination of this Agreement.

 

11.                               INDEMNIFICATION; LIMITATION OF LIABILITY

 

11.1                        ADAGENE indemnity. ADAGENE will indemnify, hold harmless and defend ADCT, its Affiliates, and their respective directors, officers, employees and agents (each an “ADCT Indemnitee”) against any and all losses, damages, liabilities, judgments, fines, amounts paid in settlement, expenses and costs of defense (including, without limitation, reasonable attorneys’ fees and witness fees) (“Losses”) resulting from any claim, action or proceeding brought or initiated by a Third Party (“Third Party Claim”) against them to the extent that such Third Party Claim arises out of (a) the breach or alleged breach of any representation or warranty by ADAGENE under this Agreement; or (b) the gross negligence or willful misconduct of ADAGENE, its Affiliates or their respective Representatives; or (c) the use, handling, or storage of ADAGENE Materials by ADAGENE or by ADCT as a result of following any specific instruction received from ADAGENE; or (d) from ADAGENE’s conduct and activities pursuant to the Development Plan; provided, that such indemnity shall not apply to the extent ADCT has an indemnification obligation pursuant to Section 10.2 hereof.

 

11.2                        ADCT indemnity. ADCT will indemnify, hold harmless and defend ADAGENE, its Affiliates, and their respective directors, officers, employees and agents (each, a “ADAGENE Indemnitee”) against any and all Losses resulting from any Third Party Claim against them to the extent that such Third Party Claim arises out of (a) the breach of any representation or warranty by ADCT under this Agreement; or (b) the gross negligence or willful misconduct of ADCT, its Affiliates or their respective Representatives; or (c) the use, handling, or storage of ADAGENE Material or Conjugated Material by ADCT or from ADCT’s conduct and activities pursuant to the Development Plan; provided, that such indemnity shall not apply to the extent ADAGENE has an indemnification obligation pursuant to Section 10.1 hereof.

 

11.3                        Conditions to indemnification. A Party seeking indemnification under this Section 10 (the “Indemnified Party”) in respect of a Third Party Claim shall give prompt notice of such Third Party Claim to the Party from which recovery is sought (the “Indemnifying Party”) and shall permit the Indemnifying Party to assume direction and control of the defense of the Third Party Claim, provided that the Indemnifying Party shall (a) act reasonably and in good faith with respect to all matters relating to the defense or settlement of such Third Party Claim as the defense or settlement relates to the Indemnified Party, and (b) shall not settle or otherwise resolve such Third Party Claim without the Indemnified Party’s prior written consent (which consent shall not be unreasonably withheld, conditioned or delayed); provided that the Indemnifying Party may, without the Indemnified Party’s prior written consent, agree or consent to any settlement or other resolution of such Third Party Claim which requires solely money damages paid by the Indemnifying Party.

 

28

 

11.4                        Limitation of liability. EXCEPT FOR EITHER PARTY’S BREACH OF SECTIONS 4 AND 7 HEREOF, NEITHER PARTY WILL BE LIABLE WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR ANY SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, EXEMPLARY OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION, ANY DAMAGES RESULTING FROM LOSS OF PROFITS OR LOSS OF BUSINESS). A Party’s monetary liability under a Third Party Claim for such Third Party’s special, incidental, indirect or consequential damages, or for any exemplary or punitive damages payable to such Third Party in connection with such Third Party Claim, shall be deemed to be the direct damages of such Party for purposes of this Section 11.4.

 

12.                               MISCELLANEOUS

 

12.1                        Governing law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York without regard to any choice of law principle that would dictate the application of the law of another jurisdiction and excluding of the United Nations Convention on Contracts for the International Sale of Goods. This Agreement has been prepared in the English language and the English language shall control its interpretation.

 

12.2                        Arbitration. The Parties agree to use their reasonable efforts to resolve any dispute arising out of this Agreement by amicable negotiation. The Parties shall be obligated to provide each other written notice of a dispute arising out of this Agreement. If any dispute arising out of this Agreement, including validity, breach, or termination thereof, cannot be resolved within thirty (30) days after notice of such dispute, then such dispute shall be settled through binding arbitration conducted by the International Chamber of Commerce in accordance with the then prevailing Rules of Arbitration of the International Chamber of Commerce in force on the date when the notice of arbitration is submitted (for purposes of this Section, the “Rules”), except as modified in this Agreement, applying the substantive law specified in this Section. The number of arbitrators shall be three (3), wherein each of the Parties select one of the arbitrators and the selected arbitrators shall select the third arbitrator. All arbitrators shall have expertise in the pharmaceutical industry. The arbitration shall take place in New York city and shall be conducted in English.

 

12.3                        Notices. Except as otherwise expressly provided in the Agreement, any notice required under this Agreement shall be in writing and shall specifically refer to this Agreement. Notices shall be sent via one of the following means and will be effective (a) on the date of delivery, if delivered in person; (b) on the date of receipt, if sent by email (with delivery confirmed); or (c) on the date of receipt, if sent by private express courier or by first class certified mail, return receipt requested. Any notice sent via email shall be followed by a copy of such notice by private express courier or by first class mail. Notices shall be sent to the other Party at the addresses set forth below. Either Party may change its addresses for purposes of this Article 12.3 by sending written notice to the other Party.

 

29

 

If to ADCT:

ADC Therapeutics SA

Route de la Corniche 3b

1066 Epalinges

Switzerland

Attn: General Counsel, Dominique Graz

Email: [***]

 

If to ADAGENE:

ADAGENE Inc.

 

Attn.:Kristine She

VP of Operations

Adagene (Suzhou) Limited

3F, Building C14,218 Xinghu St.,

Suzhou Industrial Park, China 215123

Email: [***]

 

12.4                        Independent contractors. The Parties hereto are independent contractors and nothing contained in this Agreement shall be deemed or construed to create a partnership, joint venture, employment, franchise, agency or fiduciary relationship between the Parties.

 

12.5                        Entire agreement. This Agreement and its Annexes constitute the entire agreement between the Parties relating to the subject matter of this Agreement and supersedes all prior oral and written communications, negotiations, representations, agreements, between the Parties with respect to the subject matter of this Agreement.

 

12.6                        Amendment. No amendment, change or modification to this Agreement shall be effective unless in writing and executed by an authorized Representative of each Party.

 

12.7                        Waiver. No course of dealing or failure of either Party to strictly enforce any term, right or condition of this Agreement shall be construed as a general waiver or relinquishment of such term, right or condition. Any waiver of any provision of this Agreement must be consented to by the non-waiving Party and shall not constitute a waiver of any other provision of this Agreement by implication or estoppel.

 

12.8                        Assignment. Neither Party may assign this Agreement without the prior written consent of the non-assigning Party. Notwithstanding the foregoing, either Party may assign this Agreement to (i) an Affiliate or (ii) any purchaser of all or substantially all of the assets of such Party or to which this Agreement relates, or of all of its capital stock, or to any successor corporation or entity resulting from any merger or consolidation of such Party with or into such corporation or entity. Subject to the foregoing, this Agreement will benefit and bind the Parties’ successors and assigns.

 

30

 

12.9                        No agency. The Parties hereto understand and agree that this Agreement is limited to the activities, rights and obligations as expressly set forth herein. Nothing in this Agreement shall be construed to establish any agency, employment, partnership, joint venture, franchise or similar or special relationship between the Parties. Neither Party shall have the right or authority to assume or create any obligations or to make any representations, warranties or commitments on behalf of the other Party, whether express or implied, or to bind the other Party in any respect whatsoever.

 

12.10                 Headings. The captions and headings to this Agreement are for convenience only and are to be of no force or effect in construing or interpreting any of the provisions of this Agreement.

 

12.11                 Severability. The Parties do not intend to violate any public policy or statutory or common law. However, if any sentence, paragraph, clause or combination of this Agreement is in violation of any law or is found to be otherwise unenforceable, such sentence, paragraph, clause or combination of the same shall be deleted and the remainder of this Agreement shall remain binding, provided that such deletion does not alter the basic purpose and structure of this Agreement.

 

12.12                 Survival. In addition to any provisions that specify survival or non-survival in the event of expiration or termination of this Agreement, the provisions of Sections 2.2, 4, 6, 7, 8, 9, 10, 11 and this Section 12 shall survive any termination of this Agreement.

 

12.13                 Affiliates. Each Party shall have the right to exercise its rights or perform its obligations through one (1) or more of its Affiliates, provided that such Party shall remain primarily responsible for the action or omission of such Affiliates, subject to Section 12.14.

 

12.14                 Guarantee. ADAGENE hereby agrees to be primarily responsible for the actions and/or omissions of ADAGENE and ADAGENE Affiliates under this Agreement and shall guarantee ADAGENE’s and ADAGENE Affiliates’ performance under this Agreement. In the event ADAGENE or any of the ADAGENE Affiliates assigns directly or indirectly any ADAGENE Patents and/or the SAFEbody Technology to another person or entity, such assignment shall only be valid towards ADCT if such person or entity has validly agreed in writing to assume all obligations of its assignor under this Agreement, including, in particular, such primary responsibility and guarantee hereunder. Any assignment not in compliance with this Section 12.14 shall be null, void and of no effect.

 

12.15                 Counterparts. This Agreement may be executed in two or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument. If any signature is delivered by e-mail delivery of a “pdf” format, such signature shall create a valid and binding obligation of the Party executing (or on whose behalf such signature is executed) with the same force and effect as if such “pdf” signature page were an original thereof.

 

[Signature page follows — the rest of this page intentionally left blank.]

 

31

 

IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their respective officers hereunto duly authorized, on the date set forth above.

 

ADC Therapeutics SA

 

	
By:
    	
/s/ C J Martin
    	
 
    
	
Name:
    	
C J Martin
    	
 
    
	
Title:
    	
CEO
    	
 
    
	
 
    	
 
    	
 
    
	
ADAGENE Inc.
    	
 
    
	
 
    	
 
    	
 
    
	
By:
    	
/s/ Peter Luo
    	
 
    
	
Name:
    	
Peter Luo
    	
 
    
	
Title:
    	
4/12/2019
    	
 
    

 

32

 

Annex 1

 

Development Plan

 

[***]

 

33

 

Annex 2

 

License Agreement

(Provided separately)

 

34

 

Annex 3

 

Chinese Territory License Terms

(Provided separately)

 

35

 

Annex 4

 

[***] Reserved Target

 

[***]

 

36

 

Annex 5

 

ADAGENE PATENT APPLICATIONS AND KNOW-HOW

 

[***]

 

37

 

Annex 6

 

Initial Press Release

(Provided separately)

 

38

 

Annex 7

 

List of ADAGENE Affiliates

with registered address and contact details

 

[***]

 

39

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00319-of-00352.parquet"}]]